WO2011140249A2 - Antibodies that bind csf1r - Google Patents

Antibodies that bind csf1r Download PDF

Info

Publication number
WO2011140249A2
WO2011140249A2 PCT/US2011/035231 US2011035231W WO2011140249A2 WO 2011140249 A2 WO2011140249 A2 WO 2011140249A2 US 2011035231 W US2011035231 W US 2011035231W WO 2011140249 A2 WO2011140249 A2 WO 2011140249A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
light chain
heavy chain
antibody
Prior art date
Application number
PCT/US2011/035231
Other languages
French (fr)
Other versions
WO2011140249A3 (en
Inventor
Justin Wong
Maximiliano Vasquez
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18151214.6A priority Critical patent/EP3357510B1/en
Priority to LTEP11778283.9T priority patent/LT2566517T/en
Priority to NZ603193A priority patent/NZ603193A/en
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Priority to EP11778283.9A priority patent/EP2566517B1/en
Priority to PL11778283T priority patent/PL2566517T3/en
Priority to RS20190025A priority patent/RS58211B1/en
Priority to CA2797399A priority patent/CA2797399C/en
Priority to JP2013509230A priority patent/JP6008842B2/en
Priority to ES11778283T priority patent/ES2706412T3/en
Priority to BR112012027994-7A priority patent/BR112012027994B1/en
Priority to SG2012079133A priority patent/SG185035A1/en
Priority to KR1020207011504A priority patent/KR20200044999A/en
Priority to CN201180022404.5A priority patent/CN103179985B/en
Priority to KR1020127031635A priority patent/KR101838698B1/en
Priority to KR1020187006772A priority patent/KR102105776B1/en
Priority to DK11778283.9T priority patent/DK2566517T3/en
Priority to AU2011248083A priority patent/AU2011248083B2/en
Priority to EA201291161A priority patent/EA036336B1/en
Priority to SI201131627T priority patent/SI2566517T1/en
Priority to MX2015007635A priority patent/MX355418B/en
Priority to EP20182161.8A priority patent/EP3943154A1/en
Priority to MX2012012790A priority patent/MX2012012790A/en
Publication of WO2011140249A2 publication Critical patent/WO2011140249A2/en
Priority to IL222629A priority patent/IL222629B/en
Publication of WO2011140249A3 publication Critical patent/WO2011140249A3/en
Priority to AU2015202477A priority patent/AU2015202477C1/en
Priority to AU2016262662A priority patent/AU2016262662B2/en
Priority to IL255524A priority patent/IL255524B/en
Priority to IL257712A priority patent/IL257712B/en
Priority to HRP20190047TT priority patent/HRP20190047T1/en
Priority to CY191100027T priority patent/CY1121102T1/en
Priority to AU2019200691A priority patent/AU2019200691B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Antibodies that bind CSF IR are provided.
  • Antibody heavy chains and light chains that are capable of forming antibodies that bind CSFI R are also provided.
  • antibodies, heavy chains, and light chains comprising one or more particular complementarity determining regions (CDRs) are provided.
  • Polynucleotides encoding antibodies to CSFIR are provided. Polynucleotides encoding antibody heavy chains or lights chains are also provided. Methods of treatment using antibodies to CSF IR are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
  • Colony stimulating factor 1 receptor (referred to herein as CSFIR; also referred to in the art as FMS, FIM2, C-FMS, and CD115) is a single-pass
  • transmembrane receptor with an N-terminal extracellular domain (ECD) and a C- terminal intracellular domain with tyrosine kinase activity.
  • ECD extracellular domain
  • CSF1 or the interleukin 34 ligand referred to herein as IL34; Lin et al, Science 320: 807-11 (2008)
  • IL34 interleukin 34 ligand
  • CSF1 and IL34 stimulate monocyte survival, proliferation, and differentiation into macrophages.
  • CSF1 tumor-associated macrophages
  • TAMs tumor-associated macrophages
  • CSF1 has been found to promote tumor growth and progression to metastasis in, for example, human breast cancer xenografts in mice. See, e.g., Paulus et al., Cancer Res. 66: 4349-56 (2006).
  • CSFIR appears to play a role in osteolytic bone destruction in bone metastasis, as a small molecule inhibitor of receptor tyrosine kinase activity suppresses that destruction. See, e.g., Ohno et al., Mol. Cancer Ther. 5: 2634-43 (2006).
  • CSF1 and its receptor have also been found to be involved in various inflammatory and autoimmune diseases. See, e.g., Hamilton, Nat. Rev. 8: 533-44 (2008). For example, synovial endothelial cells from joints afflicted with rheumatoid arthritis have been found to produce CSF1 , suggesting a role for CSF1 and its receptor in the disease.
  • Blocking CSFIR activity with an antibody results in positive clinical effects in mouse models of arthritis, including a reduction in the destmction of bone and cartilage and a reduction in macrophage numbers. See, e.g., Kitaura et al., J. Clin. Invest. 1 15: 3418-3427 (2005).
  • Mature differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts contribute to pathology of various diseases such as rheumatoid arthritis, multiple sclerosis and diseases of bone loss.
  • Differentiated myeloid lineage cells are derived from peripheral blood monocyte intermediates.
  • CSFI R stimulation contributes to development of monocytes from bone marrow precursors, to monocyte proliferation and sui'vival, and to differentiation of peripheral blood monocytes into differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts.
  • CSFIR stimulation thus contributes to proliferation, sui'vival, activation, and maturation of differentiated myeloid lineage cells, and in the pathologic setting, CSFI R stimulation contributes to the ability of differentiated myeloid lineage cells to mediate disease pathology.
  • the present inventors have invented a new set of antibodies, including humanized antibodies, directed against human CSFI R extracellular domain (CSFIR ECD).
  • CSFIR ECD humanized antibodies
  • a Fab phage display library was made from spleens of mice that were immunized with a human CSFIR ECD-Fc fusion protein. 1056 phage clones expressing Fabs that bind to CSF-1R ECD-Fc were isolated through panning of this library. When the 1056 Fabs were expressed as purified protein, 668 were found to bind to CSFIR ECD. Of those 668 binding Fabs, only 121 Fabs blocked binding of CSF1 and/or IL34 to CSFI R.
  • humanized antibodies retained subnanomolar binding affinities for human CSFIR ECD. See, e.g., Table 5. These humanized antibodies block binding of both ligands CSFl and IL34 to human CSFIR, and many also block binding of both CSFl and IL34 to cynomolgus monkey CSFIR. See, e.g., Table 4.
  • Humanized versions of 0301 and 031 1 retained similarly strong binding to both human and cynomolgus monkey CSFIR ECD, with binding affinity differences for the two species of less than about 2-fold.
  • phosphorylation of human CSFIR and also block ligand-induced proliferation and survival responses in primary human monocytes. See, e.g., Tables 6 and 7, and Figures 10 and 1 1.
  • these antibodies are useful for treating diseases involving, for example, ligand-induced proliferation and survival responses in primary human monocytes.
  • Blocking CSFlR-induced responses with an anti-CSFIR antibody should inhibit proliferation, survival, activation, maturation of differentiated myeloid lineage cells and attenuate their ability to mediate disease pathology.
  • blocking CSFlR-induced responses with an anti-CSFI R antibody should inhibit differentiation of peripheral blood monocyte intermediates into differentiated myeloid lineage cells, decreasing the number of pathology-mediating differentiated myeloid lineage cells.
  • the humanized anti-CSFIR antibodies described herein can be used to treat chronic diseases with extant symptoms by inhibiting the ability of differentiated myeloid lineage cells to mediate disease pathology.
  • the humanized antibodies can also be used to treat chronic diseases that are relapsing and remitting in nature by inhibiting the development of new pathology-mediating myeloid lineage cells differentiated from peripheral blood monocytes during the remitting phase of the disease, thus attenuating the number of and new formation of the pathology-mediating cells.
  • an isolated antibody comprising a heavy chain and a light chain is provided, wherein the antibody binds to CSF1R.
  • the heavy chain and/or light chain have the following structure.
  • the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
  • the light chain comprises a sequence that is at least 90%o, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
  • the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45
  • the light chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
  • the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (e) SEQ ID NOs: 27, 28, and 29.
  • the LC CDR1, LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
  • the heavy chain comprises an HC CDR1 , HC CDR2, and HC CDR3, wherein the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (c) SEQ ID NOs: 27, 28, and 29; and the light chain comprises an LC CDR1 , LC CDR2, and LC CDR3, wherein the LC CDR1 , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
  • an isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
  • a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 47; and (j) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 48; (k) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 49; (1) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least
  • an antibody comprising a heavy chain and a light chain
  • the antibody comprises: (a) a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO: 15, an HC CDR2 having the sequence of SEQ ID NO: 16, and an HC CDR3 having the sequence of SEQ ID NO: 17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 18, a LC CDR2 having the sequence of SEQ ID NO: 19, and a LC CDR3 having the sequence of SEQ ID NO: 20; (b) a heavy chain comprising a heavy chain (HC) CDRl having the sequence of SEQ ID NO: 21 , an HC CDR2 having the sequence of SEQ ID NO: 22, and an HC CDR3 having the sequence of SEQ ID NO: 23, and a light chain comprising a light chain (LC) CDRl having the sequence of SEQ ID NO: 24, a LC
  • an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 60; (b) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 61 ; or (c) a heavy chain comprising a sequence of SEQ ID NO: 58 and a light chain comprising a sequence of SEQ ID NO: 65.
  • an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 60; (b) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 61 ; or (c) a heavy chain consisting of the sequence of SEQ ID NO: 58 and a light chain consisting of the sequence of SEQ ID NO: 65.
  • an antibody is a humanized antibody.
  • an antibody is selected from a Fab, an Fv, an scFv, a Fab ⁇ and a (Fab') 2 .
  • an antibody is a chimeric antibody.
  • an antibody is selected from an IgA, an IgG, and an IgD.
  • an antibody is an IgG.
  • an antibody is an IgG4.
  • an antibody is an IgG4 comprising an S241P mutation in at least one IgG4 heavy chain constant region.
  • an antibody binds to human CSF1R and/or binds to cynomolgus CSF1R. In some embodiments, an antibody blocks ligand binding to CSF1 R. In some embodiments, an antibody blocks binding of CSF1 and/or IL34 to CSF1 R. In some embodiments, an antibody inhibits ligand-induced CSF1R phosphorylation. In some embodiments, an antibody inhibits CSF1- and/or IL34-induced CSF1R phosphoiylation. In some embodiments, an antibody binds to human CSF1R with an affinity (K D ) of less than 1 nM. In some embodiments, antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 01- IL34.
  • a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
  • an isolated nucleic acid comprising a polynucleotide sequence that encodes a heavy chain described above. In some embodiments, an isolated nucleic acid encodes a light chain described above. In some embodiments, an isolated nucleic acid encodes a heavy chain described above and a light chain described above. In some embodiments, a composition is provided, wherein the composition comprises a first nucleic acid that comprises a polynucleotide sequence that encodes a heavy chain described above, and a second nucleic acid that comprises a polynucleotide sequence that encodes a light chain described above.
  • a host cell comprising a nucleic acid or a composition described above is provided.
  • a host cell is a eukaryotic host cell.
  • a host cell is a mammalian host cell.
  • a host cell is selected from a CHO cell, a 293 cell, an NSO cell, and a PER.C6 cell.
  • a host cell is a 293-6E cell or a DG44 cell.
  • methods of treating disease comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R.
  • a method of treating multiple sclerosis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
  • a method of treating rheumatoid arthritis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
  • a method of treating osteolytic bone loss comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
  • the osteolytic bone loss is selected from osteoporosis, metastasis-induced osteolytic bone loss, and rheumatoid arthritis- induced bone loss.
  • a method of treating cancer comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
  • the cancer is selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
  • a method of treating an inflammatory condition comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSFIR is provided.
  • antibodies that bind CSF IR and compositions comprising antibodies that bind CSFIR are provided for use in methods of treatment of human or animals. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating rheumatoid arthritis in a human or animal. In some embodiments, antibodies that bind CSFI R and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating multiple sclerosis in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating cancer in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating an inflammatory condition in a human or animal.
  • FIG. 1 shows an alignment of the humanized heavy chain variable regions for each of humanized antibodies Abl to Abl 6, as discussed in Example 4. Boxed residues are amino acids in the human acceptor sequence that were changed back to the corresponding mouse residue.
  • FIG. 2 shows an alignment of the humanized light chain variable regions for each of humanized antibodies Abl to Ab 16, as discussed in Example 4 Boxed amino acids are residues in the human acceptor sequence that were changed back to the corresponding mouse residue.
  • FIG. 3 shows binding curves for certain humanized antibodies binding to human CSFIR ECD, as described in Example 5.
  • Figure 3 A shows binding curves for parental chimeric antibodies (cAb) 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (hO3Ol-LOH0, h0301-L0Hl, h0301-L0H2, h0301-LlH0, h0301 -LlHl , and Ii0301-L1H2, respectively).
  • Figure 3B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , Ii0302-L1 H1 , h0302-L2Hl , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively).
  • Figure 3C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1 .2, 031 1.3 , and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1-L1 H2, respectively).
  • FIG. 4 shows binding curves for certain humanized antibodies binding to cynomolgus CSF1 R ECD, as described in Example 5.
  • Figure 4A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301-L0H2, h0301 - L1H0, h0301 -LlH l , and h0301 -Ll H2, respectively).
  • Figure 4B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
  • Figure 4C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2,
  • 031 1.3, and 031 1.4 (h031 1 -LOHl , h0311-LlHl , h031 1 -L0H2, and h031 1 -L1H2, respectively).
  • FIG. 5 shows binding curves for certain humanized antibodies binding to mouse CSF1R ECD, as described in Example 5.
  • Figure 5 A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3,
  • FIG. 5B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4,
  • FIG. 5C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 0311.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1 -LI H2, respectively).
  • FIG. 6 shows inhibition of CSF1 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6.
  • Figure 6 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and Ii0301 -L1 H2, respectively).
  • Figure 6B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , h0302-L! Hl , h0302-L2H l , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
  • Figure 6C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1 .1 , 031 1.2, 031 1.3, and 031 1 .4 (h031 1 -L0H1 , h031 1 -L1H1 , h0311 -L0H2, and h0311 -L1H2, respectively).
  • FIG. 7 shows inhibition of IL34 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6.
  • Figure 7 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and h0301-Ll H2, respectively).
  • Figure 7B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
  • Figure 7C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI HI , h031 1 -L0H2, and h031 1 -LI H2, respectively).
  • FIG. 8 shows blocking of human CSF1 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7.
  • Figure 8A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301-L0Hl , h0301- L0H2, h0301-LlH0, Ii0301 -L1H1 , and h0301 -LlH2, respectively).
  • Figure 8B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302- L2H1 , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively).
  • Figure 8C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2, 031 1 .3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -L1H1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
  • FIG. 9 shows blocking of human IL34 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7.
  • Figure 9 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -LOH0, h0301 -L0Hl , h0301 - L0H2, h0301 -LlH0, h0301 -LI Hl , and h0301-Ll H2, respectively).
  • Figure 9B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , h0302-LlHl , h0302- L2H1 , h0302-L0H2, Ii0302-L1H2, and h0302-L2H2, respectively).
  • Figure 9C shows blocking curves for parental cAb 0311 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h0311 -LI H 1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
  • FIG. 10 shows blocking of CSFl - (A) and IL34- (B) induced CSFIR phosphorylation in CHO cells expressing human CSFIR by humanized antibodies 0301 -L0H0, 0301 -L1 H0, and 031 1 -LOHl , as described in Example 9.
  • FIG. 11 shows blocking of CSFl- (A) and IL34- (B) induced monoclyte proliferation/survival responses by humanized antibodies 0301-L0H0, 0301 -LI HO, and 031 1 -LOHl , as described in Example 10.
  • FIG. 12A-C shows that humanized antibodies 0301-L0H0, 0301- LIHO, and 031 1-LOHl do not stimulate primary monocyte proliferation or survival, using monocytes from three different donors, as described in Example 11.
  • Methods of treating diseases comprising administering novel antibodies to CSF I R are provided. All of the antibodies have binding affinities for human CSFIR ECD of less than 2 nM, and all but two of the humanized antibodies have sub-nanomolar binding affinities for human CSFIR ECD. Further, the new antibodies block binding of both CSFl and IL34 to human CSFIR, and inhibit ligand- induced phosphorylation of human CSFIR. Many of the new antibodies also block binding of CSFl and 1L34 to cynomolgus CSFI R, which facilitates in vivo experiments to support the development of anti-CSFIR antibody therapeutics. The new antibodies are therefore well suited for therapeutic use in human diseases, including, but not limited to, cancer, autoimmune diseases, and inflammatory conditions.
  • nucleic acid molecule and “polynucleotide” may be used interchangeably, and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and/or non-natural nucleotides, and include, but are not limited to, DNA, NA, and PNA.
  • Nucleic acid sequence refers to the linear sequence of nucleotides that comprise the nucleic acid molecule or polynucleotide.
  • polypeptide and protein are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition.
  • the terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like.
  • a "polypeptide” refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
  • the term “CSFIR” refers herein to the full-length CSFIR, which includes the N-terminal ECD, the transmembrane domain, and the intracellular tyrosine kinase domain, with or without an N-terminal leader sequence.
  • the CSFIR is a human CSFIR having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • CSFIR extracellular domain refers to a CSFIR polypeptide that lacks the intracellular and transmembrane domains.
  • CSFIR ECDs include the full-length CSFIR ECD and CSFIR ECD fragments that are capable of binding CSFIR and/or IL34.
  • the human full-length CSFIR ECD is defined herein as comprising either amino acids 1 to 512 (i.e., including the leader sequence) or amino acids 20 to 512 (i.e., lacking the leader sequence) of SEQ ID NO: 2.
  • a human CSFIR ECD fragment comprises amino acids 20 to 506 of SEQ ID NO: 2 (see SEQ ID NO:5).
  • a human CSFIR fragment ends at amino acid 507, 508, 509, 510, or 51 1.
  • a cynoCSF 1 R ECD comprises the sequence of SEQ ID NO: 7 (with leader sequence) or amino acids 20 to 506 of SEQ ID NO: 7 (without leader sequence).
  • antibody refers to a molecule comprising at least complementarity-determining region (CDR) 1 , CDR2, and CDR3 of a heavy chain and at least CDR1 , CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen.
  • the term antibody includes, but is not limited to, fragments that are capable of binding antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', and (Fab') 2 .
  • the term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as mouse, human, cynomolgus monkey, etc.
  • an antibody comprises a heavy chain variable region and a light chain variable region.
  • an antibody comprises at least one heavy chain comprising a heavy chain variable region and at least a portion of a heavy chain constant region, and at least one light chain comprising a light chain variable region and at least a portion of a light chain constant region.
  • an antibody comprises two heavy chains, wherein each heavy chain comprises a heavy chain variable region and at least a portion of a heavy chain constant region, and two light chains, wherein each light chain comprises a light chain variable region and at least a portion of a light chain constant region.
  • a single-chain Fv or any other antibody that comprises, for example, a single polypeptide chain comprising all six CDRs (three heavy chain CDRs and three light chain CDRs) is considered to have a heavy chain and a light chain.
  • the heavy chain is the region of the antibody that comprises the three heavy chain CDRs and the light chain in the region of the antibody that comprises the three light chain CDRs.
  • heavy chain variable region refers to a region comprising heavy chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3.
  • a heavy chain variable region also comprises at least a portion of an FR1 and/or at least a portion of an FR4.
  • a heavy chain CDRl corresponds to Kabat residues 26 to 35;
  • a heavy chain CDR2 corresponds to Kabat residues 50 to 65;
  • a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991 , NIH, Bethesda, Md.); and Figure 1.
  • a heavy chain CDRl corresponds to Kabat residues 31 to 35; a heavy chain CDR2 corresponds to Kabat residues 50 to 65; and a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See id.
  • heavy chain constant region refers to a region comprising at least three heavy chain constant domains, C H 1 , CH2, and CH3.
  • Nonlimiting exemplary heavy chain constant regions include ⁇ , ⁇ , and a.
  • Nonlimiting exemplary heavy chain constant regions also include ⁇ and ⁇ .
  • Each heavy constant region corresponds to an antibody isotype.
  • an antibody comprising a ⁇ constant region is an IgG antibody
  • an antibody comprising a ⁇ constant region is an IgD antibody
  • an antibody comprising an a constant region is an IgA antibody.
  • an antibody comprising a ⁇ constant region is an IgM antibody
  • an antibody comprising an ⁇ constant region is an IgE antibody.
  • IgG antibodies include, but are not limited to, IgG l (comprising a ⁇ constant region), IgG2 (comprising a ⁇ 2 constant region), IgG3 (comprising a 73 constant region), and IgG4 (comprising a ⁇ 4 constant region) antibodies;
  • IgA antibodies include, but are not limited to, IgAl (comprising an a] constant region) and lgA2 (comprising an ao constant region) antibodies; and IgM antibodies include, but are not limited to, IgMl and IgM2.
  • a heavy chain constant region comprises one or more mutations (or substitutions), additions, or deletions that confer a desired characteristic on the antibody.
  • a nonlimiting exemplary mutation is the S241P mutation in the IgG4 hinge region (between constant domains C H 1 and CH2), which alters the lgG4 motif CPSCP to CPPCP, which is similar to the corresponding motif in IgG 1. That mutation, in some embodiments, results in a more stable IgG4 antibody. See, e.g., Angal et al., Mol. Immunol. 30: 105-108 (1993); Bloom et al., Prot. Sci. 6: 407-415 (1997); Schuurman et al., Mol. Immunol. 38: 1-8 (2001 ).
  • heavy chain refers to a polypeptide comprising at least a heavy chain variable region, with or without a leader sequence.
  • a heavy chain comprises at least a portion of a heavy chain constant region.
  • full-length heavy chain refers to a polypeptide comprising a heavy chain variable region and a heavy chain constant region, with or without a leader sequence.
  • light chain variable region refers to a region comprising light chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3.
  • a light chain variable region also comprises an FR1 and/or an FR4.
  • a light chain CDRl coiTesponds to Kabat residues 24 to 34;
  • a light chain CDR2 corresponds to Kabat residues 50 to 56;
  • light chain constant region refers to a region comprising a light chain constant domain
  • CL- Nonlimiting exemplary light chain constant regions include ⁇ and .
  • light chain refers to a polypeptide comprising at least a light chain variable region, with or without a leader sequence.
  • a light chain comprises at least a portion of a light chain constant region.
  • full-length light chain refers to a polypeptide comprising a light chain variable region and a light chain constant region, with or without a leader sequence.
  • a "chimeric antibody” as used herein refers to an antibody comprising at least one variable region from a first species (such as mouse, rat, cynomolgus monkey, etc.) and at least one constant region from a second species (such as human, cynomolgus monkey, etc.).
  • a chimeric antibody comprises at least one mouse variable region and at least one human constant region.
  • a chimeric antibody comprises at least one cynomolgus variable region and at least one human constant region.
  • all of the variable regions of a chimeric antibody are from a first species and all of the constant regions of the chimeric antibody are from a second species.
  • a “humanized antibody” as used herein refers to an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the corresponding amino acid from a human variable region.
  • a humanized antibody comprises at least one human constant region or fragment thereof.
  • a humanized antibody is an Fab, an scFv, a (Fab') 2 , etc.
  • CDR-grafted antibody refers to a humanized antibody in which the complementarity detemiining regions (CDRs) of a first (non- human) species have been grafted onto the framework regions (FRs) of a second (human) species.
  • a "human antibody '' as used herein refers to antibodies produced in humans, antibodies produced in non-human animals that comprise human immunoglobulin genes, such as XenoMouse®, and antibodies selected using in vitro methods, such as phage display, wherein the antibody repertoire is based on a human immunoglobulin sequences.
  • leader sequence refers to a sequence of amino acid residues located at the N terminus of a polypeptide that facilitates secretion of a polypeptide from a mammalian cell.
  • a leader sequence may be cleaved upon export of the polypeptide from the mammalian cell, forming a mature protein.
  • Leader sequences may be natural or synthetic, and they may be heterologous or homologous to the protein to which they are attached.
  • Exemplary leader sequences include, but are not limited to, antibody leader sequences, such as, for example, the amino acid sequences of SEQ ID NOs.: 3 and 4, which correspond to human light and heavy chain leader sequences, respectively.
  • Nonlimiting exemplary leader sequences also include leader sequences from heterologous proteins.
  • an antibody lacks a leader sequence.
  • an antibody comprises at least one leader sequence, which may be selected from native antibody leader sequences and heterologous leader sequences.
  • vector is used to describe a polynucleotide that may be engineered to contain a cloned polynucleotide or polynucleotides that may be propagated in a host cell.
  • a vector may include one or more of the following elements: an origin of replication, one or more regulatory sequences (such as, for example, promoters and/or enhancers) that regulate the expression of the polypeptide of interest, and/or one or more selectable marker genes (such as, for example, antibiotic resistance genes and genes that may be used in coloriinetric assays, e.g., ⁇ - galactosidase).
  • expression vector refers to a vector that is used to express a polypeptide of interest in a host cell.
  • a "host cell” refers to a cell that may be or has been a recipient of a vector or isolated polynucleotide.
  • Host cells may be prokaryotic cells or eukaryotic cells.
  • Exemplary eukaiyotic cells include mammalian cells, such as primate or non- primate animal cells; fungal cells, such as yeast; plant cells; and insect cells.
  • Nonlimiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Cracell), and 293 and CHO cells, and their derivatives, such as 293- 6E and DG44 cells, respectively.
  • isolated refers to a molecule that has been separated from at least some of the components with which it is typically found in nature.
  • a polypeptide is referred to as “isolated” when it is separated from at least some of the components of the cell in which it was produced.
  • a polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered to be “isolating" the polypeptide.
  • a polynucleotide is referred to as "isolated" when it is not part of the larger polynucleotide (such as, for example, genomic DNA or mitochondrial DNA, in the case of a DNA polynucleotide) in which it is typically found in nature, or is separated from at least some of the components of the cell in which it was produced, e.g., in the case of an RNA polynucleotide.
  • a DNA polynucleotide that is contained in a vector inside a host cell may be referred to as “isolated” so long as that polynucleotide is not found in that vector in nature.
  • subject and “patient” are used interchangeably herein to refer to a human.
  • methods of treating other mammals including, but not limited to, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, manmialian laboratoiy animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are also provided.
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • MS multiple sclerosis
  • Demyelination occurs when the myelin sheath becomes inflamed, injured, and detaches from the nerve fiber.
  • cancer refers to a proliferative disorder associated with uncontrolled cell proliferation, unrestrained cell growth, and decreased cell deathiapoptosis.
  • Cancer includes, but is not limited to, breast cancer, prostate cancer, lung cancer, kidney cancer, thyroid cancer, esophageal cancer, melanoma, follicular lymphomas, uveal melanoma, brain cancer, head and neck cancer, pulmonary adenocarcinoma, including, but not limited to, colon cancer, cardiac tumors, pancreatic cancer, retinoblastoma, glioblastoma, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, Kaposi's sarcoma, ovarian cancer, leukemia (including acute leukemias (
  • metalastasis and “cancer metastasis” are used interchangeably herein to refer to the ability of a cancer cell to spread to other tissues.
  • metalastasis to bone ' ' refers to the ability of certain types of cancer including, but not limited to, breast, prostate, lung, kidney, thyroid, and melanoma, to metastasize to bone.
  • osteolytic disorders is used herein to refer to any condition that is caused by an increase in the activity of osteoclasts, which are cells responsible for bone resorption.
  • the terms “osteolysis” and “osteolytic bone loss” may be used interchangeably to refer to osteoclast-mediated bone resorption or bone loss associated with an osteolytic disorder.
  • Osteolytic disorders may occur in subjects with a predisposition to develop an osteolytic disorder, or they may occur in subjects with a disease that leads to or contributes to an osteolytic disorder by stimulating osteoclast activity.
  • the osteolytic disorder may include osteolytic bone loss and cancer metastasis-induced osteolytic bone loss.
  • the osteolytic bone disorder includes metabolic bone disease, including endocrinopathies, such as hypercortisolism, hypogonadism, primary or secondaiy hyperparathyroidism, and hyperthyroidism; dietaiy deficiency, including rickets, osteomalacia, scurvy, and malnutrition; osteoporosis; drug use, including glucocorticoids (glucocorticoid- induced osteoporosis), heparin, and alcohol; chronic disease, including malabsorption syndromes; chronic renal failure, including renal osteodystrophy; chronic liver disease, including hepatic osteodystrophy; inherited disease, including osteogenesis imperfecta and homocystinuria; and bone inflammation associated with arthritis, rheumatoid arthritis, psoriatic arthritis, fibrous dysplasia, periodontal disease, and Paget's disease.
  • endocrinopathies such as hypercortisolism, hypogonadism, primary or
  • osteolysis or osteolytic bone loss resulting from cancer cell metastasis to bone are used interchangeably herein to refer to osteolysis or osteolytic bone loss resulting from cancer cell metastasis to bone.
  • cancer metastasis-induced osteoclast activation is used herein to refer to the ability of cancer cells that have metastasized to bone to induce the activation of osteoclasts.
  • tumor is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth.
  • a tumor may be benign, pre- malignant, or malignant; malignant tumor cells are cancerous.
  • Tumor cells may be solid tumor cells or leukemic tumor cells.
  • tumor growth is used herein to refer to proliferation or growth by a cell or cells that comprise a tumor that leads to a corresponding increase in the size of the tumor.
  • CSFIR-dependent tumor growth' is used herein to refer to the requirement of a tumor cell or cells for CSFIR- mediated function(s) in order for the tumor cell or cells to proliferate or grow.
  • Treatment covers any administration or application of a therapeutic for disease in a mammal, including a human, and includes inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, partially or fully relieving the disease, or curing the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
  • inhibitors refer to a decrease or cessation of any phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that characteristic.
  • a "pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a "pharmaceutical composition" for administration to a subject.
  • a pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the fonnulation.
  • the phannaceutically acceptable earner is appropriate for the fonnulation employed.
  • the carrier ideally is not irritable to the skin and does not cause injection site reaction.
  • Anti-CSFIR antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and/ or light chain CDRs discussed herein.
  • humanized antibodies that bind CSF1R are provided.
  • Humanized antibodies are useful as therapeutic molecules because humanized antibodies reduce or eliminate the human immune response to non-human antibodies (such as the human anti-mouse antibody (HAMA) response), which can result in an immune response to an antibody therapeutic, and decreased effictiveness of the therapeutic.
  • HAMA human anti-mouse antibody
  • Nonlimiting exemplaiy humanized antibodies include Abl through Abl 6, described herein.
  • Nonlimiting exemplaiy humanized antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from Abl to Abl 6 and/or a light chain variable region of an antibody selected from Abl to Abl 6.
  • Nonlimiting exemplaiy humanized antibodies include antibodies comprising a heavy chain variable region selected from SEQ ID NOs: 39 to 45 and/or a light chain variable region selected from SEQ ID NOs: 46 to 52.
  • Exemplaiy humanized antibodies also include, but are not limited to, humanized antibodies comprising heavy chain CDRl , CDR2, and CDR3, and/or light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
  • a humanized anti-CSFIR antibody comprises heavy chain CDRl , CDR2, and CDR3 and/or a light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
  • Nonlimiting exemplaiy humanized anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDRl, CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29.
  • Nonlimiting exemplaiy humanized anti-CSFIR antibodies also include antibodies comprising sets of light chain CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
  • Nonlimiting exemplaiy humanized anti-CSF 1 R antibodies include antibodies comprising the sets of heavy chain CDRl , CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 in Table 1 (SEQ ID NOs shown; see Table 8 for sequences). Each row of Table 1 shows the heavy chain CDRl, CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 of an exemplaiy antibody.
  • a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, and wherein the antibody binds CSF1R.
  • a humanized anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1R.
  • a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 11 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
  • whether a particular polypeptide is, for example, at least 95% identical to an amino acid sequence can be determined using, e.g., a computer program.
  • the percentage of identity is calculated over the full length of the reference amino acid sequence.
  • a humanized anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a humanized anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, a humanized anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
  • one or more of the amino acid substitutions are conservative amino acid substitutions.
  • One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
  • Exemplary humanized anti-CSFIR antibodies also include antibodies that compete for binding to CSF1 R with an antibody described herein.
  • a humanized anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
  • a humanized antibody described herein comprises one or more human constant regions.
  • the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
  • the human light chain constant region is of an isotype selected from K and ⁇ .
  • a humanized antibody described herein comprises a human IgG constant region.
  • a humanized antibody described herein comprises a human IgG4 heavy chain constant region.
  • a humanized antibody described herein comprises an S241P mutation in the human IgG4 constant region.
  • a humanized antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
  • the choice of heavy chain constant region can determine whether or not an antibody will have effector function in vivo.
  • effector function includes antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC), and can result in killing of the cell to which the antibody is bound.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • cell killing may be desirable, for example, when the antibody binds to a cell that supports the maintenance or growth of the tumor.
  • Exemplaiy cells that may support the maintenance or growth of a tumor include, but are not limited to, tumor cells themselves, cells that aid in the recruitment of vasculature to the tumor, and cells that provide ligands, growth factors, or counter-receptors that support or promote tumour growth or rumour survial.
  • an anti-CSFlR antibody comprising a human IgGl heavy chain or a human IgG3 heavy chain is selected.
  • effector function may not be desirable.
  • anti-CSFlR antibodies developed for the treatment of cancer may not be suitable for use in treatment of MS and/or RA and/or osteolysis.
  • an anti-CSFlR antibody that lacks significant effector function is used in treatment of MS and/or RA and/or osteolysis.
  • an anti-CSFlR antibody for treatment of MS and/or RA and/or osteolysis comprises a human IgG4 or IgG2 heavy chain constant region.
  • an IgG4 constant region comprises an S241P mutation.
  • An antibody may be humanized by any method.
  • Nonlimiting exemplary methods of humanization include methods described, e.g., in U.S. Patent Nos. 5,530,101 ; 5,585,089; 5,693,761 ; 5,693,762; 6,180,370; Jones et al, Nature 321 : 522-525 (1986); Rieclimann et al, Nature 332: 323-27 (1988); Verhoeyen et al., Science 239: 1534-36 (1988); and U.S. Publication No. US 2009/0136500.
  • a humanized antibody is an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the amino acid from the corresponding location in a human framework region.
  • at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 1 1 , at least 12, at least 15, or at least 20 amino acids in the framework regions of a non-human variable region are replaced with an amino acid from one or more corresponding locations in one or more human framework regions.
  • some of the corresponding human amino acids used for substitution are from the framework regions of different human
  • one or more of the non- human amino acids may be replaced with corresponding amino acids from a human framework region of a first human antibody or encoded by a first human
  • one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a second human antibody or encoded by a second human immunoglobulin gene, one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a third human antibody or encoded by a third human immunoglobulin gene, etc.
  • all of the corresponding human amino acids being used for substitution in a single framework region for example, FR2 need not be from the same human framework. In some embodiments, however, all of the corresponding human amino acids being used for substitution are from the same human antibody or encoded by the same human immunoglobulin gene.
  • an antibody is humanized by replacing one or more entire framework regions with corresponding human framework regions.
  • a human framework region is selected that has the highest level of homology to the non-human framework region being replaced.
  • such a humanized antibody is a CDR-grafted antibody.
  • one or more framework amino acids are changed back to the corresponding amino acid in a mouse framework region.
  • Such "back mutations” are made, in some embodiments, to retain one or more mouse framework amino acids that appear to contribute to the structure of one or more of the CDRs and/or that may be involved in antigen contacts and/or appear to be involved in the overall structural integrity of the antibody.
  • ten or fewer, nine or fewer, eight or fewer, seven or fewer, six or fewer, five or fewer, four or fewer, three or fewer, two or fewer, one, or zero back mutations are made to the framework regions of an antibody following CDR grafting.
  • a humanized antibody also comprises a human heavy chain constant region and/or a human light chain constant region.
  • an anti-CSFIR antibody is a chimeric antibody.
  • an anti-CSFI R antibody comprises at least one non-human variable region and at least one human constant region.
  • all of the variable regions of an anti-CSFIR antibody are non-human variable regions, and all of the constant regions of an anti-CSFIR antibody are human constant regions.
  • one or more variable regions of a chimeric antibody are mouse variable regions.
  • the human constant region of a chimeric antibody need not be of the same isotype as the non-human constant region, if any, it replaces. Chimeric antibodies are discussed, e.g., in U.S. Patent No. 4,816,567; and Morrison et al.
  • Nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising the heavy and/or light chain variable regions of an antibody selected from 0301 , 0302, and 031 1 .
  • Additional nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising heavy chain CDR1 , CDR2, and CDR3, and/or light chain CDR1 , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
  • Nonlimiting exemplaiy chimeric anti-CSFIR antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14.
  • Nonlimiting exemplaiy anti-CSFIR antibodies include antibodies comprising a set of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
  • a chimeric anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R.
  • a chimeric anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF 1 R.
  • a chimeric anti-CSFI R antibody comprises a heavy chain comprising a variable region sequence that is at least 90%o, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%o, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%), at least 91 %, at least 92%, at least 93% » at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%» identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
  • a chimeric anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a chimeric anti-CSFI R antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein.
  • a chimeric anti-CSFI R antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
  • one or more of the amino acid substitutions are conservative amino acid substitutions.
  • One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
  • Exemplary chimeric anti-CSFIR antibodies also include chimeric antibodies that compete for binding to CSFIR with an antibody described herein.
  • a chimeric anti-CSFIR antibody is provided that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
  • a chimeric antibody described herein comprises one or more human constant regions.
  • the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
  • the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
  • a chimeric antibody described herein comprises a human IgG constant region.
  • a chimeric antibody described herein comprises a human IgG4 heavy chain constant region.
  • a chimeric antibody described herein comprises an S241P mutation in the human IgG4 constant region.
  • a chimeric antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
  • effector function may depend on the particular method of treatment intended for an antibody.
  • a chimeric anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected.
  • a chimeric anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected.
  • Human antibodies can be made by any suitable method.
  • Nonlimiting exemplary methods include making human antibodies in transgenic mice that comprise human immunoglobulin loci. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551 -55 (1993); Jakobovits et al., Nature 362: 255-8 ( 1993); Lonberg et al, Nature 368: 856-9 (1994); and U.S. Patent Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 5,545,807; 6,300,129; 6,255,458; 5,877,397; 5,874,299; and 5,545,806.
  • Nonlimiting exemplary methods also include making human antibodies using phage display libraries. See, e.g., Hoogenboom et al., J. Mol. Biol. 227: 381 -8 ( 1992); Marks et al., J. Mol. Biol. 222: 581 -97 (1991 ); and PCT
  • a human anti-CSFIR antibody binds to a polypeptide having the sequence of SEQ ID NO: 1.
  • Exemplary human anti-CSFIR antibodies also include antibodies that compete for binding to CSF1R with an antibody described herein.
  • a human anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
  • a human anti-CSFI antibody comprises one or more human constant regions.
  • the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
  • the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
  • a human antibody described herein comprises a human IgG constant region.
  • a human antibody described herein comprises a human IgG4 heavy chain constant region.
  • a human antibody described herein comprises an S241P mutation in the human IgG4 constant region.
  • a human antibody described herein comprises a human IgG4 constant region and a human light chain.
  • a human anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected. In some embodiments, when effector function is not desirable, a human anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected. Additional Exemplary Anti-CSFlR Antibodies
  • Exemplaiy anti-CSFlR antibodies also include, but are not limited to, mouse, humanized, human, chimeric, and engineered antibodies that comprise, for example, one or more of the CDR sequences described herein.
  • an anti-CSFlR antibody comprises a heavy chain variable region described herein.
  • an anti-CSFlR antibody comprises a light chain variable region described herein.
  • an anti-CSFlR antibody comprises a heavy chain variable region described herein and a light chain variable region described herein.
  • an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein.
  • an anti-CSFlR antibody comprises light chain CDR1 , CDR2, and CDR3 described herein. In some embodiments, an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein and light chain CDR1 , CDR2, and CDR3 described herein.
  • an anti-CSFlR antibody comprises a heavy chain variable region of an antibody selected from Fabs 0301, 0302, and 031 1.
  • Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from humanized antibodies Abl to Abl 6.
  • Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
  • an anti-CSFlR antibody comprises a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 31 1.
  • Nonlimiting exemplaiy anti-CSFl R antibodies also include antibodies comprising a light chain variable region of an antibody selected from humanized antibodies Abl to Abl6.
  • Nonlimiting exemplaiy anti-CSFlR antibodies include antibodies comprising a light chain variable region comprising a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
  • an anti-CSFlR antibody comprises a heavy chain variable region and a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 0311.
  • Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region and a light chain variable region of an antibody selected from humanized antibodies Abl to Abl 6.
  • Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14; SEQ ID NOs: 39 and 40; SEQ ID NOs: 41 and 42; SEQ ID NOs: 43 and 44; SEQ ID NOs: 45 and 46; SEQ ID NOs: 47 and 48; SEQ ID NOs: 49 and 50; and SEQ ID NOs: 51 and 52.
  • Nonlimiting exemplary anti- CSF1 R antibodies also include antibodies comprising the following pairs of heavy and light chains: SEQ ID NOs: 33 and 34; SEQ ID NOs: 35 and 36; and SEQ ID NOs: 37 and 38.
  • an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
  • Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28,and 29.
  • an anti-CSFIR antibody comprises light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
  • Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of light chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
  • an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
  • Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising the sets of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
  • an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R.
  • an anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1 R.
  • an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSFIR.
  • an anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
  • one or more of the amino acid substitutions are conservative amino acid substitutions.
  • One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
  • Exemplary anti-CSFIR antibodies also include antibodies that compete for binding to CSFIR with an antibody described herein. Thus, in some embodiments
  • an anti-CSFIR antibody that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
  • an antibody described herein comprises one or more human constant regions.
  • the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
  • the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
  • an antibody described herein comprises a human IgG constant region.
  • an antibody described herein comprises a human IgG4 heavy chain constant region.
  • an antibody described herein comprises an S241P mutation in the human IgG4 constant region.
  • an antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
  • effector function may depend on the particular method of treatment intended for an antibody.
  • an anti-CSFl R antibody comprising a human IgG 1 heavy chain constant region or a human IgG3 heavy chain constant region is selected.
  • an anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected.
  • anti-CSFIR antibody heavy chain variable regions are provided.
  • an anti-CSFIR antibody heavy chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
  • An anti-CSFIR antibody heavy chain variable region comprises a heavy chain CDR1 , FR2, CDR2, FR3, and CDR3.
  • an anti- CSFIR antibody heavy chain variable region further comprises a heavy chain FR1 and/or FR4.
  • Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions having an amino acid sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
  • an anti-CSFIR antibody heavy chain variable region comprises a CDR1 comprising a sequence selected from SEQ ID NOs: 15, 21, and 27.
  • an anti-CSFIR antibody heavy chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 16, 22, and 28.
  • an anti-CSFI R antibody heavy chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 17, 23, and 29.
  • Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions comprising sets of CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29.
  • an anti-CSFIR antibody heavy chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the heavy chain, together with a light chain, is capable of forming an antibody that binds CSFIR.
  • an anti-CSFI R antibody heavy chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody heavy chain comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, and a heavy chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody heavy chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the heavy chain comprising the mutated CDR.
  • a heavy chain comprises a heavy chain constant region.
  • a heavy chain comprises a human heavy chain constant region.
  • the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
  • the human heavy chain constant region is an IgG constant region.
  • a heavy chain comprises a human igG4 heavy chain constant region.
  • the human IgG4 heavy chain constant region comprises an S241P mutation.
  • a heavy chain when effector function is desirable, comprises a human IgG 1 or IgG3 heavy chain constant region. In some embodiments, when effector function is less desirable, a heavy chain comprises a human IgG4 or lgG2 heavy chain constant region.
  • anti-CSFIR antibody light chain variable regions are provided.
  • an anti-CSFIR antibody light chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
  • An anti-CSFIR antibody light chain variable region comprises a light chain CDRl , FR2, CDR2, FR3, and CDR3.
  • an anti-CSFIR antibody light chain variable region further comprises a light chain FR1 and/or FR4.
  • Nonlimiting exemplary light chain variable regions include light chain variable regions having an amino acid sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
  • an anti-CSFIR antibody light chain variable region comprises a CDRl comprising a sequence selected from SEQ ID NOs: 18, 24 and 30.
  • an anti-CSFIR antibody light chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31.
  • an anti-CSFIR antibody light chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
  • Nonlimiting exemplary light chain variable regions include, but are not limited to, light chain variable regions comprising sets of CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
  • an anti-CSFIR antibody light chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the light chain, together with a heavy chain, is capable of forming an antibody that binds CSF1R.
  • an anti-CSFIR antibody light chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody light chain comprises at least one CDR selected from a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody light chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the light chain comprising the mutated CDR.
  • a light chain comprises a human light chain constant region.
  • a human light chain constant region is selected from a human ⁇ and a human ⁇ light chain constant region.
  • additional molecules that bind CSFIR are provided.
  • Such molecules include, but are not limited to, non-canonical scaffolds, such as anti-calins, adnectins, ankyrin repeats, etc. See, e.g., Hosse et al., Prot. Sci. 15: 14 (2006); Fiedler, M. and Skerra, A., "Non-Antibody Scaffolds," pp.467-499 in Handbook of Therapeutic Antibodies, Dubel, S., ed., Wiley- VCH, Weinheim, Germany, 2007.
  • an antibody having a structure described above binds to the CSFIR with a binding affinity (K D ) of less than 1 nM, blocks binding of CSFl and/or IL34 to CSFI R, and inhibits CSFIR phosphorylation induced by CSFl and/or IL34.
  • an anti-CSFIR antibody binds to the extracellular domain of CSFIR (CSF1R-ECD).
  • an anti- CSFIR antibody has a binding affinity (K D ) for CSFIR of less than 1 nM, less than 0.5 nM, less than 0.1 nM, or less than 0.05 nM.
  • an anti- CSFIR antibody has a K D of between 0.01 and 1 nM, between 0.01 and 0.5 nM, between 0.01 and 0.1 nM, between 0.01 and 0.05 nM, or between 0.02 and 0.05 nM.
  • an anti-CSFIR antibody blocks ligand binding to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of CSFl to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of IL34 to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of both CSFl and IL34 to CSFIR. In some embodiments, an antibody that blocks ligand binding binds to the extracellular domain of CSFIR. An antibody is considered to "block ligand binding to CSFI R" when it reduces the amount of detectable binding of a ligand to CSF1R by at least 50%, using the assay described in Example 7.
  • an antibody reduces the amount of detectable binding of a ligand to CSF1R by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 7.
  • the antibody is said to block ligand binding by at least 50%, at least 60%, at least 70%, etc.
  • an anti-CSFIR antibody inhibits ligand-induced CSF1 R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits CSF1 -induced CSF1R phosphoiylation. In some embodiments, an anti-CSFIR antibody inhibits IL34-induced CSF1R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits both CSF1 -induced and IL34-induced CSF1R phosphoiylation. An antibody is considered to "inhibit ligand-induced CSF1R phosphoiylation" when it reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 50%, using the assay described in Example 6.
  • an antibody reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 6.
  • the antibody is said to inhibit ligand-induced CSF1R phosphorylation by at least at least 50%, at least 60%, at least 70%, etc.
  • an antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34.
  • An antibody is considered to "inhibit monocyte proliferation and/or survival responses" when it reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 50%, using the assay described in Example 10.
  • an antibody reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 10.
  • the antibody is said to inhibit monocyte proliferation and/or survival responses by at least at least 50%, at least 60%, at least 70%, etc.
  • an anti-CSFIR antibody is conjugated to a label and/or a cytotoxic agent.
  • a label is a moiety that facilitates detection of the antibody and/or facilitates detection of a molecule to which the antibody binds.
  • Nonlimiting exemplary labels include, but are not limited to, radioisotopes, fluorescent groups, enzymatic groups, chemiluminescent groups, biotin, epitope tags, metal-binding tags, etc.
  • One skilled in the art can select a suitable label according to the intended application.
  • a cytotoxic agent is a moiety that reduces the proliferative capacity of one or more cells.
  • a cell has reduced proliferative capacity when the cell becomes less able to proliferate, for example, because the cell undergoes apoptosis or otherwise dies, the cell fails to proceed through the cell cycle and/or fails to divide, the cell differentiates, etc.
  • Nonlimiting exemplary cytotoxic agents include, but are not limited to, radioisotopes, toxins, and chemotherapeutic agents.
  • One skilled in the art can select a suitable cytotoxic according to the intended application.
  • a label and/or a cytotoxic agent is conjugated to an antibody using chemical methods in vitro.
  • Nonlimiting exemplary chemical methods of conjugation are known in the art, and include services, methods and/or reagents commercially available from, e.g., Thermo Scientific Life Science Research Produces (formerly Pierce; Rockford, IL), Prozyme (Hayward, CA), SACRI Antibody Services (Calgaiy, Canada), AbD Serotec (Raleigh, NC), etc.
  • the label and/or cytotoxic agent when a label and/or cytotoxic agent is a polypeptide, the label and/or cytotoxic agent can be expressed from the same expression vector with at least one antibody chain to produce a polypeptide comprising the label and/or cytotoxic agent fused to an antibody chain.
  • a suitable method for conjugating a label and/or cytotoxic agent to an antibody can be selected from the same expression vector with at least one antibody chain to produce a polypeptide comprising the label and/or cytotoxic agent fused to an antibody chain.
  • a leader sequence from a heterologous protein may be desirable.
  • a leader sequence is selected from SEQ ID NOs: 3 and 4, which are light chain and heavy chain leader sequences, respectively.
  • employing heterologous leader sequences may be advantageous in that a resulting mature polypeptide may remain unaltered as the leader sequence is removed in the ER during the secretion process.
  • the addition of a heterologous leader sequence may be required to express and secrete some proteins.
  • leader sequence sequences are described, e.g., in the online Leader sequence Database maintained by the Department of Biochemistry, National University of Singapore. See Choo et al, BMC Bioinformatics, 6: 249 (2005); and PCT Publication No. WO 2006/081430. Nucleic Acid Molecules Encoding Anti-CSFlR Antibodies
  • nucleic acid molecules comprising polynucleotides that encode one or more chains of anti-CSFlR antibodies are provided.
  • a nucleic acid molecule comprises a polynucleotide that encodes a heavy chain or a light chain of an anti-CSFlR antibody.
  • a nucleic acid molecule comprises both a polynucleotide that encodes a heavy chain and a polynucleotide that encodes a light chain, of an anti-CSFlR antibody.
  • a first nucleic acid molecule comprises a first polynucleotide that encodes a heavy chain and a second nucleic acid molecule comprises a second polynucleotide that encodes a light chain.
  • the heavy chain and the light chain are expressed from one nucleic acid molecule, or from two separate nucleic acid molecules, as two separate polypeptides.
  • a single polynucleotide encodes a single polypeptide comprising both a heavy chain and a light chain linked together.
  • a polynucleotide encoding a heavy chain or light chain of an anti-CSFlR antibody comprises a nucleotide sequence that encodes a leader sequence, which, when translated, is located at the N terminus of the heavy chain or light chain.
  • the leader sequence may be the native heavy or light chain leader sequence, or may be another heterologous leader sequence.
  • Nucleic acid molecules may be constructed using recombinant DNA techniques conventional in the art.
  • a nucleic acid molecule is an expression vector that is suitable for expression in a selected host cell.
  • Vectors comprising polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are provided. Vectors comprising
  • polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are also provided.
  • Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc.
  • a vector comprises a first polynucleotide sequence encoding a heavy chain and a second polynucleotide sequence encoding a light chain.
  • the heavy chain and light chain are expressed from the vector as two separate polypeptides.
  • the heavy chain and light chain are expressed as part of a single polypeptide, such as, for example, when the antibody is an scFv.
  • a first vector comprises a polynucleotide that encodes a heavy chain and a second vector comprises a polynucleotide that encodes a light chain.
  • the first vector and second vector are transfected into host cells in similar amounts (such as similar molar amounts or similar mass amounts).
  • a mole- or mass-ratio of between 5: 1 and 1 :5 of the first vector and the second vector is transfected into host cells.
  • a mass ratio of between 1 : 1 and 1 :5 for the vector encoding the heavy chain and the vector encoding the light chain is used.
  • a mass ratio of 1 :2 for the vector encoding the heavy chain and the vector encoding the light chain is used.
  • a vector is selected that is optimized for expression of polypeptides in CHO or CHO-derived cells, or in NSO cells.
  • Exemplary such vectors are described, e.g., in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004).
  • a vector is chosen for in vivo expression of anti- CSF1R heavy chains and/or anti-CSFIR light chains in animals, including humans.
  • expression of the polypeptide is under the control of a promoter that functions in a tissue-specific manner.
  • tissue-specific promoters are described, e.g., in PCT Publication No. WO 2006/076288.
  • anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in prokaryotic cells, such as bacterial cells; or in eukaiyotic cells, such as fungal cells (such as yeast), plant cells, insect cells, and mammalian cells. Such expression may be earned out, for example, according to procedures known in the art.
  • eukaiyotic cells that may be used to express polypeptides include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S and DG44 cells;
  • anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in yeast. See, e.g., U.S. Publication No. US 2006/0270045 Al .
  • a particular eukaiyotic host cell is selected based on its ability to make desired post-translational
  • CHO cells produce polypeptides that have a higher level of sialylation than the same polypeptide produced in 293 cells.
  • Introduction of one or more nucleic acids into a desired host cell may be accomplished by any method, including but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Nonlimiting exemplaiy methods are described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3 ld ed. Cold Spring Harbor Laboratory Press (2001). Nucleic acids may be transiently or stably transfected in the desired host cells, according to any suitable method.
  • one or more polypeptides may be produced in vivo in an animal that has been engineered or transfected with one or more nucleic acid molecules encoding the polypeptides, according to any suitable method.
  • Anti-CSFlR antibodies may be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include the CSF1R ECD and ligands that bind antibody constant regions. For example, a Protein A, Protein G, Protein A/G, or an antibody affinity column may be used to bind the constant region and to purify an anti-CSFlR antibody. Hydrophobic interactive clnOmatography, for example, a butyl or phenyl column, may also suitable for purifying some
  • polypeptides Many methods of purifying polypeptides are known in the art.
  • an anti-CSFlR antibody is produced in a cell-free system.
  • Nonlimiting exemplary cell-free systems are described, e.g., in
  • Antibodies of the invention, and compositions comprising antibodies of the invention are provided for use in methods of treatment for humans or animals. Methods of treating disease comprising administering anti-CSRIR antibodies are also provided. Nonlimiting exemplaiy diseases that can be treated with anti-CSFlR antibodies include, but are not limited to, RA, MS, cancer, metastasis-induced osteolytic bone loss, osteolytic disorders, and hypercalcemia-induced bone loss. [0166] In some embodiments, methods of treating inflammatory conditions comprising administering an anti-CSFIR antibody are provided. In some embodiments,
  • an inflammatory condition is selected from psoriasis, SLE (lupus), COPD, atopic demiatitis, and atherosclerosis, macrophage activation syndrome, and histiocytosis X.
  • methods of treating an inflammatory condition comprising administering an anti-CSFIR antibody are provided, wherein the inflammatory condition is selected from: proliferative vascular disease, acute respiratory distress syndrome, cytokine -mediated toxicity, interleukin-2 toxicity, appendicitis, peptic, gastric and duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatos
  • methods of treating cancer comprising administering an anti-CSFIR antibody.
  • the cancer is a CSF1 -secreting cancer.
  • the cancer is one or more cancers selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, and ovarian cancer.
  • an anti-CSFI R antibody is useful for treating one or more cancers selected from lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
  • anti-CSFIR antibodies may be administered in vivo by various routes, including, but not limited to, oral, intra-arterial, parenteral, intranasal, intramuscular, intracardiac, intraventricular, intratracheal, buccal, rectal, intraperitoneal, intradermal, topical, transdermal, and intrathecal, or otherwise by implantation or inhalation.
  • the subject compositions may be formulated into preparations in solid, semi-solid, liquid, or gaseous forms; including, but not limited to, tablets, capsules, powders, granules, ointments, solutions, suppositories, enemas, injections, inhalants, and aerosols.
  • a nucleic acid molecule encoding an anti-CSFI R antibody may be coated onto gold microparticles and delivered intradermally by a particle bombardment device, or "gene gun,” as described in the literature (see, e.g., Tang et al., Nature 356: 152-154 (1992)).
  • a particle bombardment device or "gene gun”
  • the appropriate formulation and route of administration may be selected according to the intended application.
  • compositions comprising anti-CSFIR antibodies are provided in formulations with a wide variety of pharmaceutically acceptable earners (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Phis, 20th ed. (2003); Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3 rd ed., Pharmaceutical Press (2000)).
  • Various pharmaceutically acceptable earners which include vehicles, adjuvants, and diluents, are available.
  • Non-limiting exemplary earners include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
  • compositions comprising anti-CSFIR antibodies may be formulated for injection, including subcutaneous administration, by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preserva tives.
  • the compositions may be formulated for inhalation, for example, using pressurized acceptable propellants such as
  • compositions may also be formulated, in various embodiments, into sustained release microcapsules, such as with biodegradable or non-biodegradable polymers.
  • a non-limiting exemplary biodegradable formulation includes poly lactic acid-glycolic acid polymer.
  • a non- limiting exemplary non-biodegradable formulation includes a polyglycerin fatty acid ester. Certain methods of making such fomiulations are described, for example, in EP 1 125 584 Al .
  • compositions comprising an anti-CSFI R antibody, with or without one or more additional agents.
  • a unit dosage is supplied in single-use prefilled syringe for injection.
  • the composition contained in the unit dosage may comprise saline, sucrose, or the like; a buffer, such as phosphate, or the like; and/or be formulated within a stable and effective pH range.
  • the composition may be provided as a lyophilized powder that may be reconstituted upon addition of an appropriate liquid, for example, sterile water.
  • the composition comprises one or more substances that inhibit protein aggregation, including, but not limited to, sucrose and arginine.
  • a composition of the invention comprises heparin and/or a proteoglycan.
  • compositions are administered in an amount effective for treatment or prophylaxis of the specific indication.
  • the therapeutically effective amount is typically dependent on the weight of the subject being treated, his or her physical or health condition, the extensiveness of the condition to be treated, or the age of the subject being treated.
  • anti-CSFIR antibodies may be administered in an amount in the range of about 10 ⁇ g/kg body weight to about 100 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 50 fig/kg body weight to about 5 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 100 g kg body weight to about 10 mg/kg body weight per dose.
  • anti-CSFIR antibodies may be administered in an amount in the range of about 100 ng/kg body weight to about 20 mg/kg body weight per dose. In some embodiments, anti-CSFI R antibodies may be administered in an amount in the range of about 0.5 mg/kg body weight to about 20 mg/kg body weight per dose.
  • the anti-CSFIR antibody compositions may be administered as needed to subjects. Detemiination of the frequency of administration may be made by persons skilled in the art, such as an attending physician based on considerations of the condition being treated, age of the subject being treated, severity of the condition being treated, general state of health of the subject being treated and the like.
  • an effective dose of an anti-CSFIR antibody is administered to a subject one or more times.
  • an effective dose of an anti- CSFIR antibody is administered to the subject once a month, more than once a month, such as, for example, eveiy two months or eveiy three months.
  • an effective dose of an anti-CSFIR antibody is administered less than once a month, such as, for example, eveiy two weeks or eveiy week.
  • An effective dose of an anti-CSFIR antibody is administered to the subject at least once.
  • the effective dose of an anti-CSFIR antibody may be administered multiple times, including for periods of at least a month, at least six months, or at least a year.
  • Anti-CSFIR antibodies may be administered alone or with other modes of treatment. They may be provided before, substantially contemporaneous with, or after other modes of treatment, for example, surgery, chemotherapy, radiation therapy, or the administration of a biologic, such as another therapeutic antibody.
  • anti-CSFI R antibodies may be administered with other therapeutic agents, for example, methotrexate, anti-TNF agents such as
  • glucocorticoids such as prednisone
  • anti-CSFIR antibodies may be administered with other therapeutic agents, for example, interferon alpha; interferon beta; prednisone; anti-alpha4 integrin antibodies such as Tysabri; anti-CD20 antibodies such as Rituxan; FTY720 (Fingolimod); and Cladribine (Leustatin).
  • Example 1 Selection of Fabs that bind CSFIR extracellular domain (ECD)
  • mice were immunized with a human CSFIR extracellular domain Fc fusion, hCSFI R ECD.506-Fc (SEQ ID NO: 6). Spleens from immunized mice were isolated, and a Fab phage display library was created from the spenocytes. Fab- expressing phage were selected for binding to human CSFIR ECD. Fabs from positive-binding phage were expressed and purified from bacteria. A total of 1056 Fab clones were selected for further analysis.
  • Fabs were screened for the ability to bind human CSFIR ECD, block binding of human CSFl to human CSFIR ECD, and block binding of human IL34 to human CSFI R ECD. Sequence analysis and clusertering of the Fabs that were selected from that screen was then performed and certain unique Fabs were selected.
  • the unique Fabs were further analyzed for the ability to bind human CSFIR ECD, the ability to bind cynomolgus CSFIR ECD, and the ability to bind mouse CSFIR ECD.
  • the Fabs were also analyzed for the ability to block human CSFl binding to human CSFIR ECD and the ability to block human IL34 binding to human CSFIR ECD, and the ability to inliibit ligand-induced CSFIR phosphorylation in the presence of CSFl or IL34. (Data not shown.)
  • Example 2 Reformatting of anti-CSFIR Fabs to make chimeric antibodies
  • Fab VH regions cloned into and expressed from vector pTT5 (Biotechnology Research Institute, Montreal, Canada; and National Research Research Council of Canada, Ottawa, Canada) modified to contain a mouse IgH leader sequence (SEQ ID NO: 4) and a human IgG4 heavy chain constant region with the S241P mutation (SEQ ID NO: 94).
  • Fab VL regions were cloned into and expressed from vector pTT5 modified to contain a mouse IgK leader sequence (SEQ ID NO: 3) and a human IgK light chain constant region (SEQ ID NO: 95). Fab V regions were inserted in such a way as not to introduce non-antibody derived amino acid sequences into the final proteins.
  • the chimeric antibodies were transiently expressed and purified substantially as described below in Example 5.
  • the 1 1 chimeric antibodies were assayed for binding to human, cynoinolgus, and mouse CSFI R ECD.
  • the chimeric antibodies were also assayed for the ability to block binding of human CSF1 to human CSF ] R ECD, the ability to block binding of human IL34 to human CSFIR ECD, the ability to block binding of human CSF1 to cynomolgus CSFIR ECD, and the ability to inhibit ligand-induced CSFI R phosphorylation in the presence of CSF1 or IL34.
  • the chimeric antibodies were further assayed for binding to CSFIR on the surface of cells.
  • the chimeric antibodies were assayed to confirm that they do not induce CSFI R phosphorylation in the absence of ligand. (Data not shown.)
  • chimeric anti-CSFIR antibodies 0301 , 0302, and 031 1 were selected for humanization.
  • the antibodies were humanized by changing certain amino acid residues in the framework regions of the heavy and light chain variable regions.
  • the criteria used for humanization were as described previously, e.g., in U.S. Publication No. US 2009/0136500.
  • cAb 0301 three humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of six humanized antibodies, Abl to Ab6.
  • cAb 0302 two humanized heavy chain variable regions and three humanized light chain variable regions were designed, for a total of six humanized antibodies, Ab7 to Abl 2.
  • cAb 0311 two humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of four humanized antibodies, Abl 3 to Abl 6.
  • Table 8 shows the full sequences for the humanized heavy chains and humanized light chains of antibodies Abl to Abl 6. The name and SEQ ID NOs of the humanized heavy chain and humanized light chain of each of those antibodies is shown in Table 2.
  • Example 5 Humanized auti-CSFlR antibodies bind to human and cynomolgus CSF1R ECD, but not to mouse CSF1R ECD
  • the 16 humanized antibodies were transiently expressed in CHO cells, as follows. CHO-3E7 cells were co-transfected with individual heavy and light chain expression plasmids at a mass ratio of 1 heavy chain plasmid to 2 light chain plasmids using polyethyleneinimine (PEI) at a DNA:PEI ratio of 1 :5. Total DNA used per transfection was 1.5 ⁇ g/ml of cells.
  • PEI polyethyleneinimine
  • Humanized antibodies were purified from transfected cell supematants using HiTrap Protein A HP columns (GE Healthcare) followed by further purification using Phenyl HP columns (GE Healthcare).
  • Antibody containing supematants were loaded onto HiTrap Protein A HP columns pre-equilibrated with PBS/0.5M NaCl.
  • Antibody loaded columns were washed with 10 column volumes PBS/0.5M NaCl, and eluted with a mixed linear-step gradient of 0.1 M Glycine, pH 2.7/ 0.5 M NaCl directly into 100 ul of 1M Tris buffer, pH 8.0.
  • Antibody containing eluates were dialyzed against PBS, after which 2.4 M (NH 4 ) 2 S0 4 (Sigma) was added to achieve a conductivity equal to that of 1 OmM Potassium Phosphate pH7.0/l .2 M (NH 4 ) 2 S0 4 .
  • Antibodies were then loaded on 1 ml Phenyl HP columns (GE Healthcare) pre- equilibrated with lOmM Potassium Phosphate pH7.0/1.2 M (NH 4 ) 2 S0 4 .
  • Antibody loaded columns were washed with 15 column volumes lOmM Potassium Phosphate pH7.0/l .2 M (NH 4 ) 2 S0 , and eluted with a 20 column volume gradient of 10 niM Potassium Phosphate, pH 7.0.
  • Antibody containing fractions were pooled and dialyzed against PBS.
  • humanized antibodies along with their parental chimeric antibodies (cAbs), were assayed for binding to human, cynomolgus, and mouse CSF1R ECD, as follows.
  • cynomolgus CSFIR ECD was determined as described above for human CSFIR, except the wells of the clear-bottom ELISA plates were coated overnight with 2 ⁇ g/ml recombinant cynoCSFIR ECD-Fc (FivePrime Therapeutics, SEQ ID NO: 8, but without the 19 amino acid leader sequence).
  • Table 3 shows the EC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software) for each humanized antibody binding to human CSFIR ECD and cynomolgus CSFIR ECD. Because none of the chimeric antibodies detectably bound to mouse CSFIR ECD, an EC50 could not be calculated from that data. Table 3 also includes the calculated EC50s for the parental chimeric antibodies.
  • Example 6 Humanized anti-CSFIR antibodies inhibit ligaiid-induced CSFIR phosphorylation
  • CSFIR is phosphorylated in the presence of ligands CSFl or IL34.
  • CSFIR SEQ ID NO: 2
  • CSFIR SEQ ID NO: 2
  • CSF1R (SEQ ID NO: 2)-transfected CHO cells were incubated with 0.002 to 8 ⁇ ig/ml of each humanized antibody or a parental chimeric antibody for 60 min on ice, after which 3.3 nM of human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was added to the cells. The cells were incubated for 3 minutes at 37°C, and then lysed by addition of 1/1 Ox volume of lOx cell lysis buffer (Cell Signaling
  • the amount of phosphorylated CSF1R in the cell lysates was quantified using a human phospho-M-CSF R ELISA kit (R&D Systems) according to the manufacturer's instructions.
  • Example 7 Humanized anti-CSFIR antibodies block human CSF1 and human IL34 binding to human and cynomolgous CSF1R
  • the humanized antibodies along with the parental chimeric antibodies (cAbs), were tested for their ability to block human CSF1 binding to human and cynomolgus CSF1R ECD, as follows.
  • Recombinant Human CSF1 (M-CSF; R&D Systems) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies).
  • M-CSF Recombinant Human CSF1
  • NH2-Biotin Labeling Kit Dojindo Molecular Technologies
  • One hundred ⁇ of 1 ⁇ g/ml biotinylated CSF1 in PBST/0.1 % BSA was added to the wells of Reacti- Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions.
  • the humanized antibodies were tested for their ability to block human IL34 binding to human CSF1R ECD.
  • the blocking activity of each humanized antibody was determined as described above for blocking of CSF1 , except recombinant human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies), and then 100 ⁇ of 1 ⁇ g ml biotinylated recombinant IL34 in PBST/0.1 % BSA was added to the wells of Reacti-Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions.
  • Table 4 shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for inhibition of ligand-induced CSFI R phosphoiylation by each humanized antibody.
  • Table 4 also shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for blocking of ligand binding to CSF I R ECD by each humanized antibody.
  • Table 4 shows the number of amino acids in the framework regions of the light and heavy chain of each humanized antibody that were back-mutated to the corresponding mouse amino acid residue.
  • humanized antibody h0301 LlHl has one amino acid in a light chain framework region that was back-mutated to the mouse amino acid, and one amino acid in the heavy chain framework regions that was back- mutated to the mouse amino acid.
  • the back-mutated amino acid in the light chain framework is at position 1 in framework 1
  • the back- mutated amino acid in the heavy chain is at position 71 in framework 3 according to Kabat numbering (see Figure I B).
  • the k a , 13 ⁇ 4, and 3 ⁇ 4 for binding to human CSF1R ECD was determined for each of the humanized antibodies as follows.
  • Binding kinetics of anti-CSFIR humanized antibodies to CSF1R ECD was determined using Biacore T100 Surface Plasmon Resononance (SPR) (GE Healthcare Life Sciences, Piscataway, NY). Each of the humanized anti-CSFIR antibodies was captured on a CM5 sensor chip immobilized with anti-Human IgG antibody using the Human antibody capture kit (GE Healthcare Life Sciences, Piscataway, NY) at 150RU so that the Rmax value for hCSFIR ECD.506 (SEQ ID NO: 5) binding was 100RU. Rmax values of less than 150RU are recommended for accurately determining kinetic values.
  • SPR Surface Plasmon Resononance
  • hCSFIR ECD.506 was injected at six concentrations (90 nM, 30 nM, 10 nM, 3.33 nM, 1.1 1 nM, and 0 nM) for 2 minutes and dissociation was observed for 5 minutes to detemiine humanized antibody/hCSFIR ECD binding kinetic parameters.
  • the association constant, dissociation constant, affinity, and binding capacity of each of the Fabs for human CSF1 R ECD was calculated using the Biacore T100 Evaluation software package using the 1 : 1 binding model.
  • huAb 0302-L0H2 3.40 x 106 1.79 x 10-03 0.53 huAb 0302-Ll H2 2.71 x 106 1.53 x 10-03 0.56 huAb 0302-L2H2 1.84 x 106 8.40 x 10-04 0.46 huAb 031 1 -L0H 1 1.22 x 106 5.40 x 10-04 0.44 huAb 031 1 -LI HI 1.32 x 106 6.64 x 10-04 0.50 huAb 031 1 -L0H2 1.34 x 106 4.73 x 10-04 0.35 huAb 031 1 -LlH2 1.51 x 106 6.09 x 10-04 0.40
  • Example 10 Humanized anti-CSFIR antibodies block ligand-induced proliferation/survival responses of primary human monocytes
  • Humanized antibodies 0301-L0H0, 0301-LlHO, and 0311-LOHl were tested for their ability to block ligand-induced monocyte proliferation/survival responses as follows.
  • Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor blood by centrifugation onto a Ficoll-Paque cushion (GE).
  • Peripheral blood monocytes were subsequently isoated from the recovered PBMC fraction by centrifugation onto a 48.5% PercollTM cushion (GE Healthcare Bio-Sciences). After recovery from the PercollTM cushion, the purified peripheral blood monocytes were stimuated with 162 pM recombinant human CSF1 or 1.6 nM recombinant human IL34 (both from R&D Systems) in the presence or absence of serial dilutions of humanised antibody 0301 -LOHO, humanised antibody 0301 -LI HO, or humanised antibody 0311-LOHl .
  • Example 11 Humanized anti-CSFlR antibodies do not directly stimulate primary human monocyte proliferation or survival responses
  • Humanized antibodies 0301 -L0H0, 0301 -LI HO, and 031 1 -L0H1 were tested for their ability to directly stimulate primary monocyte proliferation and/or survival, as follows.
  • Human peripheral blood monocytes were isolated as described in Example 10. Serial dilutions of humanised antibody 0301-LOHO, humanised antibody 0301-L1H0, or humanised antibody 031 1 -LOHl were added to the monocytes in the absence of stimulation either by exogenous CSF1 or by exogenous IL34. After incubation at 37°C for 48 hours, relative ATP content of each individual cuture was assessed using CellTiter Glo® reagent (Promega) as in Example 10. The experiment was earned out on peripheral blood monocytes from three different donors.
  • Table 8 provides certain sequences discussed herein. All polypeptide and antibody sequences are shown without leader sequences, unless otherwise indicated.
  • NLKVMVEAYP GLQGFNWTYL GPFSDHQPEP KLANATTKDT YRHTFTLSLP
  • RLKPSEAGRY SFLARNPGGW RALTFELTLR YPPEVSVIWT FINGSGTLLC AASGYPQPNV TWLQCSGHTD RCDEAQVLQV WDDPYPEVLS QEPFHKVTVQ SLLTVETLEH NQTYECRAHN SVGSGSWAFI PISAGAH
  • DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
  • EIQLQQSGPE LVRPGASVKM SCKASGYTFS DFNIHWVKQK PGQGLEWIGY INPYTDVTVY NEKFKGKATL TSDRSSSTAY MDLSSLTSED SAVYYCASYF DGTFDYALDY WGQGTSITVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSW TVPSSSLGTK
  • EIQLQQSGPD LMKPGASVKM SCKASGYIFT DYNMHWVKQN QGKSLEWMGE INPNNGVWY NQKFKGTTTL TVDKSSSTAY MDLHSLTSED SAVYYCTRAL YHSNFGWYFD SWGKGTTLTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
  • DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSHMNWY QQKPGQPPKL LIYTASNLES GIPARFSGSG SGADFTLTIH PVEEEDAATY YCQQGNEDPW
  • DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
  • DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
  • DTLMISRTPE VTCWVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)

Abstract

Antibodies that bind CSF1 R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Description

ANTIBODIES THAT BIND CSFIR
[001] This application claims the benefit of U.S. Provisional Application No. 61 /331 ,177, filed May 4, 2010, which is incorporated by reference herein in its entirety for any purpose.
TECHNICAL FIELD
[002] Antibodies that bind CSF IR are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSFI R are also provided. In addition, antibodies, heavy chains, and light chains comprising one or more particular complementarity determining regions (CDRs) are provided.
Polynucleotides encoding antibodies to CSFIR are provided. Polynucleotides encoding antibody heavy chains or lights chains are also provided. Methods of treatment using antibodies to CSF IR are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
BACKGROUND
[003] Colony stimulating factor 1 receptor (referred to herein as CSFIR; also referred to in the art as FMS, FIM2, C-FMS, and CD115) is a single-pass
transmembrane receptor with an N-terminal extracellular domain (ECD) and a C- terminal intracellular domain with tyrosine kinase activity. Ligand binding of CSF1 or the interleukin 34 ligand (referred to herein as IL34; Lin et al, Science 320: 807-11 (2008)) to CSFIR leads to receptor dimerization, upregulation of CSFIR protein tyrosine kinase activity, phosphorylation of CSFIR tyrosine residues, and
downstream signaling events. Both CSF1 and IL34 stimulate monocyte survival, proliferation, and differentiation into macrophages.
[004] Many tumor cells have been found to secrete CSF1 , which activates monocyte/macrophage cells through CSFIR. The level of CSF1 in tumors has been shown to correlate with the level of tumor-associated macrophages (TAMs) in the tumor. Higher levels of TAMs have been found to correlate with poorer patient prognoses. In addition, CSF1 has been found to promote tumor growth and progression to metastasis in, for example, human breast cancer xenografts in mice. See, e.g., Paulus et al., Cancer Res. 66: 4349-56 (2006). Further, CSFIR appears to play a role in osteolytic bone destruction in bone metastasis, as a small molecule inhibitor of receptor tyrosine kinase activity suppresses that destruction. See, e.g., Ohno et al., Mol. Cancer Ther. 5: 2634-43 (2006). [005] CSF1 and its receptor have also been found to be involved in various inflammatory and autoimmune diseases. See, e.g., Hamilton, Nat. Rev. 8: 533-44 (2008). For example, synovial endothelial cells from joints afflicted with rheumatoid arthritis have been found to produce CSF1 , suggesting a role for CSF1 and its receptor in the disease. Blocking CSFIR activity with an antibody results in positive clinical effects in mouse models of arthritis, including a reduction in the destmction of bone and cartilage and a reduction in macrophage numbers. See, e.g., Kitaura et al., J. Clin. Invest. 1 15: 3418-3427 (2005).
[006] Mature differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts contribute to pathology of various diseases such as rheumatoid arthritis, multiple sclerosis and diseases of bone loss. Differentiated myeloid lineage cells are derived from peripheral blood monocyte intermediates. CSFI R stimulation contributes to development of monocytes from bone marrow precursors, to monocyte proliferation and sui'vival, and to differentiation of peripheral blood monocytes into differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts. CSFIR stimulation thus contributes to proliferation, sui'vival, activation, and maturation of differentiated myeloid lineage cells, and in the pathologic setting, CSFI R stimulation contributes to the ability of differentiated myeloid lineage cells to mediate disease pathology.
[007] Additional antagonists of CSFIR signaling would therefore be useful in the treatment of various CSFlR-related diseases, such as cancer, inflammatory conditions, and autoimmune diseases.
SUMMARY
[008] The present inventors have invented a new set of antibodies, including humanized antibodies, directed against human CSFI R extracellular domain (CSFIR ECD). A Fab phage display library was made from spleens of mice that were immunized with a human CSFIR ECD-Fc fusion protein. 1056 phage clones expressing Fabs that bind to CSF-1R ECD-Fc were isolated through panning of this library. When the 1056 Fabs were expressed as purified protein, 668 were found to bind to CSFIR ECD. Of those 668 binding Fabs, only 121 Fabs blocked binding of CSF1 and/or IL34 to CSFI R. Only 33 of those Fabs were found to block binding of both CSF1 and IL34 to CSFIR. Upon sequencing, the 33 Fabs represented 19 unique sets of sequences. Eleven Fabs with subnanomolar affinity for human CSFIR ECD were chosen to make chimeric antibodies for further study. Based on the human and cynomolgus monkey CSFIR binding affinities, blocking of CSFl and IL34 binding to CSFIR, and inhibition of ligand-induced phorphorylation of CSFIR, three chimeric antibodies were selected for humanization, and sixteen humanized antibodies were made based on those three chimeric antibodies.
[009] Fourteen of the sixteen humanized antibodies retained subnanomolar binding affinities for human CSFIR ECD. See, e.g., Table 5. These humanized antibodies block binding of both ligands CSFl and IL34 to human CSFIR, and many also block binding of both CSFl and IL34 to cynomolgus monkey CSFIR. See, e.g., Table 4.
[010] For therapeutic drug development, it is beneficial to have antibodies that bind to both human and cynomolgus monkey antigens with similar affinity. The three chimeric antibodies chosen for humanization were selected in part because they had similar binding affinities for human and cynomolgus CSFIR ECD. Most of the humanized versions of one of the chimeric antibodies, 0302, however, lost significant binding affinity for cynomolgus monkey CSFIR ECD upon humanization, although they retained strong human CSFI R ECD binding affinity. See, e.g.. Table 3.
Humanized versions of 0301 and 031 1 retained similarly strong binding to both human and cynomolgus monkey CSFIR ECD, with binding affinity differences for the two species of less than about 2-fold.
[01 1 ] Based on CSF 1 R binding affinities, ligand inhibition, and the potential for immunogenicity, three humanized antibodies were selected for additional studies. The three humanized antibodies were derived from the two chimeric antibodies that did not significantly lose cynomolgus monkey CSFIR binding affinity upon humanization. Those three humanized antibodies inhibit ligand-induced
phosphorylation of human CSFIR, and also block ligand-induced proliferation and survival responses in primary human monocytes. See, e.g., Tables 6 and 7, and Figures 10 and 1 1. Thus, these antibodies are useful for treating diseases involving, for example, ligand-induced proliferation and survival responses in primary human monocytes.
[012] Blocking CSFlR-induced responses with an anti-CSFIR antibody should inhibit proliferation, survival, activation, maturation of differentiated myeloid lineage cells and attenuate their ability to mediate disease pathology. In addition, blocking CSFlR-induced responses with an anti-CSFI R antibody should inhibit differentiation of peripheral blood monocyte intermediates into differentiated myeloid lineage cells, decreasing the number of pathology-mediating differentiated myeloid lineage cells.
[013] Accordingly, the humanized anti-CSFIR antibodies described herein can be used to treat chronic diseases with extant symptoms by inhibiting the ability of differentiated myeloid lineage cells to mediate disease pathology. The humanized antibodies can also be used to treat chronic diseases that are relapsing and remitting in nature by inhibiting the development of new pathology-mediating myeloid lineage cells differentiated from peripheral blood monocytes during the remitting phase of the disease, thus attenuating the number of and new formation of the pathology-mediating cells.
[014] In some embodiments, an isolated antibody comprising a heavy chain and a light chain is provided, wherein the antibody binds to CSF1R. In some embodiments, the heavy chain and/or light chain have the following structure.
[015] In some embodiments, the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45. In some embodiments, the light chain comprises a sequence that is at least 90%o, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52. In some embodiments, the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, and the light chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
[016] In some embodiments, the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (e) SEQ ID NOs: 27, 28, and 29. In some embodiments, the LC CDR1, LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
[017] In some embodiments, the heavy chain comprises an HC CDR1 , HC CDR2, and HC CDR3, wherein the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (c) SEQ ID NOs: 27, 28, and 29; and the light chain comprises an LC CDR1 , LC CDR2, and LC CDR3, wherein the LC CDR1 , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
[018] In some embodiments, an isolated antibody is provided, wherein the antibody comprises a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 9 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 10;
(b) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 1 1 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 12;
(c) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 13 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 14;
(d) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 46;
(e) a heavy chain comprising a sequence that is at least 95%0, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 46;
(f) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 46;
(g) a heavy chain comprising a sequence that is at least 95%>, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 47;
(h) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 47;
(i) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 47; and (j) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 48; (k) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 49; (1) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 50; (m) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 48; (n) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 49; (o) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 50; (p) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 44 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 51 ; (q) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 44 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 52; (r) a heavy chain comprising a sequence that is at least 95%o, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 45 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 51 ; or (s) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 45 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 52.
[019] In some embodiments, an antibody is provided, wherein the antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO: 15, an HC CDR2 having the sequence of SEQ ID NO: 16, and an HC CDR3 having the sequence of SEQ ID NO: 17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 18, a LC CDR2 having the sequence of SEQ ID NO: 19, and a LC CDR3 having the sequence of SEQ ID NO: 20; (b) a heavy chain comprising a heavy chain (HC) CDRl having the sequence of SEQ ID NO: 21 , an HC CDR2 having the sequence of SEQ ID NO: 22, and an HC CDR3 having the sequence of SEQ ID NO: 23, and a light chain comprising a light chain (LC) CDRl having the sequence of SEQ ID NO: 24, a LC CDR2 having the sequence of SEQ ID NO: 25, and a LC CDR3 havmg the sequence of SEQ ID NO: 26; or (c) a heavy chain comprising a heavy chain (HC) CDRl having the sequence of SEQ ID NO: 27, an HC CDR2 having the sequence of SEQ ID NO: 28, and an HC CDR3 having the sequence of SEQ ID NO: 29, and a light chain comprising a light chain (LC) CDRl having the sequence of SEQ ID NO: 30, a LC CDR2 having the sequence of SEQ ID NO: 31 , and a LC CDR3 having the sequence of SEQ ID NO: 32.
[020] In some embodiments, an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 60; (b) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 61 ; or (c) a heavy chain comprising a sequence of SEQ ID NO: 58 and a light chain comprising a sequence of SEQ ID NO: 65. In some embodiments, an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 60; (b) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 61 ; or (c) a heavy chain consisting of the sequence of SEQ ID NO: 58 and a light chain consisting of the sequence of SEQ ID NO: 65.
[021] In some embodiments, an antibody is a humanized antibody. In some embodiments, an antibody is selected from a Fab, an Fv, an scFv, a Fab\ and a (Fab')2. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is selected from an IgA, an IgG, and an IgD. In some embodiments, an antibody is an IgG. In some embodiments, an antibody is an IgG4. In some embodiments, an antibody is an IgG4 comprising an S241P mutation in at least one IgG4 heavy chain constant region.
[022] In some embodiments, an antibody binds to human CSF1R and/or binds to cynomolgus CSF1R. In some embodiments, an antibody blocks ligand binding to CSF1 R. In some embodiments, an antibody blocks binding of CSF1 and/or IL34 to CSF1 R. In some embodiments, an antibody inhibits ligand-induced CSF1R phosphorylation. In some embodiments, an antibody inhibits CSF1- and/or IL34-induced CSF1R phosphoiylation. In some embodiments, an antibody binds to human CSF1R with an affinity (KD) of less than 1 nM. In some embodiments, antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 01- IL34.
[023] In some embodiments, a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
[024] In some embodiments, an isolated nucleic acid is provided, wherein the isolated nucleic acid comprises a polynucleotide sequence that encodes a heavy chain described above. In some embodiments, an isolated nucleic acid encodes a light chain described above. In some embodiments, an isolated nucleic acid encodes a heavy chain described above and a light chain described above. In some embodiments, a composition is provided, wherein the composition comprises a first nucleic acid that comprises a polynucleotide sequence that encodes a heavy chain described above, and a second nucleic acid that comprises a polynucleotide sequence that encodes a light chain described above. In some embodiments, a host cell comprising a nucleic acid or a composition described above is provided. In some embodiments, a host cell is a eukaryotic host cell. In some embodiments, a host cell is a mammalian host cell. In some embodiments, a host cell is selected from a CHO cell, a 293 cell, an NSO cell, and a PER.C6 cell. In some embodiments, a host cell is a 293-6E cell or a DG44 cell.
[025] In some embodiments, methods of treating disease comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided. In some embodiments, a method of treating multiple sclerosis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided. In some embodiments, a method of treating rheumatoid arthritis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided. In some embodiments, a method of treating osteolytic bone loss comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided. In some embodiments, the osteolytic bone loss is selected from osteoporosis, metastasis-induced osteolytic bone loss, and rheumatoid arthritis- induced bone loss. In some embodiments, a method of treating cancer comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided. In some embodiments, the cancer is selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
[026] In some embodiments, a method of treating an inflammatory condition comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSFIR is provided.
[027] In some embodiments, antibodies that bind CSF IR and compositions comprising antibodies that bind CSFIR are provided for use in methods of treatment of human or animals. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating rheumatoid arthritis in a human or animal. In some embodiments, antibodies that bind CSFI R and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating multiple sclerosis in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating cancer in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating an inflammatory condition in a human or animal.
BRIEF DESCRIPTION OF THE FIGURES
[028] FIG. 1 shows an alignment of the humanized heavy chain variable regions for each of humanized antibodies Abl to Abl 6, as discussed in Example 4. Boxed residues are amino acids in the human acceptor sequence that were changed back to the corresponding mouse residue.
[029] FIG. 2 shows an alignment of the humanized light chain variable regions for each of humanized antibodies Abl to Ab 16, as discussed in Example 4 Boxed amino acids are residues in the human acceptor sequence that were changed back to the corresponding mouse residue.
[030] FIG. 3 shows binding curves for certain humanized antibodies binding to human CSFIR ECD, as described in Example 5. Figure 3 A shows binding curves for parental chimeric antibodies (cAb) 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (hO3Ol-LOH0, h0301-L0Hl, h0301-L0H2, h0301-LlH0, h0301 -LlHl , and Ii0301-L1H2, respectively). Figure 3B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , Ii0302-L1 H1 , h0302-L2Hl , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively). Figure 3C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1 .2, 031 1.3 , and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1-L1 H2, respectively).
[031 ] FIG. 4 shows binding curves for certain humanized antibodies binding to cynomolgus CSF1 R ECD, as described in Example 5. Figure 4A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301-L0H2, h0301 - L1H0, h0301 -LlH l , and h0301 -Ll H2, respectively). Figure 4B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively). Figure 4C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2,
031 1.3, and 031 1.4 (h031 1 -LOHl , h0311-LlHl , h031 1 -L0H2, and h031 1 -L1H2, respectively).
[032] FIG. 5 shows binding curves for certain humanized antibodies binding to mouse CSF1R ECD, as described in Example 5. Figure 5 A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3,
0301 .4, 0301.5, and 0301.6 (h0301 -L0H0, h0301 -L0Hl , h0301 -L0H2, h0301-LlH0, Ii0301-L1H1, and h0301 -LlH2, respectively). Figure 5B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4,
0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302-LOH2, h0302- L1H2, and h0302-L2H2, respectively). Figure 5C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 0311.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1 -LI H2, respectively).
[033] FIG. 6 shows inhibition of CSF1 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6. Figure 6 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and Ii0301 -L1 H2, respectively). Figure 6B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , h0302-L! Hl , h0302-L2H l , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively). Figure 6C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1 .1 , 031 1.2, 031 1.3, and 031 1 .4 (h031 1 -L0H1 , h031 1 -L1H1 , h0311 -L0H2, and h0311 -L1H2, respectively).
[034] FIG. 7 shows inhibition of IL34 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6. Figure 7 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and h0301-Ll H2, respectively). Figure 7B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively). Figure 7C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI HI , h031 1 -L0H2, and h031 1 -LI H2, respectively).
[035] FIG. 8 shows blocking of human CSF1 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7. Figure 8A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301-L0Hl , h0301- L0H2, h0301-LlH0, Ii0301 -L1H1 , and h0301 -LlH2, respectively). Figure 8B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302- L2H1 , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively). Figure 8C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2, 031 1 .3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -L1H1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
[036] FIG. 9 shows blocking of human IL34 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7. Figure 9 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -LOH0, h0301 -L0Hl , h0301 - L0H2, h0301 -LlH0, h0301 -LI Hl , and h0301-Ll H2, respectively). Figure 9B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , h0302-LlHl , h0302- L2H1 , h0302-L0H2, Ii0302-L1H2, and h0302-L2H2, respectively). Figure 9C shows blocking curves for parental cAb 0311 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h0311 -LI H 1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
[037] FIG. 10 shows blocking of CSFl - (A) and IL34- (B) induced CSFIR phosphorylation in CHO cells expressing human CSFIR by humanized antibodies 0301 -L0H0, 0301 -L1 H0, and 031 1 -LOHl , as described in Example 9.
[038] FIG. 11 shows blocking of CSFl- (A) and IL34- (B) induced monoclyte proliferation/survival responses by humanized antibodies 0301-L0H0, 0301 -LI HO, and 031 1 -LOHl , as described in Example 10.
[039] FIG. 12A-C shows that humanized antibodies 0301-L0H0, 0301- LIHO, and 031 1-LOHl do not stimulate primary monocyte proliferation or survival, using monocytes from three different donors, as described in Example 11.
DETAILED DESCRIPTION
[040] Methods of treating diseases comprising administering novel antibodies to CSF I R are provided. All of the antibodies have binding affinities for human CSFIR ECD of less than 2 nM, and all but two of the humanized antibodies have sub-nanomolar binding affinities for human CSFIR ECD. Further, the new antibodies block binding of both CSFl and IL34 to human CSFIR, and inhibit ligand- induced phosphorylation of human CSFIR. Many of the new antibodies also block binding of CSFl and 1L34 to cynomolgus CSFI R, which facilitates in vivo experiments to support the development of anti-CSFIR antibody therapeutics. The new antibodies are therefore well suited for therapeutic use in human diseases, including, but not limited to, cancer, autoimmune diseases, and inflammatory conditions.
[041 ] The section headings used herein are for organizational puiposes only and are not to be construed as limiting the subject matter described.
Definitions
[042] Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinaiy skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[043] Exemplary techniques used in connection with recombinant DNA, oligonucleotide synthesis, tissue culture and transformation (e.g., electroporation, lipofection), enzymatic reactions, and purification techniques are known in the art. Many such techniques and procedures are described, e.g., in Sambrook et al.
Molecular Cloning: A Laboratoiy Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), among other places. In addition, exemplary techniques for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients are also known in the art.
[044] In this application, the use of "or" means "and/or" unless stated otherwise. In the context of a multiple dependent claim, the use of "or" refers back to more than one preceding independent or dependent claim in the alternative only. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.
[045] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
[046] The terms "nucleic acid molecule" and "polynucleotide" may be used interchangeably, and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and/or non-natural nucleotides, and include, but are not limited to, DNA, NA, and PNA. "Nucleic acid sequence" refers to the linear sequence of nucleotides that comprise the nucleic acid molecule or polynucleotide.
[047] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition. The terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for puiposes of the present invention, a "polypeptide" refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification. [048] The term "CSFIR" refers herein to the full-length CSFIR, which includes the N-terminal ECD, the transmembrane domain, and the intracellular tyrosine kinase domain, with or without an N-terminal leader sequence. In some embodiments, the CSFIR is a human CSFIR having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
[049] The term "CSFIR extracellular domain" ("CSFIR ECD") as used herein refers to a CSFIR polypeptide that lacks the intracellular and transmembrane domains. CSFIR ECDs include the full-length CSFIR ECD and CSFIR ECD fragments that are capable of binding CSFIR and/or IL34. The human full-length CSFIR ECD is defined herein as comprising either amino acids 1 to 512 (i.e., including the leader sequence) or amino acids 20 to 512 (i.e., lacking the leader sequence) of SEQ ID NO: 2. In some embodiments, a human CSFIR ECD fragment comprises amino acids 20 to 506 of SEQ ID NO: 2 (see SEQ ID NO:5). In some embodiments, a human CSFIR fragment ends at amino acid 507, 508, 509, 510, or 51 1. In some embodiments, a cynoCSF 1 R ECD comprises the sequence of SEQ ID NO: 7 (with leader sequence) or amino acids 20 to 506 of SEQ ID NO: 7 (without leader sequence).
[050] The term "antibody" as used herein refers to a molecule comprising at least complementarity-determining region (CDR) 1 , CDR2, and CDR3 of a heavy chain and at least CDR1 , CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen. The term antibody includes, but is not limited to, fragments that are capable of binding antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', and (Fab')2. The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as mouse, human, cynomolgus monkey, etc.
[051] In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, an antibody comprises at least one heavy chain comprising a heavy chain variable region and at least a portion of a heavy chain constant region, and at least one light chain comprising a light chain variable region and at least a portion of a light chain constant region. In some embodiments, an antibody comprises two heavy chains, wherein each heavy chain comprises a heavy chain variable region and at least a portion of a heavy chain constant region, and two light chains, wherein each light chain comprises a light chain variable region and at least a portion of a light chain constant region. As used herein, a single-chain Fv (scFv), or any other antibody that comprises, for example, a single polypeptide chain comprising all six CDRs (three heavy chain CDRs and three light chain CDRs) is considered to have a heavy chain and a light chain. In some such embodiments, the heavy chain is the region of the antibody that comprises the three heavy chain CDRs and the light chain in the region of the antibody that comprises the three light chain CDRs.
[052] The term "heavy chain variable region" as used herein refers to a region comprising heavy chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3. In some embodiments, a heavy chain variable region also comprises at least a portion of an FR1 and/or at least a portion of an FR4. In some embodiments, a heavy chain CDRl corresponds to Kabat residues 26 to 35; a heavy chain CDR2 corresponds to Kabat residues 50 to 65; and a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991 , NIH, Bethesda, Md.); and Figure 1. In some embodiments, a heavy chain CDRl corresponds to Kabat residues 31 to 35; a heavy chain CDR2 corresponds to Kabat residues 50 to 65; and a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See id.
[053] The term "heavy chain constant region" as used herein refers to a region comprising at least three heavy chain constant domains, CH1 , CH2, and CH3. Nonlimiting exemplary heavy chain constant regions include γ, δ, and a. Nonlimiting exemplary heavy chain constant regions also include ε and μ. Each heavy constant region corresponds to an antibody isotype. For example, an antibody comprising a γ constant region is an IgG antibody, an antibody comprising a δ constant region is an IgD antibody, and an antibody comprising an a constant region is an IgA antibody. Further, an antibody comprising a μ constant region is an IgM antibody, and an antibody comprising an ε constant region is an IgE antibody. Certain isotypes can be further subdivided into subclasses. For example, IgG antibodies include, but are not limited to, IgG l (comprising a γι constant region), IgG2 (comprising a γ2 constant region), IgG3 (comprising a 73 constant region), and IgG4 (comprising a γ4 constant region) antibodies; IgA antibodies include, but are not limited to, IgAl (comprising an a] constant region) and lgA2 (comprising an ao constant region) antibodies; and IgM antibodies include, but are not limited to, IgMl and IgM2.
[054] In some embodiments, a heavy chain constant region comprises one or more mutations (or substitutions), additions, or deletions that confer a desired characteristic on the antibody. A nonlimiting exemplary mutation is the S241P mutation in the IgG4 hinge region (between constant domains CH1 and CH2), which alters the lgG4 motif CPSCP to CPPCP, which is similar to the corresponding motif in IgG 1. That mutation, in some embodiments, results in a more stable IgG4 antibody. See, e.g., Angal et al., Mol. Immunol. 30: 105-108 (1993); Bloom et al., Prot. Sci. 6: 407-415 (1997); Schuurman et al., Mol. Immunol. 38: 1-8 (2001 ).
[055] The term "heavy chain" as used herein refers to a polypeptide comprising at least a heavy chain variable region, with or without a leader sequence. In some embodiments, a heavy chain comprises at least a portion of a heavy chain constant region. The term "full-length heavy chain" as used herein refers to a polypeptide comprising a heavy chain variable region and a heavy chain constant region, with or without a leader sequence.
[056] The term "light chain variable region" as used herein refers to a region comprising light chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3. In some embodiments, a light chain variable region also comprises an FR1 and/or an FR4. In some embodiments, a light chain CDRl coiTesponds to Kabat residues 24 to 34; a light chain CDR2 corresponds to Kabat residues 50 to 56; and a light chain CDR3 coiTesponds to Kabat residues 89 to 97. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991 , NIH, Bethesda, Md.); and Figure 1.
[057] The term "light chain constant region" as used herein refers to a region comprising a light chain constant domain, CL- Nonlimiting exemplary light chain constant regions include λ and .
[058] The term "light chain" as used herein refers to a polypeptide comprising at least a light chain variable region, with or without a leader sequence. In some embodiments, a light chain comprises at least a portion of a light chain constant region. The term "full-length light chain" as used herein refers to a polypeptide comprising a light chain variable region and a light chain constant region, with or without a leader sequence.
[059] A "chimeric antibody" as used herein refers to an antibody comprising at least one variable region from a first species (such as mouse, rat, cynomolgus monkey, etc.) and at least one constant region from a second species (such as human, cynomolgus monkey, etc.). In some embodiments, a chimeric antibody comprises at least one mouse variable region and at least one human constant region. In some embodiments, a chimeric antibody comprises at least one cynomolgus variable region and at least one human constant region. In some embodiments, all of the variable regions of a chimeric antibody are from a first species and all of the constant regions of the chimeric antibody are from a second species.
[060] A "humanized antibody" as used herein refers to an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the corresponding amino acid from a human variable region. In some embodiments, a humanized antibody comprises at least one human constant region or fragment thereof. In some embodiments, a humanized antibody is an Fab, an scFv, a (Fab')2, etc.
[061 ] A "CDR-grafted antibody" as used herein refers to a humanized antibody in which the complementarity detemiining regions (CDRs) of a first (non- human) species have been grafted onto the framework regions (FRs) of a second (human) species.
[062] A "human antibody'' as used herein refers to antibodies produced in humans, antibodies produced in non-human animals that comprise human immunoglobulin genes, such as XenoMouse®, and antibodies selected using in vitro methods, such as phage display, wherein the antibody repertoire is based on a human immunoglobulin sequences.
[063] The term "leader sequence" refers to a sequence of amino acid residues located at the N terminus of a polypeptide that facilitates secretion of a polypeptide from a mammalian cell. A leader sequence may be cleaved upon export of the polypeptide from the mammalian cell, forming a mature protein. Leader sequences may be natural or synthetic, and they may be heterologous or homologous to the protein to which they are attached. Exemplary leader sequences include, but are not limited to, antibody leader sequences, such as, for example, the amino acid sequences of SEQ ID NOs.: 3 and 4, which correspond to human light and heavy chain leader sequences, respectively. Nonlimiting exemplary leader sequences also include leader sequences from heterologous proteins. In some embodiments, an antibody lacks a leader sequence. In some embodiments, an antibody comprises at least one leader sequence, which may be selected from native antibody leader sequences and heterologous leader sequences.
[064] The term "vector" is used to describe a polynucleotide that may be engineered to contain a cloned polynucleotide or polynucleotides that may be propagated in a host cell. A vector may include one or more of the following elements: an origin of replication, one or more regulatory sequences (such as, for example, promoters and/or enhancers) that regulate the expression of the polypeptide of interest, and/or one or more selectable marker genes (such as, for example, antibiotic resistance genes and genes that may be used in coloriinetric assays, e.g., β- galactosidase). The term "expression vector" refers to a vector that is used to express a polypeptide of interest in a host cell.
[065] A "host cell" refers to a cell that may be or has been a recipient of a vector or isolated polynucleotide. Host cells may be prokaryotic cells or eukaryotic cells. Exemplary eukaiyotic cells include mammalian cells, such as primate or non- primate animal cells; fungal cells, such as yeast; plant cells; and insect cells.
Nonlimiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Cracell), and 293 and CHO cells, and their derivatives, such as 293- 6E and DG44 cells, respectively.
[066] The term "isolated" as used herein refers to a molecule that has been separated from at least some of the components with which it is typically found in nature. For example, a polypeptide is referred to as "isolated" when it is separated from at least some of the components of the cell in which it was produced. Where a polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered to be "isolating" the polypeptide. Similarly, a polynucleotide is referred to as "isolated" when it is not part of the larger polynucleotide (such as, for example, genomic DNA or mitochondrial DNA, in the case of a DNA polynucleotide) in which it is typically found in nature, or is separated from at least some of the components of the cell in which it was produced, e.g., in the case of an RNA polynucleotide. Thus, a DNA polynucleotide that is contained in a vector inside a host cell may be referred to as "isolated" so long as that polynucleotide is not found in that vector in nature.
[067] The terms "subject" and "patient" are used interchangeably herein to refer to a human. In some embodiments, methods of treating other mammals, including, but not limited to, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, manmialian laboratoiy animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are also provided.
[068] The term "rheumatoid arthritis" ("RA") refers to a chronic autoimmune disease characterized primarily by inflammation of the lining (synovium) of the joints, which can lead to joint damage, resulting in chronic pain, loss of function, and disability. Because RA can affect multiple organs of the body, including skin, lungs, and eyes, it is referred to as a systemic illness.
[069] The term "multiple sclerosis" ("MS"') refers to the chronic, autoimmune, demyelinating disease of the CNS in which the body generates antibodies and white blood cells against the cells that produce the myelin sheath. "Demyelination" occurs when the myelin sheath becomes inflamed, injured, and detaches from the nerve fiber.
[070] The term "cancer" refers to a proliferative disorder associated with uncontrolled cell proliferation, unrestrained cell growth, and decreased cell deathiapoptosis. Cancer includes, but is not limited to, breast cancer, prostate cancer, lung cancer, kidney cancer, thyroid cancer, esophageal cancer, melanoma, follicular lymphomas, uveal melanoma, brain cancer, head and neck cancer, pulmonary adenocarcinoma, including, but not limited to, colon cancer, cardiac tumors, pancreatic cancer, retinoblastoma, glioblastoma, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, Kaposi's sarcoma, ovarian cancer, leukemia (including acute leukemias (for example, acute lymphocytic leukemia, acute myelocytic leukemia, including myeloblasts, promyelocyte, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (for example, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia), myelodysplasia syndrome polycythemia vera, lymphomas (for example, Hodgkin*s disease, non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain diseases, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, endometrial cancer, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, and menangioma. The terms "metastasis" and "cancer metastasis" are used interchangeably herein to refer to the ability of a cancer cell to spread to other tissues. For example, "metastasis to bone'' refers to the ability of certain types of cancer including, but not limited to, breast, prostate, lung, kidney, thyroid, and melanoma, to metastasize to bone.
[071 ] The term "osteolytic disorders" is used herein to refer to any condition that is caused by an increase in the activity of osteoclasts, which are cells responsible for bone resorption. The terms "osteolysis" and "osteolytic bone loss" may be used interchangeably to refer to osteoclast-mediated bone resorption or bone loss associated with an osteolytic disorder. Osteolytic disorders may occur in subjects with a predisposition to develop an osteolytic disorder, or they may occur in subjects with a disease that leads to or contributes to an osteolytic disorder by stimulating osteoclast activity. In exemplary embodiments of the present invention, the osteolytic disorder may include osteolytic bone loss and cancer metastasis-induced osteolytic bone loss. In further exemplary embodiments of the present invention, the osteolytic bone disorder includes metabolic bone disease, including endocrinopathies, such as hypercortisolism, hypogonadism, primary or secondaiy hyperparathyroidism, and hyperthyroidism; dietaiy deficiency, including rickets, osteomalacia, scurvy, and malnutrition; osteoporosis; drug use, including glucocorticoids (glucocorticoid- induced osteoporosis), heparin, and alcohol; chronic disease, including malabsorption syndromes; chronic renal failure, including renal osteodystrophy; chronic liver disease, including hepatic osteodystrophy; inherited disease, including osteogenesis imperfecta and homocystinuria; and bone inflammation associated with arthritis, rheumatoid arthritis, psoriatic arthritis, fibrous dysplasia, periodontal disease, and Paget's disease.
[072] The terms "metastasis-induced osteolytic bone loss," and "cancer metastasis-induced osteolytic bone loss," are used interchangeably herein to refer to osteolysis or osteolytic bone loss resulting from cancer cell metastasis to bone. The term "cancer metastasis-induced osteoclast activation" is used herein to refer to the ability of cancer cells that have metastasized to bone to induce the activation of osteoclasts.
[073] The term "tumor" is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth. A tumor may be benign, pre- malignant, or malignant; malignant tumor cells are cancerous. Tumor cells may be solid tumor cells or leukemic tumor cells. The term "tumor growth" is used herein to refer to proliferation or growth by a cell or cells that comprise a tumor that leads to a corresponding increase in the size of the tumor. The term "CSFIR-dependent tumor growth'" is used herein to refer to the requirement of a tumor cell or cells for CSFIR- mediated function(s) in order for the tumor cell or cells to proliferate or grow.
[074] "Treatment," as used herein, covers any administration or application of a therapeutic for disease in a mammal, including a human, and includes inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, partially or fully relieving the disease, or curing the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
[075] The terms "inhibition" or "inhibit" refer to a decrease or cessation of any phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that characteristic.
[076] A "pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a "pharmaceutical composition" for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the fonnulation. The phannaceutically acceptable earner is appropriate for the fonnulation employed. For example, if the therapeutic agent is to be administered orally, the earner may be a gel capsule. If the therapeutic agent is to be administered subcutaneously, the carrier ideally is not irritable to the skin and does not cause injection site reaction.
Anti-CSFIR Antibodies
[077] The present inventors have invented a new set of antibodies directed against CSF1R. Anti-CSFIR antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and/ or light chain CDRs discussed herein.
Exemplary Humanized Antibodies
[078] In some embodiments, humanized antibodies that bind CSF1R are provided. Humanized antibodies are useful as therapeutic molecules because humanized antibodies reduce or eliminate the human immune response to non-human antibodies (such as the human anti-mouse antibody (HAMA) response), which can result in an immune response to an antibody therapeutic, and decreased effictiveness of the therapeutic.
[079] Nonlimiting exemplaiy humanized antibodies include Abl through Abl 6, described herein. Nonlimiting exemplaiy humanized antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from Abl to Abl 6 and/or a light chain variable region of an antibody selected from Abl to Abl 6. Nonlimiting exemplaiy humanized antibodies include antibodies comprising a heavy chain variable region selected from SEQ ID NOs: 39 to 45 and/or a light chain variable region selected from SEQ ID NOs: 46 to 52. Exemplaiy humanized antibodies also include, but are not limited to, humanized antibodies comprising heavy chain CDRl , CDR2, and CDR3, and/or light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
[080] In some embodiments, a humanized anti-CSFIR antibody comprises heavy chain CDRl , CDR2, and CDR3 and/or a light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1. Nonlimiting exemplaiy humanized anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDRl, CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29. Nonlimiting exemplaiy humanized anti-CSFIR antibodies also include antibodies comprising sets of light chain CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
[081 ] Nonlimiting exemplaiy humanized anti-CSF 1 R antibodies include antibodies comprising the sets of heavy chain CDRl , CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 in Table 1 (SEQ ID NOs shown; see Table 8 for sequences). Each row of Table 1 shows the heavy chain CDRl, CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 of an exemplaiy antibody.
Table 1 : Heavy chain and light chain CDRs
Figure imgf000023_0001
92 Further exemplary humanized antibodies
[082] In some embodiments, a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, and wherein the antibody binds CSF1R. In some embodiments, a humanized anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1R. In some embodiments, a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 11 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
[083] As used herein, whether a particular polypeptide is, for example, at least 95% identical to an amino acid sequence can be determined using, e.g., a computer program. When determining whether a particular sequence is, for example, 95% identical to a reference sequence, the percentage of identity is calculated over the full length of the reference amino acid sequence.
[084] In some embodiments, a humanized anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a humanized anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, a humanized anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
[085] Exemplary humanized anti-CSFIR antibodies also include antibodies that compete for binding to CSF1 R with an antibody described herein. Thus, in some embodiments, a humanized anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
Exemplaiy humanized antibody constant regions
[086] In some embodiments, a humanized antibody described herein comprises one or more human constant regions. In some embodiments, the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD. In some embodiments, the human light chain constant region is of an isotype selected from K and λ. In some embodiments, a humanized antibody described herein comprises a human IgG constant region. In some embodiments, a humanized antibody described herein comprises a human IgG4 heavy chain constant region. In some such embodiments, a humanized antibody described herein comprises an S241P mutation in the human IgG4 constant region. In some embodiments, a humanized antibody described herein comprises a human IgG4 constant region and a human κ light chain.
[087] The choice of heavy chain constant region can determine whether or not an antibody will have effector function in vivo. Such effector function, in some embodiments, includes antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC), and can result in killing of the cell to which the antibody is bound. In some methods of treatment, including methods of treating some cancers, cell killing may be desirable, for example, when the antibody binds to a cell that supports the maintenance or growth of the tumor. Exemplaiy cells that may support the maintenance or growth of a tumor include, but are not limited to, tumor cells themselves, cells that aid in the recruitment of vasculature to the tumor, and cells that provide ligands, growth factors, or counter-receptors that support or promote tumour growth or rumour survial. In some embodiments, when effector function is desirable, an anti-CSFlR antibody comprising a human IgGl heavy chain or a human IgG3 heavy chain is selected.
[088] In some methods of treatment, effector function may not be desirable. For example, in some embodiments, it may be desirable that antibodies used in the treatment of MS and/or RA and/or osteolysis do not have effector function. Thus, in some embodiments, anti-CSFlR antibodies developed for the treatment of cancer may not be suitable for use in treatment of MS and/or RA and/or osteolysis. Accordingly, in some embodiments, an anti-CSFlR antibody that lacks significant effector function is used in treatment of MS and/or RA and/or osteolysis. In some embodiments, an anti-CSFlR antibody for treatment of MS and/or RA and/or osteolysis comprises a human IgG4 or IgG2 heavy chain constant region. In some embodiments, an IgG4 constant region comprises an S241P mutation.
[089] An antibody may be humanized by any method. Nonlimiting exemplary methods of humanization include methods described, e.g., in U.S. Patent Nos. 5,530,101 ; 5,585,089; 5,693,761 ; 5,693,762; 6,180,370; Jones et al, Nature 321 : 522-525 (1986); Rieclimann et al, Nature 332: 323-27 (1988); Verhoeyen et al., Science 239: 1534-36 (1988); and U.S. Publication No. US 2009/0136500.
[090] As noted above, a humanized antibody is an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the amino acid from the corresponding location in a human framework region. In some embodiments, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 1 1 , at least 12, at least 15, or at least 20 amino acids in the framework regions of a non-human variable region are replaced with an amino acid from one or more corresponding locations in one or more human framework regions.
[091 ] In some embodiments, some of the corresponding human amino acids used for substitution are from the framework regions of different human
immunoglobulin genes. That is, in some such embodiments, one or more of the non- human amino acids may be replaced with corresponding amino acids from a human framework region of a first human antibody or encoded by a first human
immunoglobulin gene, one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a second human antibody or encoded by a second human immunoglobulin gene, one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a third human antibody or encoded by a third human immunoglobulin gene, etc. Further, in some embodiments, all of the corresponding human amino acids being used for substitution in a single framework region, for example, FR2, need not be from the same human framework. In some embodiments, however, all of the corresponding human amino acids being used for substitution are from the same human antibody or encoded by the same human immunoglobulin gene.
[092] In some embodiments, an antibody is humanized by replacing one or more entire framework regions with corresponding human framework regions. In some embodiments, a human framework region is selected that has the highest level of homology to the non-human framework region being replaced. In some embodiments, such a humanized antibody is a CDR-grafted antibody.
[093] In some embodiments, following CDR-grafting, one or more framework amino acids are changed back to the corresponding amino acid in a mouse framework region. Such "back mutations" are made, in some embodiments, to retain one or more mouse framework amino acids that appear to contribute to the structure of one or more of the CDRs and/or that may be involved in antigen contacts and/or appear to be involved in the overall structural integrity of the antibody. In some embodiments, ten or fewer, nine or fewer, eight or fewer, seven or fewer, six or fewer, five or fewer, four or fewer, three or fewer, two or fewer, one, or zero back mutations are made to the framework regions of an antibody following CDR grafting.
[094] In some embodiments, a humanized antibody also comprises a human heavy chain constant region and/or a human light chain constant region.
Exemplary Chimeric Antibodies
[095] In some embodiments, an anti-CSFIR antibody is a chimeric antibody. In some embodiments, an anti-CSFI R antibody comprises at least one non-human variable region and at least one human constant region. In some such embodiments, all of the variable regions of an anti-CSFIR antibody are non-human variable regions, and all of the constant regions of an anti-CSFIR antibody are human constant regions. In some embodiments, one or more variable regions of a chimeric antibody are mouse variable regions. The human constant region of a chimeric antibody need not be of the same isotype as the non-human constant region, if any, it replaces. Chimeric antibodies are discussed, e.g., in U.S. Patent No. 4,816,567; and Morrison et al. Proc. Natl. Acad. Sci. USA 81 : 6851-55 (1984). [096] Nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising the heavy and/or light chain variable regions of an antibody selected from 0301 , 0302, and 031 1 . Additional nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising heavy chain CDR1 , CDR2, and CDR3, and/or light chain CDR1 , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
[097] Nonlimiting exemplaiy chimeric anti-CSFIR antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14.
[098] Nonlimiting exemplaiy anti-CSFIR antibodies include antibodies comprising a set of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
Further exemplaiy chimeric antibodies
[099] In some embodiments, a chimeric anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R. In some embodiments, a chimeric anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF 1 R. In some embodiments, a chimeric anti-CSFI R antibody comprises a heavy chain comprising a variable region sequence that is at least 90%o, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%o, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%), at least 91 %, at least 92%, at least 93%», at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%» identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
[0100] In some embodiments, a chimeric anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a chimeric anti-CSFI R antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, a chimeric anti-CSFI R antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
[0101 ] Exemplary chimeric anti-CSFIR antibodies also include chimeric antibodies that compete for binding to CSFIR with an antibody described herein. Thus, in some embodiments, a chimeric anti-CSFIR antibody is provided that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
Exemplary chimeric antibody constant regions
[0102] In some embodiments, a chimeric antibody described herein comprises one or more human constant regions. In some embodiments, the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD. In some embodiments, the human light chain constant region is of an isotype selected from κ and λ. In some embodiments, a chimeric antibody described herein comprises a human IgG constant region. In some embodiments, a chimeric antibody described herein comprises a human IgG4 heavy chain constant region. In some such embodiments, a chimeric antibody described herein comprises an S241P mutation in the human IgG4 constant region. In some embodiments, a chimeric antibody described herein comprises a human IgG4 constant region and a human κ light chain.
[0103] As noted above, whether or not effector function is desirable may depend on the particular method of treatment intended for an antibody. Thus, in some embodiments, when effector function is desirable, a chimeric anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected. In some embodiments, when effector function is not desirable, a chimeric anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected. Exemplary Human Antibodies
[0104] Human antibodies can be made by any suitable method. Nonlimiting exemplary methods include making human antibodies in transgenic mice that comprise human immunoglobulin loci. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551 -55 (1993); Jakobovits et al., Nature 362: 255-8 ( 1993); Lonberg et al, Nature 368: 856-9 (1994); and U.S. Patent Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 5,545,807; 6,300,129; 6,255,458; 5,877,397; 5,874,299; and 5,545,806.
[0105] Nonlimiting exemplary methods also include making human antibodies using phage display libraries. See, e.g., Hoogenboom et al., J. Mol. Biol. 227: 381 -8 ( 1992); Marks et al., J. Mol. Biol. 222: 581 -97 (1991 ); and PCT
Publication No. WO 99/10494.
[0106] In some embodiments, a human anti-CSFIR antibody binds to a polypeptide having the sequence of SEQ ID NO: 1. Exemplary human anti-CSFIR antibodies also include antibodies that compete for binding to CSF1R with an antibody described herein. Thus, in some embodiments, a human anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
[0107] In some embodiments, a human anti-CSFI antibody comprises one or more human constant regions. In some embodiments, the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD. In some embodiments, the human light chain constant region is of an isotype selected from κ and λ. In some embodiments, a human antibody described herein comprises a human IgG constant region. In some embodiments, a human antibody described herein comprises a human IgG4 heavy chain constant region. In some such embodiments, a human antibody described herein comprises an S241P mutation in the human IgG4 constant region. In some embodiments, a human antibody described herein comprises a human IgG4 constant region and a human light chain.
[0108] In some embodiments, when effector function is desirable, a human anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected. In some embodiments, when effector function is not desirable, a human anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected. Additional Exemplary Anti-CSFlR Antibodies
[0109] Exemplaiy anti-CSFlR antibodies also include, but are not limited to, mouse, humanized, human, chimeric, and engineered antibodies that comprise, for example, one or more of the CDR sequences described herein. In some embodiments, an anti-CSFlR antibody comprises a heavy chain variable region described herein. In some embodiments, an anti-CSFlR antibody comprises a light chain variable region described herein. In some embodiments, an anti-CSFlR antibody comprises a heavy chain variable region described herein and a light chain variable region described herein. In some embodiments, an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein. In some embodiments, an anti-CSFlR antibody comprises light chain CDR1 , CDR2, and CDR3 described herein. In some embodiments, an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein and light chain CDR1 , CDR2, and CDR3 described herein.
[01 10] In some embodiments, an anti-CSFlR antibody comprises a heavy chain variable region of an antibody selected from Fabs 0301, 0302, and 031 1.
Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from humanized antibodies Abl to Abl 6. Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
[01 1 1] In some embodiments, an anti-CSFlR antibody comprises a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 31 1. Nonlimiting exemplaiy anti-CSFl R antibodies also include antibodies comprising a light chain variable region of an antibody selected from humanized antibodies Abl to Abl6. Nonlimiting exemplaiy anti-CSFlR antibodies include antibodies comprising a light chain variable region comprising a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
[0112] In some embodiments, an anti-CSFlR antibody comprises a heavy chain variable region and a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 0311. Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region and a light chain variable region of an antibody selected from humanized antibodies Abl to Abl 6. Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14; SEQ ID NOs: 39 and 40; SEQ ID NOs: 41 and 42; SEQ ID NOs: 43 and 44; SEQ ID NOs: 45 and 46; SEQ ID NOs: 47 and 48; SEQ ID NOs: 49 and 50; and SEQ ID NOs: 51 and 52. Nonlimiting exemplary anti- CSF1 R antibodies also include antibodies comprising the following pairs of heavy and light chains: SEQ ID NOs: 33 and 34; SEQ ID NOs: 35 and 36; and SEQ ID NOs: 37 and 38.
[01 13] In some embodiments, an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1. Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28,and 29.
[0114] In some embodiments, an anti-CSFIR antibody comprises light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1. Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of light chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
[01 15] In some embodiments, an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
[01 16] Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising the sets of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
Further exemplaiy antibodies
[01 17] In some embodiments, an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R. In some embodiments, an anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1 R. In some embodiments, an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSFIR.
[01 18] In some embodiments, an anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
[0119] Exemplary anti-CSFIR antibodies also include antibodies that compete for binding to CSFIR with an antibody described herein. Thus, in some
embodiments, an anti-CSFIR antibody is provided that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
Exemplaiy antibody constant regions
[0120] In some embodiments, an antibody described herein comprises one or more human constant regions. In some embodiments, the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD. In some embodiments, the human light chain constant region is of an isotype selected from κ and λ. In some embodiments, an antibody described herein comprises a human IgG constant region. In some embodiments, an antibody described herein comprises a human IgG4 heavy chain constant region. In some such embodiments, an antibody described herein comprises an S241P mutation in the human IgG4 constant region. In some embodiments, an antibody described herein comprises a human IgG4 constant region and a human κ light chain.
[0121] As noted above, whether or not effector function is desirable may depend on the particular method of treatment intended for an antibody. Thus, in some embodiments, when effector function is desirable, an anti-CSFl R antibody comprising a human IgG 1 heavy chain constant region or a human IgG3 heavy chain constant region is selected. In some embodiments, when effector function is not desirable, an anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected.
Exemplary Anti-CSFIR Heavy Chain Variable Regions
[0122] In some embodiments, anti-CSFIR antibody heavy chain variable regions are provided. In some embodiments, an anti-CSFIR antibody heavy chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
[0123] An anti-CSFIR antibody heavy chain variable region comprises a heavy chain CDR1 , FR2, CDR2, FR3, and CDR3. In some embodiments, an anti- CSFIR antibody heavy chain variable region further comprises a heavy chain FR1 and/or FR4. Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions having an amino acid sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
[0124] In some embodiments, an anti-CSFIR antibody heavy chain variable region comprises a CDR1 comprising a sequence selected from SEQ ID NOs: 15, 21, and 27.
[0125] In some embodiments, an anti-CSFIR antibody heavy chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 16, 22, and 28.
[0126] In some embodiments, an anti-CSFI R antibody heavy chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 17, 23, and 29.
[0127] Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions comprising sets of CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29. [0128] In some embodiments, an anti-CSFIR antibody heavy chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the heavy chain, together with a light chain, is capable of forming an antibody that binds CSFIR.
[0129] In some embodiments, an anti-CSFI R antibody heavy chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody heavy chain comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, and a heavy chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody heavy chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the heavy chain comprising the mutated CDR.
[0130] In some embodiments, a heavy chain comprises a heavy chain constant region. In some embodiments, a heavy chain comprises a human heavy chain constant region. In some embodiments, the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD. In some embodiments, the human heavy chain constant region is an IgG constant region. In some embodiments, a heavy chain comprises a human igG4 heavy chain constant region. In some such embodiments, the human IgG4 heavy chain constant region comprises an S241P mutation.
[0131] In some embodiments, when effector function is desirable, a heavy chain comprises a human IgG 1 or IgG3 heavy chain constant region. In some embodiments, when effector function is less desirable, a heavy chain comprises a human IgG4 or lgG2 heavy chain constant region.
Exemplary Anti-CSFIR Light Chain Variable Regions
[0132] In some embodiments, anti-CSFIR antibody light chain variable regions are provided. In some embodiments, an anti-CSFIR antibody light chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
[0133] An anti-CSFIR antibody light chain variable region comprises a light chain CDRl , FR2, CDR2, FR3, and CDR3. In some embodiments, an anti-CSFIR antibody light chain variable region further comprises a light chain FR1 and/or FR4. Nonlimiting exemplary light chain variable regions include light chain variable regions having an amino acid sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
[0134] In some embodiments, an anti-CSFIR antibody light chain variable region comprises a CDRl comprising a sequence selected from SEQ ID NOs: 18, 24 and 30.
[0135] In some embodiments, an anti-CSFIR antibody light chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31.
[0136] In some embodiments, an anti-CSFIR antibody light chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
[0137] Nonlimiting exemplary light chain variable regions include, but are not limited to, light chain variable regions comprising sets of CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
[0138] In some embodiments, an anti-CSFIR antibody light chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the light chain, together with a heavy chain, is capable of forming an antibody that binds CSF1R.
[0139] In some embodiments, an anti-CSFIR antibody light chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody light chain comprises at least one CDR selected from a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody light chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the light chain comprising the mutated CDR.
[0140] In some embodiments, a light chain comprises a human light chain constant region. In some embodiments, a human light chain constant region is selected from a human κ and a human λ light chain constant region.
Exemplary Additional CSFIR Binding Molecules
[0141] In some embodiments, additional molecules that bind CSFIR are provided. Such molecules include, but are not limited to, non-canonical scaffolds, such as anti-calins, adnectins, ankyrin repeats, etc. See, e.g., Hosse et al., Prot. Sci. 15: 14 (2006); Fiedler, M. and Skerra, A., "Non-Antibody Scaffolds," pp.467-499 in Handbook of Therapeutic Antibodies, Dubel, S., ed., Wiley- VCH, Weinheim, Germany, 2007.
Exemplary Properties of anti-CSFIR antibodies
[0142] In some embodiments, an antibody having a structure described above binds to the CSFIR with a binding affinity (KD) of less than 1 nM, blocks binding of CSFl and/or IL34 to CSFI R, and inhibits CSFIR phosphorylation induced by CSFl and/or IL34.
[0143] In some embodiments, an anti-CSFIR antibody binds to the extracellular domain of CSFIR (CSF1R-ECD). In some embodiments, an anti- CSFIR antibody has a binding affinity (KD) for CSFIR of less than 1 nM, less than 0.5 nM, less than 0.1 nM, or less than 0.05 nM. In some embodiments, an anti- CSFIR antibody has a KD of between 0.01 and 1 nM, between 0.01 and 0.5 nM, between 0.01 and 0.1 nM, between 0.01 and 0.05 nM, or between 0.02 and 0.05 nM.
[0144] In some embodiments, an anti-CSFIR antibody blocks ligand binding to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of CSFl to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of IL34 to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of both CSFl and IL34 to CSFIR. In some embodiments, an antibody that blocks ligand binding binds to the extracellular domain of CSFIR. An antibody is considered to "block ligand binding to CSFI R" when it reduces the amount of detectable binding of a ligand to CSF1R by at least 50%, using the assay described in Example 7. In some embodiments, an antibody reduces the amount of detectable binding of a ligand to CSF1R by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 7. In some such embodiments, the antibody is said to block ligand binding by at least 50%, at least 60%, at least 70%, etc.
[0145] In some embodiments, an anti-CSFIR antibody inhibits ligand-induced CSF1 R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits CSF1 -induced CSF1R phosphoiylation. In some embodiments, an anti-CSFIR antibody inhibits IL34-induced CSF1R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits both CSF1 -induced and IL34-induced CSF1R phosphoiylation. An antibody is considered to "inhibit ligand-induced CSF1R phosphoiylation" when it reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 50%, using the assay described in Example 6. In some embodiments, an antibody reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 6. In some such embodiments, the antibody is said to inhibit ligand-induced CSF1R phosphorylation by at least at least 50%, at least 60%, at least 70%, etc.
[0146] In some embodiments, an antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34. An antibody is considered to "inhibit monocyte proliferation and/or survival responses" when it reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 50%, using the assay described in Example 10. In some embodiments, an antibody reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 10. In some such embodiments, the antibody is said to inhibit monocyte proliferation and/or survival responses by at least at least 50%, at least 60%, at least 70%, etc.
Exemplary Antibody Conjugates
[0147] In some embodiments, an anti-CSFIR antibody is conjugated to a label and/or a cytotoxic agent. As used herein, a label is a moiety that facilitates detection of the antibody and/or facilitates detection of a molecule to which the antibody binds. Nonlimiting exemplary labels include, but are not limited to, radioisotopes, fluorescent groups, enzymatic groups, chemiluminescent groups, biotin, epitope tags, metal-binding tags, etc. One skilled in the art can select a suitable label according to the intended application.
[0148] As used herein, a cytotoxic agent is a moiety that reduces the proliferative capacity of one or more cells. A cell has reduced proliferative capacity when the cell becomes less able to proliferate, for example, because the cell undergoes apoptosis or otherwise dies, the cell fails to proceed through the cell cycle and/or fails to divide, the cell differentiates, etc. Nonlimiting exemplary cytotoxic agents include, but are not limited to, radioisotopes, toxins, and chemotherapeutic agents. One skilled in the art can select a suitable cytotoxic according to the intended application.
[0149] In some embodiments, a label and/or a cytotoxic agent is conjugated to an antibody using chemical methods in vitro. Nonlimiting exemplary chemical methods of conjugation are known in the art, and include services, methods and/or reagents commercially available from, e.g., Thermo Scientific Life Science Research Produces (formerly Pierce; Rockford, IL), Prozyme (Hayward, CA), SACRI Antibody Services (Calgaiy, Canada), AbD Serotec (Raleigh, NC), etc. In some embodiments, when a label and/or cytotoxic agent is a polypeptide, the label and/or cytotoxic agent can be expressed from the same expression vector with at least one antibody chain to produce a polypeptide comprising the label and/or cytotoxic agent fused to an antibody chain. One skilled in the art can select a suitable method for conjugating a label and/or cytotoxic agent to an antibody according to the intended application. Exemplary Leader Sequences
[0150] In order for some secreted proteins to express and secrete in large quantities, a leader sequence from a heterologous protein may be desirable. In some embodiments, a leader sequence is selected from SEQ ID NOs: 3 and 4, which are light chain and heavy chain leader sequences, respectively. In some embodiments, employing heterologous leader sequences may be advantageous in that a resulting mature polypeptide may remain unaltered as the leader sequence is removed in the ER during the secretion process. The addition of a heterologous leader sequence may be required to express and secrete some proteins.
[0151] Certain exemplary leader sequence sequences are described, e.g., in the online Leader sequence Database maintained by the Department of Biochemistry, National University of Singapore. See Choo et al, BMC Bioinformatics, 6: 249 (2005); and PCT Publication No. WO 2006/081430. Nucleic Acid Molecules Encoding Anti-CSFlR Antibodies
[0152] Nucleic acid molecules comprising polynucleotides that encode one or more chains of anti-CSFlR antibodies are provided. In some embodiments, a nucleic acid molecule comprises a polynucleotide that encodes a heavy chain or a light chain of an anti-CSFlR antibody. In some embodiments, a nucleic acid molecule comprises both a polynucleotide that encodes a heavy chain and a polynucleotide that encodes a light chain, of an anti-CSFlR antibody. In some embodiments, a first nucleic acid molecule comprises a first polynucleotide that encodes a heavy chain and a second nucleic acid molecule comprises a second polynucleotide that encodes a light chain.
[0153] In some such embodiments, the heavy chain and the light chain are expressed from one nucleic acid molecule, or from two separate nucleic acid molecules, as two separate polypeptides. In some embodiments, such as when an antibody is an scFv, a single polynucleotide encodes a single polypeptide comprising both a heavy chain and a light chain linked together.
[0154] In some embodiments, a polynucleotide encoding a heavy chain or light chain of an anti-CSFlR antibody comprises a nucleotide sequence that encodes a leader sequence, which, when translated, is located at the N terminus of the heavy chain or light chain. As discussed above, the leader sequence may be the native heavy or light chain leader sequence, or may be another heterologous leader sequence.
[0155] Nucleic acid molecules may be constructed using recombinant DNA techniques conventional in the art. In some embodiments, a nucleic acid molecule is an expression vector that is suitable for expression in a selected host cell.
Anti-CSFlR Antibody Expression and Production
Vectors
[0156] Vectors comprising polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are provided. Vectors comprising
polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are also provided. Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc. In some embodiments, a vector comprises a first polynucleotide sequence encoding a heavy chain and a second polynucleotide sequence encoding a light chain. In some embodiments, the heavy chain and light chain are expressed from the vector as two separate polypeptides. In some embodiments, the heavy chain and light chain are expressed as part of a single polypeptide, such as, for example, when the antibody is an scFv. [0157] In some embodiments, a first vector comprises a polynucleotide that encodes a heavy chain and a second vector comprises a polynucleotide that encodes a light chain. In some embodiments, the first vector and second vector are transfected into host cells in similar amounts (such as similar molar amounts or similar mass amounts). In some embodiments, a mole- or mass-ratio of between 5: 1 and 1 :5 of the first vector and the second vector is transfected into host cells. In some embodiments, a mass ratio of between 1 : 1 and 1 :5 for the vector encoding the heavy chain and the vector encoding the light chain is used. In some embodiments, a mass ratio of 1 :2 for the vector encoding the heavy chain and the vector encoding the light chain is used.
[0158] In some embodiments, a vector is selected that is optimized for expression of polypeptides in CHO or CHO-derived cells, or in NSO cells.
Exemplary such vectors are described, e.g., in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004).
[0159] In some embodiments, a vector is chosen for in vivo expression of anti- CSF1R heavy chains and/or anti-CSFIR light chains in animals, including humans. In some such embodiments, expression of the polypeptide is under the control of a promoter that functions in a tissue-specific manner. For example, liver-specific promoters are described, e.g., in PCT Publication No. WO 2006/076288.
Host Cells
[0160] In various embodiments, anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in prokaryotic cells, such as bacterial cells; or in eukaiyotic cells, such as fungal cells (such as yeast), plant cells, insect cells, and mammalian cells. Such expression may be earned out, for example, according to procedures known in the art. Exemplary eukaiyotic cells that may be used to express polypeptides include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S and DG44 cells;
PER.C6© cells (Cracell); and NSO cells. In some embodiments, anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in yeast. See, e.g., U.S. Publication No. US 2006/0270045 Al . In some embodiments, a particular eukaiyotic host cell is selected based on its ability to make desired post-translational
modifications to the anti-CSFIR heavy chains and/or anti-CSFIR light chains. For example, in some embodiments, CHO cells produce polypeptides that have a higher level of sialylation than the same polypeptide produced in 293 cells. [0161] Introduction of one or more nucleic acids into a desired host cell may be accomplished by any method, including but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Nonlimiting exemplaiy methods are described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3ld ed. Cold Spring Harbor Laboratory Press (2001). Nucleic acids may be transiently or stably transfected in the desired host cells, according to any suitable method.
[0162] In some embodiments, one or more polypeptides may be produced in vivo in an animal that has been engineered or transfected with one or more nucleic acid molecules encoding the polypeptides, according to any suitable method.
Purification of Anti-CSFlR Antibodies
[0163] Anti-CSFlR antibodies may be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include the CSF1R ECD and ligands that bind antibody constant regions. For example, a Protein A, Protein G, Protein A/G, or an antibody affinity column may be used to bind the constant region and to purify an anti-CSFlR antibody. Hydrophobic interactive clnOmatography, for example, a butyl or phenyl column, may also suitable for purifying some
polypeptides. Many methods of purifying polypeptides are known in the art.
Cell-free Production of Anti-CSFlR Antibodies
[0164] In some embodiments, an anti-CSFlR antibody is produced in a cell- free system. Nonlimiting exemplary cell-free systems are described, e.g., in
Sitaraman et al., Methods Mol. Biol. 498: 229-44 (2009); Spirin, Trends Biotechnol. 22: 538-45 (2004); Endo et al., Biotechnol. Adv. 21 : 695-713 (2003).
Therapeutic Compositions and Methods
Methods of Treating Diseases using Anti-CSFlR Antibodies
[0165] Antibodies of the invention, and compositions comprising antibodies of the invention, are provided for use in methods of treatment for humans or animals. Methods of treating disease comprising administering anti-CSRIR antibodies are also provided. Nonlimiting exemplaiy diseases that can be treated with anti-CSFlR antibodies include, but are not limited to, RA, MS, cancer, metastasis-induced osteolytic bone loss, osteolytic disorders, and hypercalcemia-induced bone loss. [0166] In some embodiments, methods of treating inflammatory conditions comprising administering an anti-CSFIR antibody are provided. In some
embodiments, an inflammatory condition is selected from psoriasis, SLE (lupus), COPD, atopic demiatitis, and atherosclerosis, macrophage activation syndrome, and histiocytosis X.
[0167] In some embodiments, methods of treating an inflammatory condition comprising administering an anti-CSFIR antibody are provided, wherein the inflammatory condition is selected from: proliferative vascular disease, acute respiratory distress syndrome, cytokine -mediated toxicity, interleukin-2 toxicity, appendicitis, peptic, gastric and duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis, alvealitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial viras infection, heipes mfection, HIV infection, hepatitis B viras infection, hepatitis C virus infection, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, demiatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasulitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, Alzheimer's disease, celiac disease, congestive heart failure, meningitis, encephalitis, cerebral infarction, cerebral embolism, Guillain-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, synovitis, myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcets's syndrome, allograft rejection, graft-versus-host disease, ankylosing spondylitis, Berger's disease, type 1 diabetes, type 2 diabetes, Berger's disease, Retier' s syndrome, and Hodgkins disease, or in treating inflammation associated with these conditions.
[0168] In some embodiments, methods of treating cancer comprising administering an anti-CSFIR antibody are provided. In some embodiments, the cancer is a CSF1 -secreting cancer. In some embodiments, the cancer is one or more cancers selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, and ovarian cancer. In some embodiments, an anti-CSFI R antibody is useful for treating one or more cancers selected from lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
Routes of Administration and Carriers
[0169] In various embodiments, anti-CSFIR antibodies may be administered in vivo by various routes, including, but not limited to, oral, intra-arterial, parenteral, intranasal, intramuscular, intracardiac, intraventricular, intratracheal, buccal, rectal, intraperitoneal, intradermal, topical, transdermal, and intrathecal, or otherwise by implantation or inhalation. The subject compositions may be formulated into preparations in solid, semi-solid, liquid, or gaseous forms; including, but not limited to, tablets, capsules, powders, granules, ointments, solutions, suppositories, enemas, injections, inhalants, and aerosols. A nucleic acid molecule encoding an anti-CSFI R antibody may be coated onto gold microparticles and delivered intradermally by a particle bombardment device, or "gene gun," as described in the literature (see, e.g., Tang et al., Nature 356: 152-154 (1992)). The appropriate formulation and route of administration may be selected according to the intended application.
[0170] In various embodiments, compositions comprising anti-CSFIR antibodies are provided in formulations with a wide variety of pharmaceutically acceptable earners (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Phis, 20th ed. (2003); Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., Pharmaceutical Press (2000)). Various pharmaceutically acceptable earners, which include vehicles, adjuvants, and diluents, are available. Moreover, various pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are also available. Non-limiting exemplary earners include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
[0171 ] In various embodiments, compositions comprising anti-CSFIR antibodies may be formulated for injection, including subcutaneous administration, by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preserva tives. In various embodiments, the compositions may be formulated for inhalation, for example, using pressurized acceptable propellants such as
dichlorodifluoromethane, propane, nitrogen, and the like. The compositions may also be formulated, in various embodiments, into sustained release microcapsules, such as with biodegradable or non-biodegradable polymers. A non-limiting exemplary biodegradable formulation includes poly lactic acid-glycolic acid polymer. A non- limiting exemplary non-biodegradable formulation includes a polyglycerin fatty acid ester. Certain methods of making such fomiulations are described, for example, in EP 1 125 584 Al .
[0172] Pharmaceutical packs and kits comprising one or more containers, each containing one or more doses of an anti-CSFIR antibody are also provided. In some embodiments, a unit dosage is provided wherein the unit dosage contains a predetermined amount of a composition comprising an anti-CSFI R antibody, with or without one or more additional agents. In some embodiments, such a unit dosage is supplied in single-use prefilled syringe for injection. In various embodiments, the composition contained in the unit dosage may comprise saline, sucrose, or the like; a buffer, such as phosphate, or the like; and/or be formulated within a stable and effective pH range. Alternatively, in some embodiments, the composition may be provided as a lyophilized powder that may be reconstituted upon addition of an appropriate liquid, for example, sterile water. In some embodiments, the composition comprises one or more substances that inhibit protein aggregation, including, but not limited to, sucrose and arginine. In some embodiments, a composition of the invention comprises heparin and/or a proteoglycan.
[0173] Pharmaceutical compositions are administered in an amount effective for treatment or prophylaxis of the specific indication. The therapeutically effective amount is typically dependent on the weight of the subject being treated, his or her physical or health condition, the extensiveness of the condition to be treated, or the age of the subject being treated. In general, anti-CSFIR antibodies may be administered in an amount in the range of about 10 μg/kg body weight to about 100 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 50 fig/kg body weight to about 5 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 100 g kg body weight to about 10 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 100 ng/kg body weight to about 20 mg/kg body weight per dose. In some embodiments, anti-CSFI R antibodies may be administered in an amount in the range of about 0.5 mg/kg body weight to about 20 mg/kg body weight per dose.
[0174] The anti-CSFIR antibody compositions may be administered as needed to subjects. Detemiination of the frequency of administration may be made by persons skilled in the art, such as an attending physician based on considerations of the condition being treated, age of the subject being treated, severity of the condition being treated, general state of health of the subject being treated and the like. In some embodiments, an effective dose of an anti-CSFIR antibody is administered to a subject one or more times. In various embodiments, an effective dose of an anti- CSFIR antibody is administered to the subject once a month, more than once a month, such as, for example, eveiy two months or eveiy three months. In other embodiments, an effective dose of an anti-CSFIR antibody is administered less than once a month, such as, for example, eveiy two weeks or eveiy week. An effective dose of an anti-CSFIR antibody is administered to the subject at least once. In some embodiments, the effective dose of an anti-CSFIR antibody may be administered multiple times, including for periods of at least a month, at least six months, or at least a year.
Combination Therapy
[0175] Anti-CSFIR antibodies may be administered alone or with other modes of treatment. They may be provided before, substantially contemporaneous with, or after other modes of treatment, for example, surgery, chemotherapy, radiation therapy, or the administration of a biologic, such as another therapeutic antibody. For treatment of rheumatoid arthritis, anti-CSFI R antibodies may be administered with other therapeutic agents, for example, methotrexate, anti-TNF agents such as
Remicade, Humira, Simponi, and Enbrel; glucocorticoids such as prednisone;
Leflunomide; Azotliioprine; JAK inhibitors such as CP 590690; SYK inhibitors such as R788; anti-IL-6 antibodies; anti-IL-6R antibodies; anti-CD-20 antibodies; anti- CD^ antibodies; anti-GM-CSF antibodies; and anti-GM-CSF-R antibodies. For treatment of multiple sclerosis, anti-CSFIR antibodies may be administered with other therapeutic agents, for example, interferon alpha; interferon beta; prednisone; anti-alpha4 integrin antibodies such as Tysabri; anti-CD20 antibodies such as Rituxan; FTY720 (Fingolimod); and Cladribine (Leustatin).
EXAMPLES
[0176] The examples discussed below are intended to be purely exemplary of the invention and should not be considered to limit the invention in any way. The examples are not intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (for example, amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated othenvise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
Example 1 : Selection of Fabs that bind CSFIR extracellular domain (ECD)
[0177] Mice were immunized with a human CSFIR extracellular domain Fc fusion, hCSFI R ECD.506-Fc (SEQ ID NO: 6). Spleens from immunized mice were isolated, and a Fab phage display library was created from the spenocytes. Fab- expressing phage were selected for binding to human CSFIR ECD. Fabs from positive-binding phage were expressed and purified from bacteria. A total of 1056 Fab clones were selected for further analysis.
[0178] Fabs were screened for the ability to bind human CSFIR ECD, block binding of human CSFl to human CSFIR ECD, and block binding of human IL34 to human CSFI R ECD. Sequence analysis and clusertering of the Fabs that were selected from that screen was then performed and certain unique Fabs were selected.
[0179] The unique Fabs were further analyzed for the ability to bind human CSFIR ECD, the ability to bind cynomolgus CSFIR ECD, and the ability to bind mouse CSFIR ECD. The Fabs were also analyzed for the ability to block human CSFl binding to human CSFIR ECD and the ability to block human IL34 binding to human CSFIR ECD, and the ability to inliibit ligand-induced CSFIR phosphorylation in the presence of CSFl or IL34. (Data not shown.) Example 2: Reformatting of anti-CSFIR Fabs to make chimeric antibodies
[0180] Following the Fab characterization, eleven of the Fabs were selected for reformatting to chimeric antibodies. Each Fab was reformatted to a chimeric antibody comprising a human IgG4 heavy chain constant region with the S241P mutation, and a human κ light chain constant region. Briefly, Fab VH regions cloned into and expressed from vector pTT5 (Biotechnology Research Institute, Montreal, Canada; and National Research Research Council of Canada, Ottawa, Canada) modified to contain a mouse IgH leader sequence (SEQ ID NO: 4) and a human IgG4 heavy chain constant region with the S241P mutation (SEQ ID NO: 94). Fab VL regions were cloned into and expressed from vector pTT5 modified to contain a mouse IgK leader sequence (SEQ ID NO: 3) and a human IgK light chain constant region (SEQ ID NO: 95). Fab V regions were inserted in such a way as not to introduce non-antibody derived amino acid sequences into the final proteins.
Example 3: Expression and characterization of chimeric antibodies
[0181 ] The chimeric antibodies were transiently expressed and purified substantially as described below in Example 5.
[0182] The 1 1 chimeric antibodies were assayed for binding to human, cynoinolgus, and mouse CSFI R ECD. The chimeric antibodies were also assayed for the ability to block binding of human CSF1 to human CSF ] R ECD, the ability to block binding of human IL34 to human CSFIR ECD, the ability to block binding of human CSF1 to cynomolgus CSFIR ECD, and the ability to inhibit ligand-induced CSFI R phosphorylation in the presence of CSF1 or IL34. The chimeric antibodies were further assayed for binding to CSFIR on the surface of cells. Finally, the chimeric antibodies were assayed to confirm that they do not induce CSFI R phosphorylation in the absence of ligand. (Data not shown.)
Example 4: Humanization of anti-CSFIR antibodies
[0183] From the analyses described above, chimeric anti-CSFIR antibodies 0301 , 0302, and 031 1 were selected for humanization. The antibodies were humanized by changing certain amino acid residues in the framework regions of the heavy and light chain variable regions. The criteria used for humanization were as described previously, e.g., in U.S. Publication No. US 2009/0136500.
[0184] For cAb 0301 , three humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of six humanized antibodies, Abl to Ab6. For cAb 0302, two humanized heavy chain variable regions and three humanized light chain variable regions were designed, for a total of six humanized antibodies, Ab7 to Abl 2. For cAb 0311 , two humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of four humanized antibodies, Abl 3 to Abl 6.
[0185] The sequences for each of the humanized heavy chain variable regions and humanized light chain variable regions, aligned with the sequences of the parental chimeric antibody variable regions and the sequences of the human acceptor variable framework regions are shown in Figures 1 (heavy chains) and 2 (light chains). The changes in humanized variable region sequences relative to the human acceptor variable framework region sequences are boxed. Each of the CDRs for each of the variable regions is shown in a boxed region, and labeled as "CDR" above the boxed sequences.
[0186] Table 8, below, shows the full sequences for the humanized heavy chains and humanized light chains of antibodies Abl to Abl 6. The name and SEQ ID NOs of the humanized heavy chain and humanized light chain of each of those antibodies is shown in Table 2.
Table 2: Humanized heavy chains and light chains of Abl to Abl 6
Figure imgf000049_0001
Abl 4 h0311 -Hl 58 h0311 -Ll 66
AM 5 h031 1 -H2 59 h031 1 -L0 65
Ab l 6 h031 1 -H2 59 h031 1 -Ll 66
Example 5: Humanized auti-CSFlR antibodies bind to human and cynomolgus CSF1R ECD, but not to mouse CSF1R ECD
[0187] The 16 humanized antibodies were transiently expressed in CHO cells, as follows. CHO-3E7 cells were co-transfected with individual heavy and light chain expression plasmids at a mass ratio of 1 heavy chain plasmid to 2 light chain plasmids using polyethyleneinimine (PEI) at a DNA:PEI ratio of 1 :5. Total DNA used per transfection was 1.5 μg/ml of cells.
[0188] Humanized antibodies were purified from transfected cell supematants using HiTrap Protein A HP columns (GE Healthcare) followed by further purification using Phenyl HP columns (GE Healthcare). Antibody containing supematants were loaded onto HiTrap Protein A HP columns pre-equilibrated with PBS/0.5M NaCl. Antibody loaded columns were washed with 10 column volumes PBS/0.5M NaCl, and eluted with a mixed linear-step gradient of 0.1 M Glycine, pH 2.7/ 0.5 M NaCl directly into 100 ul of 1M Tris buffer, pH 8.0. Antibody containing eluates were dialyzed against PBS, after which 2.4 M (NH4)2S04 (Sigma) was added to achieve a conductivity equal to that of 1 OmM Potassium Phosphate pH7.0/l .2 M (NH4)2S04. Antibodies were then loaded on 1 ml Phenyl HP columns (GE Healthcare) pre- equilibrated with lOmM Potassium Phosphate pH7.0/1.2 M (NH4)2S04. Antibody loaded columns were washed with 15 column volumes lOmM Potassium Phosphate pH7.0/l .2 M (NH4)2S0 , and eluted with a 20 column volume gradient of 10 niM Potassium Phosphate, pH 7.0. Antibody containing fractions were pooled and dialyzed against PBS.
[0189] The humanized antibodies, along with their parental chimeric antibodies (cAbs), were assayed for binding to human, cynomolgus, and mouse CSF1R ECD, as follows.
Human CSF1R Binding Activity
[01 90] Ninety-six well clear-bottom ELISA plates were coated overnight with 1 ^ig/ml recombinant hCSFI R ECD.506-Fc (SEQ ID NO: 6; FivePrime Therapeutics) or Human M-CSF R Fc Chimera (R&D Systems) in PBS. The next morning, wells were washed four times with 0.05% Tween20 in PBS (PBST) and blocked with Blocker-Blotto (Pierce). Fifty μΐ of 0.5x serial dilutions of the humanized antibody or parental chimeric antibody, beginning with 2000 ng/ml, diluted 1 : 1 in Blocker-Blotto were added to the CSFlR-coated wells. After incubation at room temperature (RT) for 90 min, wells were washed four times with PBST, and a 1 : 5000 dilution of a peroxidase-conjugated Goat anti-Human kappa Light chain antibody (Sigma) in Blocker-Blotto was added to each well. After incubation at RT for 60 min, wells were washed four times with PBST, and 50 μΐ o-phenylenediamine dihydrochloride peroxidase substrate (Sigma) was added to each well. After incubation at RT for 30 min, A450 values of each well were read directly on a SpectraMaxPlus
spectrophotometer with SoftMaxPro software (Molecular Devices).
[0191 ] The results of that experiment is hown in Figure 3. All of the humanized antibodies bound to human CSFIR ECD within the range of
concentrations tested.
Cynomolgus CSFIR Binding Curve
[0192] The binding curve for each humanized antibody binding to
cynomolgus CSFIR ECD was determined as described above for human CSFIR, except the wells of the clear-bottom ELISA plates were coated overnight with 2 μg/ml recombinant cynoCSFIR ECD-Fc (FivePrime Therapeutics, SEQ ID NO: 8, but without the 19 amino acid leader sequence).
[0193] The results of that experiment are shown in Figure 4. All of the humanized antibodies bound to cynomolgus CSFIR ECD within the range of concentrations tested.
Mouse CSFIR Binding Curve
[0194] The binding curve for each humanized antibody binding to mouse CSFIR ECD was determined as described above for human CSFIR, except the wells of the clear-bottom ELISA plates were coated overnight with 2 μg/ml recombinant mCSFI R ECD-Fc (FivePrime Therapeutics, SEQ ID NO: 93).
[0195] The results of that experiment are shown in Figure 5. None of the humanized antibodies, or the parental chimeric antibodies, detectably bound to mouse CSFIR ECD over the range of concentrations tested.
Calculation ofEC50s
[0196] Table 3 shows the EC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software) for each humanized antibody binding to human CSFIR ECD and cynomolgus CSFIR ECD. Because none of the chimeric antibodies detectably bound to mouse CSFIR ECD, an EC50 could not be calculated from that data. Table 3 also includes the calculated EC50s for the parental chimeric antibodies.
Table 3: Binding activity of humanized anti-CSFIR antibodies
Figure imgf000052_0001
Example 6: Humanized anti-CSFIR antibodies inhibit ligaiid-induced CSFIR phosphorylation
[0197] CSFIR is phosphorylated in the presence of ligands CSFl or IL34. The humanized antibodies, along with their parental chimeric antibodies (cAbs), were tested for their ability to inhibit CSFI R phosphoiylation induced by either ligand, as follows.
Inhibition of CSFl -Induced Phosphorylation
[0198] CSFIR (SEQ ID NO: 2)-transfected CHO cells were incubated with serial dilutions of each humanized antibody or a parental chimeric antibody, beginning at 8 ng/ml, for 60 min on ice, after which 3.3 iiM of human CSFl (M-CSF, R&D Systems) was added to the cells. (For the 0301 series of humanized antibodies, serial dilutions beginning at 2 μ^ηι] of humanized antibody and parental chimeric antibody was used.) The cells were incubated for 3 minutes at 37°C, and then lysed by addition of 1/lOx volume of lOx cell lysis buffer (Cell Signaling Technology). The amount of phosphorylated CSF1R in the cell lysates was quantified using a human phospho-M-CSF R ELISA kit (R&D Systems) according to the
manufacturer ' s instructions.
[0199] The results of that experiment are shown in Figures 6 A to 6C. All of the humanized antibodies were able to inhibit human CSF1 -induced phosphorylation of human CSF1R ECD within the range of concentrations tested.
Inhibition of IL34-Induced Phosphorylation
[0200] CSF1R (SEQ ID NO: 2)-transfected CHO cells were incubated with 0.002 to 8 ^ig/ml of each humanized antibody or a parental chimeric antibody for 60 min on ice, after which 3.3 nM of human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was added to the cells. The cells were incubated for 3 minutes at 37°C, and then lysed by addition of 1/1 Ox volume of lOx cell lysis buffer (Cell Signaling
Technology). The amount of phosphorylated CSF1R in the cell lysates was quantified using a human phospho-M-CSF R ELISA kit (R&D Systems) according to the manufacturer's instructions.
[0201] The results of that experiment are shown in Figures 7 A to 7C. All of the humanized antibodies were able to inhibit human IL34-induced phosphorylation of human CSF1R within the range of concentrations tested.
Example 7: Humanized anti-CSFIR antibodies block human CSF1 and human IL34 binding to human and cynomolgous CSF1R
Human CSF1/CSF1R Blocking Activity
[0202] The humanized antibodies, along with the parental chimeric antibodies (cAbs), were tested for their ability to block human CSF1 binding to human and cynomolgus CSF1R ECD, as follows.
[0203] Recombinant Human CSF1 (M-CSF; R&D Systems) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies). One hundred μΐ of 1 μg/ml biotinylated CSF1 in PBST/0.1 % BSA was added to the wells of Reacti- Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions. Fifty μΐ of 0.5x serial dilutions of the humanized antibody or parental chimeric antibody, beginning with 2000 ng/ml, was incubated with 50 ng/ml hCSFIR ECD.506-Fc (SEQ ID NO: 6; FivePrime Therapeutics) or 50 ng/ml cynoCSFIR ECD-Fc (FivePrime Therapeutics, SEQ ID NO: 8, but without the 19 amino acid leader sequence) in 100 μΐ PBST/0.1 % BSA for 90 min at RT, after which the admix was transferred to one or more wells of a ligand- coated plate. After 90 min at RT, wells were washed with PBST, and a 1 :5000 dilution of an Fc-fragment-specific peroxidase-conjugated goat anti-human IgG (Jackson Im iuno Research) in PBST/0.1 % BSA was added to each well. After incubation at RT for 60 min, wells were washed with PBST/0.1 % BSA, and o- phenylenediamine dihydrochloride peroxidase substrate (Sigma) was added to each well. After incubation at RT for 30 min, A450 values of each well were read directly on a SpectraMaxPlus spectrophotometer with SoftMaxPro software (Molecular Devices).
[0204] The results of that experiment for cynomolgus CSF1R are shown in Figures 8A to 8C. All of the humanized antibodies based on Fabs 0301 and 031 1 were able to block human CSF1 binding to cynomolgus CSF1R ECD within the range of concentrations tested. None of the humanized antibodies based on Fab 0302 showed similar blocking activity in that experiment compared to the blocking activity of cAb 0302.
Human IL34/CSF1R Blocking Activity
[0205] The humanized antibodies were tested for their ability to block human IL34 binding to human CSF1R ECD. The blocking activity of each humanized antibody was determined as described above for blocking of CSF1 , except recombinant human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies), and then 100 μΐ of 1 μg ml biotinylated recombinant IL34 in PBST/0.1 % BSA was added to the wells of Reacti-Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions.
[0206] The results of that experiment for cynomolgus CSF1R are shown in Figures 9A to 9C. All of the humanized antibodies based on Fabs 0301 and 031 1 were able to block human IL34 binding to cynomolgus CSFIR ECD within the range of concentrations tested. None of the humanized antibodies based on Fab 0302 showed similar blocking activity in that experiment compared to the blocking activity of cAb 0302.
Calculation of IC50s [0207] Table 4 shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for inhibition of ligand-induced CSFI R phosphoiylation by each humanized antibody. Table 4 also shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for blocking of ligand binding to CSF I R ECD by each humanized antibody. Finally, Table 4 shows the number of amino acids in the framework regions of the light and heavy chain of each humanized antibody that were back-mutated to the corresponding mouse amino acid residue. For example, humanized antibody h0301 LlHl has one amino acid in a light chain framework region that was back-mutated to the mouse amino acid, and one amino acid in the heavy chain framework regions that was back- mutated to the mouse amino acid. Referring to Figures 1 and 2, the back-mutated amino acid in the light chain framework is at position 1 in framework 1 , and the back- mutated amino acid in the heavy chain is at position 71 in framework 3 according to Kabat numbering (see Figure I B).
Table 4: Blocking activity of humanized anti-CSF IR antibodies
Figure imgf000055_0001
h0311 -L0Hl 291.3 343.2 32.47 50.4 0 + 2 h0311 -LlHl 507.5 667.4 24.68 53.69 2 + 2 h0311 -L0H2 435.5 633.3 25.96 40.79 0 + 5 h031 1 -LlH2 419 578.2 30.76 48.56 2 + 5
Example 8: Humanized anti-CSFlR antibody binding constants
[0208] The ka, 1¾, and ¾ for binding to human CSF1R ECD was determined for each of the humanized antibodies as follows.
[0209] Binding kinetics of anti-CSFIR humanized antibodies to CSF1R ECD was determined using Biacore T100 Surface Plasmon Resononance (SPR) (GE Healthcare Life Sciences, Piscataway, NY). Each of the humanized anti-CSFIR antibodies was captured on a CM5 sensor chip immobilized with anti-Human IgG antibody using the Human antibody capture kit (GE Healthcare Life Sciences, Piscataway, NY) at 150RU so that the Rmax value for hCSFIR ECD.506 (SEQ ID NO: 5) binding was 100RU. Rmax values of less than 150RU are recommended for accurately determining kinetic values. 10 niM Hepes buffered saline, pH 7.4, with 0.05% Tween20 (HPS-P; GE Healthcare Life Sciences, Piscataway, NY) was used as the ranning and dilution buffer. hCSFIR ECD.506 was injected at six concentrations (90 nM, 30 nM, 10 nM, 3.33 nM, 1.1 1 nM, and 0 nM) for 2 minutes and dissociation was observed for 5 minutes to detemiine humanized antibody/hCSFIR ECD binding kinetic parameters. The association constant, dissociation constant, affinity, and binding capacity of each of the Fabs for human CSF1 R ECD was calculated using the Biacore T100 Evaluation software package using the 1 : 1 binding model.
[0210] The results of the kinetic determinations are shown in Table 5.
Table 5: Humanised antibody binding affinity for human CSF1R
Figure imgf000056_0001
huAb 0302-L0H2 3.40 x 106 1.79 x 10-03 0.53 huAb 0302-Ll H2 2.71 x 106 1.53 x 10-03 0.56 huAb 0302-L2H2 1.84 x 106 8.40 x 10-04 0.46 huAb 031 1 -L0H 1 1.22 x 106 5.40 x 10-04 0.44 huAb 031 1 -LI HI 1.32 x 106 6.64 x 10-04 0.50 huAb 031 1 -L0H2 1.34 x 106 4.73 x 10-04 0.35 huAb 031 1 -LlH2 1.51 x 106 6.09 x 10-04 0.40
[021 1 ] All but two of the humanized antibodies showed sub-nanomolar binding affinities for human CSFIR ECD, and the remaining two humanized antibodies showed binding affinities for human CSFIR ECD of less than 2 nM.
Example 9: Humanized anti-CSFIR antibodies block ligand-induced phosphorylation
[0212] Based on the data above, including CSFI R binding and ligand inhibition, and the likelihood of immunogenic ity for each humanized antibody, three humanized antibodies were selected for further study: 0301-L0H0, 0301 -L1H0, and 031 1 -L0H1.
[0213] After confirming that 0301 -L0H0, 0301 -LlHO, and 031 1 -LOHl each bind to CSFIR on the surface of cells (data not shown), each of the antibodies was tested for the ability to block ligand-induced CSFIR phosphoiylation in CHO cells, as described in Example 6.
[0214] The results of that experiment are shown in Figure 10. All tln-ee of the humanized antibodies tested blocked both CSF1 -induced (A) and IL34-induced (B) phosphoiylation of CSF IR in CHO cells. Table 6 shows the IC50 for blocking of ligand-induced CSFIR phosphoiylation for each antibody.
Table 6: Ligand-induced phosphorylation blocking IC50 for humanized antibodies
Figure imgf000057_0001
Example 10: Humanized anti-CSFIR antibodies block ligand-induced proliferation/survival responses of primary human monocytes
[0215] Humanized antibodies 0301-L0H0, 0301-LlHO, and 0311-LOHl were tested for their ability to block ligand-induced monocyte proliferation/survival responses as follows. [0216] Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor blood by centrifugation onto a Ficoll-Paque cushion (GE
Healthcare Bio-Sciences) according to the manufacturer's instructions. Peripheral blood monocytes were subsequently isoated from the recovered PBMC fraction by centrifugation onto a 48.5% Percoll™ cushion (GE Healthcare Bio-Sciences). After recovery from the Percoll™ cushion, the purified peripheral blood monocytes were stimuated with 162 pM recombinant human CSF1 or 1.6 nM recombinant human IL34 (both from R&D Systems) in the presence or absence of serial dilutions of humanised antibody 0301 -LOHO, humanised antibody 0301 -LI HO, or humanised antibody 0311-LOHl . After incubation at 37°C for 48 hours, relative cellular ATP content of each individual culture was assessed using CellTiter-Glo® reagent (Promega) according to the manufacturer's instructions. In this assay, relative cellular ATP content is directly proportional to the number of viable cells in culture, and thus reflects monocyte proliferation/survival responses.
[0217] The results of that experiment are shown in Figure 1 1. All three of the humanized antibodies tested were able to block monocyte proliferation/survival responses following CSF1 (A) or 1L34 (B) stimulation. Table 7 shows the lC50s for blocking of ligand-induced monocyte proliferation/survival responses for each antibody. The values shown in Table 7 represent the range observed from the three different primary donors tested.
Table 7: Monocyte proliferation survival blocking IC50 for humanized antibodies
Figure imgf000058_0001
Example 11 : Humanized anti-CSFlR antibodies do not directly stimulate primary human monocyte proliferation or survival responses
[0218] Humanized antibodies 0301 -L0H0, 0301 -LI HO, and 031 1 -L0H1 were tested for their ability to directly stimulate primary monocyte proliferation and/or survival, as follows.
[0219] Human peripheral blood monocytes were isolated as described in Example 10. Serial dilutions of humanised antibody 0301-LOHO, humanised antibody 0301-L1H0, or humanised antibody 031 1 -LOHl were added to the monocytes in the absence of stimulation either by exogenous CSF1 or by exogenous IL34. After incubation at 37°C for 48 hours, relative ATP content of each individual cuture was assessed using CellTiter Glo® reagent (Promega) as in Example 10. The experiment was earned out on peripheral blood monocytes from three different donors.
[0220] The results of that experiment are shown in Figure 12. None of the humanized antibodies stimulated primary monocyte proliferation or survival in either of the prima l monocyte preparations tested.
TABLE OF SEQUENCES
[0221 ] Table 8 provides certain sequences discussed herein. All polypeptide and antibody sequences are shown without leader sequences, unless otherwise indicated.
Table 8: Sequences and Descriptions
SEQ ID Description Sequence
NO
IPVIEPSVPE LWKPGATVT LRCVGNGSVE WDGPPSPHWT LYSDGSSSIL STNNATFQNT GTYRCTEPGD PLGGSAAIHL YVKDPARPWN VLAQEWVFE DQDALLPCLL TDPVLEAGVS LVRVRGRPL RHTNYSFSPW HGFTIHRAKF IQSQDYQCSA LMGGRKVMSI SIRLKVQKVI PGPPALTLVP AELVRIRGEA AQIVCSASSV DVNFDVFLQH NNTKLAIPQQ SDFHNNRYQK VLTLNLDQVD FQHAGNYSCV ASNVQGKHST SMFFRWESA YLNLSSEQNL IQEVTVGEGL NLKVMVEAYP GLQGFN TYL GPFSDHQPEP KLANATTKDT YRHTFTLSLP RLKPSEAGRY SFLARNPGGW RALTFELTLR YPPEVSVIWT FINGSGTLLC
hCSFI R AASGYPQPNV TWLQCSGHTD RCDEAQVLQV DDPYPEVLS QEPFHKVTVQ (full-length, SLLTVETLEH NQTYECRAHN SVGSGSWAFI PISAGAHTHP PDEFLFTPW no leader VACMSIMALL LLLLLLLLYK YKQKPKYQVR KIIESYEGN SYTFIDPTQL sequence) PYNEKWEFPR NNLQFGKTLG AGAFGKWEA TAFGLGKEDA VLKVAVKMLK
STAHADEKEA LMSELKIMSH LGQHENIV L LGACTHGGPV LVITEYCCYG DLLNFLRRKA EAMLGPSLSP GQDPEGGVDY KNIHLEKKYV RRDSGFSSQG VDTYVEMRPV STSSNDSFSE QDLDKEDGRP LBLRDLLHFS SQVAQGMAFL ASKNCIHRDV AARNVLLTNG HVAKIGDFGL ARDIMNDSNY IVKGNARLPV K MAPESIFD CVYTVQSDVW SYGILLWEIF SLGLNPYPGI LVNSRFYKLV KDGYQMAQPA FAP NIYSIM QACWALEPTH RPTFQQICSF LQEQAQEDRR ERDYTNLPSS SRSGGSGSSS SELEEESSSE HLTCCEQGDI AQPLLQPNNY QFC
MGPGVLLLLL VATAWHGQGI PVIEPSVPEL WKPGATVTL RCVGNGSVEW DGPPSPHWTL YSDGSSSILS TNNATFQNTG TYRCTEPGDP LGGSAAIHLY V DPARPW V LAQEWVFED QDALLPCLLT DPVLEAGVSL VRVRGRPLMR HTNYSFSPWH GFTIHRAKFI QSQDYQCSAL MGGRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASSVD VNFDVFLQHN NTKLAIPQQS
hCSFI R DFHNNRYQKV LTLNLDQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY (full-length, LNLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK + leader LANATTKDTY RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY sequence) PPEVSVIWTF INGSGTLLCA ASGYPQPNVT WLQCSGHTDR CDEAQVLQVW
DDPYPEVLSQ EPFHKVTVQS LLTVETLEHN QTYECRAHNS VGSGSWAFIP ISAGAHTHPP DEFLFTPVW ACMSIMALLL LLLLLLLYKY KQKPKYQVRW KIIESYEGNS YTFIDPTQLP YNEKWEFPRN NLQFGKTLGA GAFGKWEAT AFGLGKEDAV LKVAVKMLKS TAHADEKEAL SELKIMSHL GQHENIVNLL GACTHGGPVL VITEYCCYGD LLNFLRRKAE AMLGPSLSPG QDPEGGVDYK IHLEKKYVR RDSGFSSQGV DTYVEMRPVS TSSNDSFSEQ DLDKEDGRPL ELRDLLHFSS QVAQGMAFLA SKNCIHRDVA ARNVLLTNGH VAKIGDFGLA RDIMNDSNYI VKGNARLPVK MAPESIFDC VYTVQSDV S YGILLWEIFS LGLNPYPGIL VNSKFYKLVK DGYQMAQPAF APKNIYSIMQ ACWALEPTHR PTFQQICSFL QEQAQEDRRE RDYTNLPSSS RSGGSGSSSS ELEEESSSEH LTCCEQGDIA QPLLQPNNYQ FC
IPVIEPSVPE LVVKPGATVT LRCVGNGSVE WDGPPSPHWT LYSDGSSSIL STNNATFQNT GTYRCTEPGD PLGGSAAIHL YVKDPARPWN VLAQEVWFE DQDALLPCLL TDPVLEAGVS LVRVRGRPLM RHTNYSFSPW HGFTIHRAKF IQSQDYQCSA LMGGRKVMSI SIRLKVQKVI PGPPALTLVP AELVRIRGEA AQIVCSASSV DVNFDVFLQH NNTKLAIPQQ SDFHNNRYQK VLTLNLDQVD
hCSFI R
FQHAGNYSCV ASNVQGKHST SMFFRWESA YLNLSSEQNL IQEVTVGEGL ECD.506
NLKVMVEAYP GLQGFNWTYL GPFSDHQPEP KLANATTKDT YRHTFTLSLP RLKPSEAGRY SFLARNPGGW RALTFELTLR YPPEVSVIWT FINGSGTLLC AASGYPQPNV TWLQCSGHTD RCDEAQVLQV WDDPYPEVLS QEPFHKVTVQ SLLTVETLEH NQTYECRAHN SVGSGSWAFI PISAGAH
IPVIEPSVPE LVVKPGATVT LRCVGNGSVE WDGPPSPHWT LYSDGSSSIL STNNATFQNT GTYRCTEPGD PLGGSAAIHL YVKDPARPWN VLAQEVWFE DQDALLPCLL TDPVLEAGVS LVRVRGRPLM RHTNYSFSPW HGFTIHRAKF IQSQDYQCSA LMGGRKVMSI SIRLKVQKVI PGPPALTLVP AELVRIRGEA AQIVCSASSV DVNFDVFLQH NNTKLAIPQQ SDFHNNRYQK VLTLNLDQVD FQHAGNYSCV ASNVQGKHST SMFFRWESA YLNLSSEQNL IQEVTVGEGL NLKVMVEAYP GLQGFNWTYL GPFSDHQPEP KLANATTKDT YRHTFTLSLP
hCSFI R RLKPSEAGRY SFLARNPGGW RALTFELTLR YPPEVSVIWT FINGSGTLLC ECD.506-Fc AASGYPQPNV TWLQCSGHTD RCDEAQVLQV WDDPYPEVLS QEPFHKVTVQ
SLLTVETLEH NQTYECRAHN SVGSGSWAFI PISAGAHEPK SSDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVWDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRWSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
MGPGVLLLLL WTAWHGQGI PVIEPSGPEL WKPGETVTL RCVGNGSVEW DGPISPHWTL YSDGPSSVLT TTNATFQNTR TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAKEVWFED QDALLPCLLT DPVLEAGVSL VRLRGRPLLR HTNYSFSPWH GFTIHRAKFI QGQDYQCSAL MGSRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASNID VDFDVFLQHN TTKLAIPQRS
ECD (with
DFHDNRYQKV LTLSLGQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
leader
LDLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK
sequence) LANATTKDTY RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY
PPEVSVIWTS INGSGTLLCA ASGYPQPNVT WLQCAGHTDR CDEAQVLQVW VDPHPEVLSQ EPFQKVTVQS LLTAETLEHN QTYECRAHNS VGSGSWAFIP ISAGAR
MGPGVLLLLL WTAWHGQGI PVIEPSGPEL WKPGETVTL RCVGNGSVEW DGPISPHWTL YSDGPSSVLT TTNATFQNTR TYRCTEPGDP LGGSAAIHLY VKDPARPWNV LAKEVWFED QDALLPCLLT DPVLEAGVSL VRLRGRPLLR HTNYSFSPWH GFTIHRAKFI QGQDYQCSAL MGSRKVMSIS IRLKVQKVIP GPPALTLVPA ELVRIRGEAA QIVCSASNID VDFDVFLQHN TTKLAIPQRS DFHDNRYQKV LTLSLGQVDF QHAGNYSCVA SNVQGKHSTS MFFRVVESAY
cynoCSFl R
LDLSSEQNLI QEVTVGEGLN LKVMVEAYPG LQGFNWTYLG PFSDHQPEPK ECD-Fc
LANATTKDTY RHTFTLSLPR LKPSEAGRYS FLARNPGGWR ALTFELTLRY
(with leader
PPEVSVIWTS INGSGTLLCA ASGYPQPNVT WLQCAGHTDR CDEAQVLQVW
sequence)
VDPHPEVLSQ EPFQKVTVQS LLTAETLEHN QTYECRAHNS VGSGSWAFIP ISAGARGSEP KSSDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVWDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK Light chain
leader METDTLLLWV LLLWVPGSTG
sequence
Heavy chain
leader MAVLGLLLCL VTFPSCVLS
sequence
Fab 0301
EVQLQQSGPE LVRPGASVKM SCKASGYTFT DNYMIWVKQS HGKSLEWIGD
heavy chain
INPYNGGTTF NQKFKGKATL TVEKSSSTAY MQLNSLTSED SAVYYCARES
variable
PYFSNLYVMD YWGQGTSVTV SS
region
Fab 0301
NIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDNYMNWY QQKPGQPPKL
light chain
LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCHLSNEDLS
variable
TFGGGTKLEI K
region
Fab 0302
EIQLQQSGPE LVKPGASVKM SCKASGYTFS DFNIHWVKQK PGQGLEWIGY
heavy chain
INPYTDVTVY NEKFKGKATL TSDRSSSTAY MDLSSLTSED SAVYYCASYF
variable
DGTFDYALDY WGQGTSITVS S
region
Fab 0302
DVWTQTPAS LAVSLGQRAT ISCRASESVD NYGLSFMNWF QQKPGQPPKL
light chain
LIYTASNLES GIPARFSGGG SRTDFTLTID PVEADDAATY FCQQSKELPW
variable
TFGGGTRLEI K
region
Fab 031 1
EIQLQQSGPD LMKPGASVKM SCKASGYIFT DYNMHWVKQN QGKSLEWMGE
heavy chain
INPNNGVWY NQKFKGTTTL TVDKSSSTAY MDLHSLTSED SAVYYCTRAL
variable
YHSNFGWYFD SWGKGTTLTV SS
region
Fab 0311
DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSHMNWY QQKPGQPPKL
light chain LIYTASNLES GIPARFSGSG SGADFTLTIH PVEEEDAATY YCQQGNEDPW variable
TFGGGTRLEI K
region
0301 heavy
GYTFTDNYMI
chain CDR1
0301 heavy
DINPYNGGTT FNQKFKG
chain CDR2
0301 heavy
ESPYFSNLYV MDY
chain CDR3
0301 light
KASQSVDYDG DNYMN
chain CDR1
0301 light
AASNLES
chain CDR2
0301 light
HLSNEDLST
chain CDR3
0302 heavy
GYTFSDFNIH
chain CDR1
0302 heavy
YINPYTDVTV YNEKFKG
chain CDR2
0302 heavy
YFDGTFDYAL DY
chain CDR3
0302 light
RASESVDNYG LSFMN
chain CDR1 0302 light
TASNLES
chain CDR2
0302 light
QQSKELPWT
chain CDR3
031 1 heavy
GYIFTDYN H
chain CDR1
031 1 heavy
EINPNNGVW YNQKFKG
chain CDR2
031 1 heavy
ALYHSNFGWY FDS
chain CDR3
031 1 light
KASQSVDYDG DSHMN
chain CDR1
031 1 light
TASNLES
chain CDR2
031 1 light
QQGNEDPWT
chain CDR3
EVQLQQSGPE LVRPGASVKM SCKASGYTFT DNYMIWVKQS HGKSLEWIGD INPYNGGTTF NQKFKGKATL TVEKSSSTAY MQLNSLTSED SAVYYCARES PYFSNLYVMD YWGQGTSVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
cAb 0301
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain
DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
NIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDNYMNWY QQKPGQPPKL LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCHLSNEDLS
cAb 0301
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIQLQQSGPE LVRPGASVKM SCKASGYTFS DFNIHWVKQK PGQGLEWIGY INPYTDVTVY NEKFKGKATL TSDRSSSTAY MDLSSLTSED SAVYYCASYF DGTFDYALDY WGQGTSITVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSW TVPSSSLGTK
cAb 0302
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD
heavy chain
TLMISRTPEV TCVWDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRWSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK
DVWTQTPAS LAVSLGQRAT ISCRASESVD NYGLSFMNWF QQKPGQPPKL LIYTASNLES GIPARFSGGG SRTDFTLTID PVEADDAATY FCQQSKELPW
cAb 0302
TFGGGTRLEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIQLQQSGPD LMKPGASVKM SCKASGYIFT DYNMHWVKQN QGKSLEWMGE INPNNGVWY NQKFKGTTTL TVDKSSSTAY MDLHSLTSED SAVYYCTRAL YHSNFGWYFD SWGKGTTLTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
cAb 031 1
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain
DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSHMNWY QQKPGQPPKL LIYTASNLES GIPARFSGSG SGADFTLTIH PVEEEDAATY YCQQGNEDPW
cAb 0311
TFGGGTRLEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
h0301-H0
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD
heavy chain
INPYNGGTTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARES
variable
PYFSNLYVMD YWGQGTLVTV SS
region
h0301-Hl
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD
heavy chain
INPYNGGTTF NQKFKGRVTI TVDKSTSTAY MELSSLRSED TAVYYCARES
variable
PYFSNLYVMD YWGQGTLVTV SS
region
h0301-H2
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWIGD
heavy chain
INPYNGGTTF NQKFKGRATL TVDKSTSTAY MELSSLRSED TAVYYCARES
variable
PYFSNLYVMD YWGQGTLVTV SS
region
H0302-H 1
QVQLVQSGAE VKKPGSSVKV SCKASGYTFS DFNIHWVRQA PGQGLEWMGY
heavy chain
INPYTDVTVY NEKFKGRVTI TSDKSTSTAY MELSSLRSED TAVYYCASYF
variable
DGTFDYALDY WGQGTLVTVS S
region
H0302-H2
QVQLVQSGAE VKKPGSSVKV SCKASGYTFS DFNIHWVRQA PGQGLEWIGY
heavy chain
INPYTDVTVY NEKFKGRATL TSDKSTSTAY MELSSLRSED TAVYYCASYF
variable
DGTFDYALDY WGQGTLVTVS S
region
H031 1 -H1
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT DYNMHWVRQA PGQGLEWMGE
heavy chain
INPNNGVWY NQKFKGRVTI TVDKSTSTAY MELSSLRSED TAVYYCTRAL
variable
YHSNFGWYFD SWGQGTLVTV SS
region
H031 1-H2
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT DYNMHWVRQA PGQGLEWMGE
heavy chain
INPNNGVWY NQKFKGTTTL TVDKSTSTAY MELSSLRSED TAVYYCTRAL
variable YHSNFGWYFD SWGQGTLVTV SS
region
h0301-L0 EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL light chain
LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS
variable
TFGGGTKVEI K
region
h0301 -Ll
NIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL
light chain
LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS
variable
TFGGGTKVEI K
region
H0302-L0
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWY QQKPGQAPRL
light chain
LIYTASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSKELPW
variable
TFGQGTKVEI K
region
H0302-L1
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWY QQKPGQAPRL
light chain
LIYTASNLES GIPARFSGSG SRTDFTLTIS SLEPEDFAVY YCQQSKELPW
variable
TFGQGTKVEI K
region
H0302-L2
EIWTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWF QQKPGQAPRL
light chain
LIYTASNLES GIPARFSGSG SRTDFTLTIS SLEPEDFAVY YCQQSKELPW
variable
TFGQGTKVEI K
region H031 1 -L0
EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDSHMNWY QQKPGQAPRL
light chain
LIYTASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQGNEDPW
variable
TFGQGTKVEI K
region
H031 1-L1
DIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDSHMNWY QQKPGQAPRL
light chain
LIYTASNLES GIPARFSGSG SGADFTLTIS SLEPEDFAVY YCQQGNEDPW
variable
TFGQGTKVEI K
region
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD INPYNGGTTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARES PYFSNLYVMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
h0301 -H0
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain
DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD INPYNGGTTF NQKFKGRVTI TVDKSTSTAY MELSSLRSED TAVYYCARES PYFSNLYVMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
h0301-Hl
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWIGD INPYNGGTTF NQKFKGRATL TVDKSTSTAY MELSSLRSED TAVYYCARES PYFSNLYVMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
h0301-H2
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain
DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYTFS DF IHWVRQA PGQGLEWMGY INPYTDVTVY NEKFKGRVTI TSDKSTSTAY MELSSLRSED TAVYYCASYF DGTFDYALDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSW TVPSSSLGTK
H0302-H1
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD
heavy chain
TLMISRTPEV TCVWDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRWSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYTFS DFNIHWVRQA PGQGLEWIGY I PYTDVTVY NEKFKGRATL TSDKSTSTAY MELSSLRSED TAVYYCASYF DGTFDYALDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSW TVPSSSLGTK
H0302-H2
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD
heavy chain
TLMISRTPEV TCVWDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRWSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT DYNMHWVRQA PGQGLEWMGE
H0311-H 1 INPNNGVWY NQKFKGRVTI TVDKSTSTAY MELSSLRSED TAVYYCTRAL heavy chain YHSNFGWYFD SWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCWVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT DYNMHWVRQA PGQGLEWMGE INPNNGVWY NQKFKGTTTL TVDKSTSTAY MELSSLRSED TAVYYCTRAL YHSNFGWYFD SWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
H031 1-H2
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK
heavy chain
DTLMISRTPE VTCWVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL
LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS
h030i-L0
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
NIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS
h0301 -Ll
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWY QQKPGQAPRL
LIYTASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSKELPW
H0302-L0
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
li ht chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWY QQKPGQAPRL LIYTASNLES GIPARFSGSG SRTDFTLTIS SLEPEDFAVY YCQQSKELPW
H0302-L1
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
Mailt chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIWTQSPAT LSLSPGERAT LSCRASESVD NYGLSFMNWF QQKPGQAPRL LIYTASNLES GIPARFSGSG SRTDFTLTIS SLEPEDFAVY YCQQSKELPW
H0302-L2
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDSHMNWY QQKPGQAPRL
LIYTASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQGNEDPW
H031 1-L0
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
DIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDSHMNWY QQKPGQAPRL
LIYTASNLES GIPARFSGSG SGADFTLTIS SLEPEDFAVY YCQQGNEDPW
H031 1 -L1
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASWCLL NNFYPREAKV
light chain QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV
THQGLSSPVT KSFNRGEC
EEVSEYCSHM IGSGHLQSLQ RLIDSQMETS CQITFEFVDQ EQLKDPVCYL
Human KKAFLLVQDI MEDTMRFRDN TPNAIAIVQL QELSLRLKSC FTKDYEEHDK CSFl ACVRTFYETP LQLLEKVKNV FNETKNLLDK DWNIFSKNCN NSFAECSSQG
HERQSEGS
Human 1L34 NEPLEMWPLT QNEECTVTGF LRDKLQYRSR LQYMKHYFPI NYKISVPYEG
VFRIANVTRL QRAQVSEREL RYLWVLVSLSATESVQDVLL EGHPSWKYLQ EVQTLLLNVQ QGLTDVEVSP KVESVLSLLN APGPNLKLVR PKALLDNCFR VMELLYCSCC KQSSVLNWQD CEVPSPQSCS PEPSLQYAAT QLYPPPPWSP SSPPHSTGSV RPVRAQGEGL LP
Human
acceptor A QVQLVQSGAE VKKPGSSVKV SCKAS
69
FR1
Human
acceptor A WVRQAPGQGL EWMG
70
FR2
Human
acceptor A RVTITADKST STAYMELSSL RSEDTAVYYC AR
71
FR3
Human
acceptor A WGQGTLVTVS S
72
FR4
Human
acceptor B QVQLVQSGAE VKKPGSSVKV SCKAS
73
FR1
Human
acceptor B WVRQAPGQGL EWMG
74
FR2
Human
acceptor B RVTITADKST STAYMELSSL RSEDTAVYYC AR
75
FR3
Human
acceptor B WGQGTLVTVSS
76
FR4
Human
acceptor C QVQLVQSGAE VKKPGSSVKV SCKAS
77
FR1
Human
acceptor C WVRQAPGQGL EWMG
78
FR2
Human
acceptor C RVTITADKST STAYMELSSL RSEDTAVYYC AR
79
FR3
Human
acceptor C WGQGTLVTVS S
SO FR4
Human
acceptor D EIVLTQSPAT LSLSPGERAT LSC
81
FR1
Human
acceptor D WYQQKPGQAP RLLIY
82
FR2
Human
acceptor D GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YC
83
FR3
Human
acceptor D FGGGTKVEIK
84
FR4 Human
acceptor E EIVLTQSPAT LSLSPGERAT LSC
85
FRl
Human
acceptor E WYQQKPGQAP RLLIY
86
FR2
Human
acceptor E GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YC
87
FR3
Human
acceptor E FGQGTKVEIK
88
FR4
Human
acceptor F EIVLTQSPAT LSLSPGERAT LSC
89
FRl
Human
acceptor F WYQQKPGQAP RLLIY
90
FR2
Human
acceptor F GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YC
91
FR3
Human
acceptor F FGQGTKVEIK
92
FR4
APVIEPSGPE LVVEPGETVT LRCVSNGSVE WDGPISPYWT LDPESPGSTL TTRNATFKNT GTYRCTELED PMAGSTTIHL YVKDPAHSWN LLAQEVTWE GQEAVLPCLI TDPALKDSVS LMREGGRQVL RKTVYFFSPW RGFIIRKAKV LDSNTYVCKT MVNGRESTST GIWLKVNRVH PEPPQIKLEP SKLVRIRGEA AQIVCSATNA EVGFNVILKR GDTKLEIPLN SDFQDNYYKK VRALSLNAVD FQDAGIYSCV ASNDVGTRTA TMNFQWESA YLNLTSEQSL LQEVSVGDSL ILTVHADAYP SIQHYNWTYL GPFFEDQRKL EFITQRAIYR YTFKLFLNRV
mCSFIR
KASEAGQYFL MAQNKAGWNN LTFELTLRYP PEVSVTWMPV NGSDVLFCDV
93 ECD-Fc
SGYPQPSVTW MECRGHTDRC DEAQALQVWN DTHPEVLSQK PFDKVIIQSQ LPIGTLKHNM TYFCKTHNSV GNSSQYFRAV SLGQSKQEPK SSDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVWDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRWSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSWT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVWDVSQED
Human
PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RWSVLTVLH QDWLNGKEYK
94 IsG4 S241 P
CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK
RTVAAPSVFI FPPSDEQLKS GTASWCLLN NFYPREAKVQ WKVDNALQSG
Human ISK NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK
95 SFNRGEC

Claims

1. An isolated antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, and wherein the antibody binds to colony stimulating factor 1 receptor (CSF1R).
2. The antibody of claim 1 , wherein the heavy chain comprises a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
3. The antibody of claim 1 , wherein the heavy chain comprises a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
4. The antibody of claim 1 , wherein the heavy chain comprises a sequence that is at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
5. The antibody of claim 1 , wherein the heavy chain comprises a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
6. The antibody of any one of claims 1 to 5, wherein the light chain comprises a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
7. The antibody of any one of claims 1 to 5, wherein the light chain comprises a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
8. The antibody of any one of claims 1 to 5, wherein the light chain comprises a sequence that is at least 97% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
9. The antibody of any one of claims 1 to 5, wherein the light chain comprises a sequence that is at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
10. The antibody of any one of claims 1 to 5, wherein the light chain comprises a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
1 1. An isolated antibody comprising a heavy chain and a light chain, wherein the light chain comprises a sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, and wherein the antibody binds to colony stimulating factor 1 receptor (CSF1R).
12. The antibody of claim 1 1 , wherein the light chain comprises a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
13. The antibody of claim 1 1, wherein the light chain comprises a sequence that is at least 97%o identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
14. The antibody of claim 1 1 , wherein the light chain comprises a sequence that is at least 99%> identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
15. The antibody of claim 1 1, wherein the light chain comprises a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
16. An isolated antibody comprising a hea\'y chain and a light chain, wherein the heavy chain comprises: (i) a heavy chain (HC) CDR1 comprising a sequence selected from SEQ ID NOs: 15, 21, and 27; (ii) an HC CDR2 comprising a sequence selected from SEQ ID NOs: 16, 22, and 28; and (iii) an HC CDR3 comprising a sequence selected from SEQ ID NOs: 17, 23, and 29, wherein the antibody binds to CSF1 R.
17. The antibody of claim 16, wherein the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (c) SEQ ID NOs: 27, 28, and 29.
18. The antibody of claim 16 or claim 17, wherein the light chain comprises (i) a light chain (LC) CDR1 comprising a sequence selected from SEQ ID NOs: 18, 24, and 30; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31 ; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
19. The antibody of claim 18, wherein the LC CDR1 , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
20. An isolated antibody comprising a heavy chain and a light chain, wherein the light chain comprises: (i) a light chain (LC) CDR1 comprising a sequence selected from SEQ ID NOs: 18, 24, and 30; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31 ; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32; and wherein the antibody binds to CSF1R.
21. The antibody of claim 20, wherein the LC CDR1 , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
22. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 9 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 10;
(b) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 1 1 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 12;
(c) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 13 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 14;
(d) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 46;
(e) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 46;
(f) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 46;
(g) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 47;
(h) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 47;
(i) a heavy chain comprising a sequence that is at least 95% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 47; and
j) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95% identical to SEQ ID NO: 48;
(k) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 42 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 49;
(1) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 42 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 50;
(m) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 43 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 48;
(n) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 43 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 49;
(o) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 43 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 50;
(p) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 44 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 51 ;
(q) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 44 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 52;
(r) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 51 ; or
(s) a heavy chain comprising a sequence that is at least 95% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
95% identical to SEQ ID NO: 52.
23. An isolated antibody comprising a heavy chain and a light chain, a the antibody comprises:
(a) a heavy chain comprising a sequence that is at least 97%o identical to SEQ ID NO: 9 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 10;
(b) a heavy chain comprising a sequence that is at least 97%o identical to SEQ ID NO: 11 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 12;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 13 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 14;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 46;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 46;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 46;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 47;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 47;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 47; and
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 48;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 49;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 50;
a heavy chain comprising a sequence that is at least 97% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 97% identical to SEQ ID NO: 48;
(n) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 43 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 49;
(o) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 43 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 50;
(p) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 44 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 51 ;
(q) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 44 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 52;
(r) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 51 ; or
(s) a heavy chain comprising a sequence that is at least 97% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
97% identical to SEQ ID NO: 52.
24. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 9 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 10;
(b) a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 1 1 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 12;
(c) a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 13 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 14;
(d) a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 46;
(e) a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 46;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 46;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 39 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 47;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 40 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 47;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 47;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 48;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 49;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 50;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 48;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 49;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 43 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 50;
a heavy chain comprising a sequence that is at least 99% identical to SEQ ID NO: 44 and a light chain comprising a sequence that is at least 99% identical to SEQ ID NO: 51 ;
(q) a heavy chain comprising a sequence that is at least 99% identical to
SEQ ID NO: 44 and a light chain comprising a sequence that is at least
99% identical to SEQ ID NO: 52;
(r) a heavy chain comprising a sequence that is at least 99% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
99% identical to SEQ ID NO: 51 ; or
(s) a heavy chain comprising a sequence that is at least 99% identical to
SEQ ID NO: 45 and a light chain comprising a sequence that is at least
99% identical to SEQ ID NO: 52.
25. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a sequence of SEQ ID NO: 9 and a light chain comprising a sequence of SEQ ID NO: 10;
(b) a heavy chain comprising a sequence of SEQ ID NO: 1 1 and a light chain comprising a sequence of SEQ ID NO: 12;
(c) a heavy chain comprising a sequence of SEQ ID NO: 13 and a light chain comprising a sequence of SEQ ID NO: 14;
(d) a heavy chain comprising a sequence of SEQ ID NO: 39 and a light chain comprising a sequence of SEQ ID NO: 46;
(e) a heavy chain comprising a sequence of SEQ ID NO: 40 and a light chain comprising a sequence of SEQ ID NO: 46;
(f) a heavy chain comprising a sequence of SEQ ID NO: 41 and a light chain comprising a sequence of SEQ ID NO: 46;
(g) a heavy chain comprising a sequence of SEQ ID NO: 39 and a light chain comprising a sequence of SEQ ID NO: 47;
(h) a heavy chain comprising a sequence of SEQ ID NO: 40 and a light chain comprising a sequence of SEQ ID NO: 47;
(i) a heavy chain comprising a sequence of SEQ ID NO: 41 and a light chain comprising a sequence of SEQ ID NO: 47; and
(j) a heavy chain comprising a sequence of SEQ ID NO: 42 and a light chain comprising a sequence of SEQ ID NO: 48;
(k) a heavy chain comprising a sequence of SEQ ID NO: 42 and a light chain comprising a sequence of SEQ ID NO: 49; (1) a heavy chain comprising a sequence of SEQ ID NO: 42 and a light chain comprising a sequence of SEQ ID NO: 50;
(m) a heavy chain comprising a sequence of SEQ ID NO: 43 and a light chain comprising a sequence of SEQ ID NO: 48;
(n) a heavy chain comprising a sequence of SEQ ID NO: 43 and a light chain comprising a sequence of SEQ ID NO: 49;
(o) a heavy chain comprising a sequence of SEQ ID NO: 43 and a light chain comprising a sequence of SEQ ID NO: 50;
(p) a heavy chain comprising a sequence of SEQ ID NO: 44 and a light chain comprising a sequence of SEQ ID NO: 51 ;
(q) a heavy chain comprising a sequence of SEQ ID NO: 44 and a light chain comprising a sequence of SEQ ID NO: 52;
(r) a heavy chain comprising a sequence of SEQ ID NO: 45 and a light chain comprising a sequence of SEQ ID NO: 51 ; or
(s) a heavy chain comprising a sequence of SEQ ID NO: 45 and a light chain comprising a sequence of SEQ ID NO: 52.
26. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a heavy chain (HC) CDR1 having the
sequence of SEQ ID NO: 15, an HC CDR2 having the sequence of SEQ ID NO: 16, and an HC CDR3 having the sequence of SEQ ID NO: 17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 18, a LC CDR2 having the sequence of SEQ ID NO: 19, and a LC CDR3 having the sequence of SEQ ID NO: 20;
(b) a heavy chain comprising a heavy chain (HC) CDR1 having the
sequence of SEQ ID NO: 21 , an HC CDR2 having the sequence of SEQ ID NO: 22, and an HC CDR3 having the sequence of SEQ ID NO: 23, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 24, a LC CDR2 having the sequence of SEQ ID NO: 25, and a LC CDR3 having the sequence of SEQ ID NO: 26; or
(c) a heavy chain comprising a heavy chain (HC) CDR1 having the
sequence of SEQ ID NO: 27, an HC CDR2 having the sequence of SEQ ID NO: 28, and an HC CDR3 having the sequence of SEQ ID NO: 29, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 30, a LC CDR2 having the sequence of SEQ ID NO: 31 , and a LC CDR3 having the sequence of SEQ ID NO: 32.
27. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 60;
(b) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 61 ; or
(c) a heavy chain comprising a sequence of SEQ ID NO: 58 and a light chain comprising a sequence of SEQ ID NO: 65.
28. An isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
(a) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 60;
(b) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 61 ; or
(c) a heavy chain consisting of the sequence of SEQ ID NO: 58 and a light chain consisting of the sequence of SEQ ID NO: 65.
29. The antibody of any one of claims 1 to 28, wherein the antibody binds to human CSF1R.
30. The antibody of any one of claims 1 to 29, wherein the antibody binds to cynomolgus CSF1 R.
31. The antibody of any one of claims 1 to 30, wherein the antibody blocks ligand binding to CSF 1 R.
32. The antibody of any one of claims 1 to 31 , wherein the antibody blocks CSF1 binding to CSF l R.
33. The antibody of any one of claims 1 to 32, wherein the antibody blocks IL34 binding to CSFlR.
34. The antibody of any one of claims 1 to 33, wherein the antibody inhibits ligand-induced CSF1R phosphorylation.
35. The antibody of any one of claims 1 to 34, wherein the antibody inhibits CSF1 -induced CSF1R phosphorylation.
36. The antibody of any one of claims 1 to 35, wherein the antibody inhibits lL34-induced CSF 1 R phosphorylation.
37. The antibody of any one of claim 1 to 36, wherein the antibody is a chimeric antibody.
38. The antibody of any one of claims 1 to 36, wherein the antibody is a humanized antibody.
39. The antibody of any one of claims 1 to 38, wherein the antibody is selected from a Fab, an Fv, an scFv, a Fab', and a (Fab')?.
40. The antibody of any one of claims 1 to 38, wherein the antibody is selected from an IgA, an IgG, and an IgD.
41. The antibody of claim 40, wherein the antibody is an IgG.
42. The antibody of claim 41, wherein the antibody is an IgG4.
43. The antibody of claim 42, wherein the antibody comprises an S241P mutation in at least one IgG4 heavy chain constant region.
44. The antibody of any one of claims 1 to 43, wherein the antibody binds to human CSF1R with an affinity (KD) of less than 1 nM.
45. The antibody of any one of claims 1 to 44, wherein the antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 or IL34.
46. A pharmaceutical composition comprising an antibody of any one of claims 1 to 45.
47. An isolated nucleic acid comprising a polynucleotide sequence that encodes an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
48. The nucleic acid of claim 47, wherein the amino acid sequence is at least 95%o identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
49. The nucleic acid of claim 47, wherein the amino acid sequence is at least 97%o identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
50. The nucleic acid of claim 47, wherein the amino acid sequence is at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
51. The nucleic acid of claim 47, wherein the amino acid sequence is selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
52. The nucleic acid of any one of claims 45 to 51 , wherein the nucleic acid further comprises a polynucleotide sequence that encodes an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
53. The nucleic acid of claim 52, wherein the amino acid sequence is at least 95% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
54. The nucleic acid of claim 52, wherein the amino acid sequence is at least 97% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
55. The nucleic acid of claim 52, wherein the amino acid sequence is at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
56. The nucleic acid of claim 52, wherein the amino acid sequence is selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
57. An isolated nucleic acid comprising a polynucleotide sequence that encodes an amino acid sequence that is at least 90% identical to a sequence selected from 10, 12, 14, and 46 to 52.
58. The nucleic acid of claim 57, wherein the amino acid sequence is at least 95% identical to a sequence selected from 10, 12, 14, and 46 to 52.
59. The nucleic acid of claim 57, wherein the amino acid sequence is at least 97% identical to a sequence selected from 10, 12, 14, and 46 to 52.
60. The nucleic acid of claim 57, wherein the amino acid sequence is at least 99% identical to a sequence selected from 10, 12, 14, and 46 to 52.
61. The nucleic acid of claim 57, wherein the amino acid sequence is selected from 10, 12, 14, and 46 to 52.
62. A composition comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid is selected from the nucleic acids of claims 47 to 51 , and wherein the second nucleic acid is selected from the nucleic acids of claims 57 to 61.
63. An isolated nucleic acid comprising a polynucleotide sequence that encodes a heavy chain, wherein the heavy chain comprises : (i) a heavy chain (HC) CDR1 comprising a sequence selected from SEQ ID NOs: 15, 21, and 27; (ii) an HC CDR2 comprising a sequence selected from SEQ ID NOs: 16, 22, and 28; and (iii) an HC CDR3 comprising a sequence selected from SEQ ID NOs: 17, 23, and 29.
64. The nucleic acid of claim 63 , wherein the HC CDR 1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (c) SEQ ID NOs: 27, 28, and 29.
65. The nucleic acid of claim 63 or claim 64, wherein the nucleic acid further comprises a polynucleotide sequence that encodes a light chain, wherein the light chain comprises (i) a light chain (LC) CDRl comprising a sequence selected from SEQ ID NOs: 18, 24, and 30; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31 ; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
66. The nucleic acid of claim 65, wherein the LC CDRl , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
67. An isolated nucleic acid comprising a polynucleotide sequence that encodes a light chain, wherein the light chain comprises: (i) a light chain (LC) CDRl comprising a sequence selected from SEQ ID NOs: 18, 24, and 30; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31 ; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
68. The nucleic acid of claim 67, wherein the LC CDRl , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
69. A composition comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid is selected from the nucleic acids of claims 63 and 64, and wherein the second nucleic acid is selected from the nucleic acids of claims 67 and 68.
70. An isolated nucleic acid comprising a first polynucleotide sequence and a second polynucleotide sequence, wherein the first polynucleotide sequence and the second polynucleotide sequence encode a heavy chain and a light chain, respectively, of an antibody of any one of claims 22 to 28.
71. A composition comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a first polynucleotide sequence and the second nucleic acid comprises a second polynucleotide sequence, wherein the first polynucleotide sequence and the second polynucleotide sequence encode a heavy chain and a light chain, respectively, of an antibody of any one of claims 22 to 28.
72. A host cell comprising a nucleic acid of any one of claims 47 to 61 , 63 to 68, and 70.
73. A host cell comprising a composition of claim 60 or claim 69 or claim
71.
74. The host cell of claim 72 or 73, wherein the host cell is a eukaryotic host cell.
75. The host cell of claim 74, wherein the host cell is a mammalian host cell.
76. The host cell of claim 75, wherein the host cell is selected from a CHO cell, a 293 cell, an NSO cell, and a PER.C6 cell.
77. The host cell of claim 76, wherein the host cell is a 293 -6E cell or a DG44 cell.
78. A method of treating multiple sclerosis comprising administering to a patient a pharmaceutical composition of claim 46.
79. A method of treating rheumatoid arthritis comprising administering to a patient a pharmaceutical composition of claim 46.
80. A method of treating osteolytic bone loss comprising administering to a patient a pharmaceutical composition of claim 46.
81. The method of claim 80, wherein the osteolytic bone loss is selected from osteoporosis, metastasis-induced osteolytic bone loss, and rheumatoid arthritis- induced bone loss.
82. A method of treating cancer comprising administering to a patient a pharmaceutical composition of claim 46.
83. The method of claim 82, wherein the cancer is selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
PCT/US2011/035231 2010-05-04 2011-05-04 Antibodies that bind csf1r WO2011140249A2 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
AU2011248083A AU2011248083B2 (en) 2010-05-04 2011-05-04 Antibodies that bind CSF1R
NZ603193A NZ603193A (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
DK11778283.9T DK2566517T3 (en) 2010-05-04 2011-05-04 ANTIBODIES THAT BIND CSF1R
EP11778283.9A EP2566517B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
PL11778283T PL2566517T3 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
RS20190025A RS58211B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
LTEP11778283.9T LT2566517T (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
JP2013509230A JP6008842B2 (en) 2010-05-04 2011-05-04 Antibody binding to CSF1R
ES11778283T ES2706412T3 (en) 2010-05-04 2011-05-04 Antibodies that bind to CSF1R
BR112012027994-7A BR112012027994B1 (en) 2010-05-04 2011-05-04 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY
SG2012079133A SG185035A1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
KR1020207011504A KR20200044999A (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
EA201291161A EA036336B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
KR1020127031635A KR101838698B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
KR1020187006772A KR102105776B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
EP18151214.6A EP3357510B1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
CA2797399A CA2797399C (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
CN201180022404.5A CN103179985B (en) 2010-05-04 2011-05-04 Antibody in conjunction with CSF1R
SI201131627T SI2566517T1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
MX2015007635A MX355418B (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r.
EP20182161.8A EP3943154A1 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r
MX2012012790A MX2012012790A (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r.
IL222629A IL222629B (en) 2010-05-04 2012-10-23 Antibodies that bind csf1r
AU2015202477A AU2015202477C1 (en) 2010-05-04 2015-05-07 Antibodies that bind csf1r
AU2016262662A AU2016262662B2 (en) 2010-05-04 2016-11-22 Antibodies that bind csf1r
IL255524A IL255524B (en) 2010-05-04 2017-11-08 Antibodies that bind csf1r
IL257712A IL257712B (en) 2010-05-04 2018-02-25 Antibodies that bind csf1r
HRP20190047TT HRP20190047T1 (en) 2010-05-04 2019-01-07 Antibodies that bind csf1r
CY191100027T CY1121102T1 (en) 2010-05-04 2019-01-14 ANTIBODIES THAT BIND CSF1R
AU2019200691A AU2019200691B2 (en) 2010-05-04 2019-02-01 Antibodies that bind CSF1R

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33117710P 2010-05-04 2010-05-04
US61/331,177 2010-05-04

Publications (2)

Publication Number Publication Date
WO2011140249A2 true WO2011140249A2 (en) 2011-11-10
WO2011140249A3 WO2011140249A3 (en) 2013-08-15

Family

ID=44902080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035231 WO2011140249A2 (en) 2010-05-04 2011-05-04 Antibodies that bind csf1r

Country Status (26)

Country Link
US (8) US8206715B2 (en)
EP (3) EP3357510B1 (en)
JP (6) JP6008842B2 (en)
KR (3) KR101838698B1 (en)
CN (4) CN112480256A (en)
AU (4) AU2011248083B2 (en)
BR (1) BR112012027994B1 (en)
CA (1) CA2797399C (en)
CY (1) CY1121102T1 (en)
DK (1) DK2566517T3 (en)
EA (1) EA036336B1 (en)
ES (2) ES2706412T3 (en)
HR (1) HRP20190047T1 (en)
HU (1) HUE042898T2 (en)
IL (3) IL222629B (en)
LT (1) LT2566517T (en)
MX (2) MX355418B (en)
NZ (3) NZ626610A (en)
PL (1) PL2566517T3 (en)
PT (1) PT2566517T (en)
RS (1) RS58211B1 (en)
SG (3) SG10201604798SA (en)
SI (1) SI2566517T1 (en)
TR (1) TR201900368T4 (en)
TW (5) TWI595008B (en)
WO (1) WO2011140249A2 (en)

Cited By (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US8747845B2 (en) 2010-05-04 2014-06-10 Five Prime Therapeutics, Inc. Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN104093740A (en) * 2012-02-06 2014-10-08 弗·哈夫曼-拉罗切有限公司 Compositions and methods for using CSF1R inhibitors
WO2015028455A1 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies
US8999327B2 (en) 2009-12-10 2015-04-07 Hoffman-La Roche Inc. Antibodies against human CSF-1R and uses thereof
JP2015514811A (en) * 2012-04-26 2015-05-21 バクシネックス インコーポレーティッド Fusion protein to facilitate the selection of cells infected with specific immunoglobulin transgenic vaccinia virus
WO2015100282A1 (en) 2013-12-24 2015-07-02 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9192667B2 (en) 2013-04-22 2015-11-24 Hoffmann-La Roche Inc. Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist
JP2015533787A (en) * 2012-08-31 2015-11-26 ファイブ プライム セラピューティックス インコーポレイテッド Method of treating a condition with an antibody that binds colony stimulating factor 1 receptor (CSF1R)
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9243066B2 (en) 2011-07-18 2016-01-26 University Of Melbourne Use of M-CSF antibodies in the treatment of osteoarthritis or pain
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
WO2016106266A1 (en) 2014-12-22 2016-06-30 Bristol-Myers Squibb Company TGFβ RECEPTOR ANTAGONISTS
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
JPWO2014054820A1 (en) * 2012-10-03 2016-08-25 株式会社カイオム・バイオサイエンス Anti-human Dlk-1 antibody having antitumor activity in vivo
WO2016140884A1 (en) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
WO2016161269A1 (en) 2015-04-03 2016-10-06 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016183118A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
US9598422B2 (en) 2014-11-05 2017-03-21 Flexus Biosciences, Inc. Immunoregulatory agents
US9643972B2 (en) 2014-11-05 2017-05-09 Flexus Biosciences, Inc. Immunoregulatory agents
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017106291A1 (en) 2015-12-15 2017-06-22 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
JP2017125040A (en) * 2017-02-28 2017-07-20 ファイブ プライム セラピューティックス インコーポレイテッド Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US9856316B2 (en) 2013-04-12 2018-01-02 Morphosys Ag Antibodies targeting M-CSF
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2018136700A1 (en) 2017-01-20 2018-07-26 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018187613A2 (en) 2017-04-07 2018-10-11 Bristol-Myers Squibb Company Anti-icos agonist antibodies and uses thereof
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
WO2018213377A1 (en) 2017-05-17 2018-11-22 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
WO2019006283A1 (en) 2017-06-30 2019-01-03 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019055537A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019089921A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
JP2019089840A (en) * 2019-02-22 2019-06-13 ファイブ プライム セラピューティックス インコーポレイテッド Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US10323004B2 (en) 2016-05-04 2019-06-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019147982A1 (en) 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
WO2019160884A1 (en) 2018-02-13 2019-08-22 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
WO2019166596A1 (en) 2018-02-28 2019-09-06 Ultrahuman Twelve Limited Csf1r binding agents
WO2019173587A1 (en) 2018-03-08 2019-09-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
WO2019191295A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019200256A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
WO2019204257A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
WO2019243832A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2020006018A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
WO2020006016A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020014327A2 (en) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
WO2020014132A2 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
US10633342B2 (en) 2016-05-04 2020-04-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10640765B2 (en) 2016-08-02 2020-05-05 Vaccinex, Inc. Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10696650B2 (en) 2017-08-17 2020-06-30 Ikena Oncology, Inc. AHR inhibitors and uses thereof
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021041588A1 (en) 2019-08-28 2021-03-04 Bristol-Myers Squibb Company Substituted pyridopyrimidinonyl compounds useful as t cell activators
WO2021055698A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
US10982001B2 (en) 2012-05-11 2021-04-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2021101919A1 (en) 2019-11-19 2021-05-27 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein
US11021481B2 (en) 2019-09-13 2021-06-01 Nimbus Saturn, Inc. Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
WO2021108528A1 (en) 2019-11-26 2021-06-03 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021133748A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
WO2021133749A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
WO2021133750A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted bicyclic piperidine derivatives useful as t cell activators
WO2021133752A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as t cell activators
WO2021129673A1 (en) * 2019-12-24 2021-07-01 Adagene (Suzhou) Limited Anti-csf1r molecules and use thereof
AU2019204985B2 (en) * 2012-05-11 2021-07-15 Five Prime Therapeutics, Inc. Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2021178488A1 (en) 2020-03-03 2021-09-10 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
WO2021188769A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
WO2021194914A1 (en) 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Substituted oxoisoindoline compounds for the treatment of cancer
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US11337970B2 (en) 2016-08-26 2022-05-24 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120354A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2022136255A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022136266A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022148979A1 (en) 2021-01-11 2022-07-14 Bicycletx Limited Methods for treating cancer
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022216573A1 (en) 2021-04-05 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
WO2022216644A1 (en) 2021-04-06 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
US11512133B2 (en) 2013-09-12 2022-11-29 Hoffmann-La Roche Inc. Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11607453B2 (en) 2017-05-12 2023-03-21 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2023061930A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
EP4249066A2 (en) 2014-12-23 2023-09-27 Bristol-Myers Squibb Company Antibodies to tigit
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
US11807692B2 (en) 2018-09-25 2023-11-07 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
US11976125B2 (en) 2017-10-13 2024-05-07 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TWI844756B (en) 2019-12-24 2024-06-11 大陸商寶船生物醫藥科技（上海）有限公司 Anti-csf1r molecules and use thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
KR102684038B1 (en) * 2015-02-09 2024-07-10 유씨비 바이오파마 에스알엘 pharmaceutical preparations

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2413087T3 (en) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of cancer
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CN109022465B (en) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 Polypeptide constructs and uses thereof
EP2961421A1 (en) * 2013-02-28 2016-01-06 University Court of the University of Edinburgh Csf1 therapeutics
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US20170023576A1 (en) * 2014-04-04 2017-01-26 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
JP6851322B2 (en) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル How to treat neurological disorders
CN113855804A (en) 2015-06-15 2021-12-31 小利兰·斯坦福大学托管委员会 Methods and compositions for treating aging-related disorders
JP6621252B2 (en) * 2015-06-17 2019-12-18 国立大学法人北海道大学 Treatment resistance reducing agent for treatment resistant cancer
KR102677543B1 (en) * 2015-09-16 2024-06-24 아블렉시스, 엘엘씨 anti-CD115 antibody
EP4353320A3 (en) 2016-04-28 2024-05-15 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
AU2018237300A1 (en) 2017-03-23 2019-10-17 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MA48480A (en) 2017-04-26 2020-03-04 Alkahest Inc DOSAGE SCHEDULE FOR THE TREATMENT OF COGNITIVE AND MOTOR DEFICIENCIES WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS
CR20200138A (en) 2017-08-25 2020-06-14 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019080889A1 (en) * 2017-10-26 2019-05-02 江苏恒瑞医药股份有限公司 Anti-csf-1r antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN108276495B (en) * 2018-01-24 2022-03-18 博生吉医药科技(苏州)有限公司 NK92MI cell and T cell modified by targeted CSF1R chimeric antigen receptor and preparation method and application thereof
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019204604A1 (en) * 2018-04-19 2019-10-24 The Board Of Trustees Of The University Of Illinois Methods and compositions of inhibiting csf1r for treating allergic inflammation
CN108948199B (en) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application thereof
CN108948198B (en) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application thereof
CN109053887B (en) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 A kind of anti-human CSF-1R monoclonal antibody and purposes
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
IL282227B1 (en) 2018-10-26 2024-04-01 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CN113301960A (en) 2018-12-13 2021-08-24 财团法人生物技术开发中心 Anti-human CSF-1R antibodies and uses thereof
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
CN112300277A (en) * 2019-07-25 2021-02-02 苏州丁孚靶点生物技术有限公司 CSF1R antibodies, genes, vectors, host cells and CSF1R antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2518911B2 (en) 1987-10-23 1996-07-31 森永乳業株式会社 Compositions and methods for the treatment of cancer characterized by overexpression of the c-fms protooncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0668914B1 (en) 1992-06-09 2000-08-16 Chiron Corporation Crystallization of m-csf
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
WO2000025803A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
WO2001030381A2 (en) 1999-10-28 2001-05-03 Hofbauer, Reinhold Use of csf-1 inhibitors
AU1759501A (en) 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
DE60233509D1 (en) 2001-06-20 2009-10-08 Fibron Ltd FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004045532A2 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
AR045563A1 (en) * 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005070447A2 (en) 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
WO2005113596A2 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP2287310B1 (en) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Compositions and methods using MGD-CSF in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
ATE454455T1 (en) 2005-01-27 2010-01-15 Five Prime Therapeutics Inc GUIDING SEQUENCES FOR GUIDING POLYPEPTIDE SECRETION AND METHOD FOR PRODUCTION
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007064437A2 (en) 2005-11-10 2007-06-07 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
CN101379400A (en) 2005-12-22 2009-03-04 诺华有限公司 Soluble human M-CSF receptor and uses thereof
CN101534858A (en) 2006-01-05 2009-09-16 诺华有限公司 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
BRPI0818003A2 (en) 2007-10-18 2019-09-24 Novartis Ag csf-1r inhibitors, compositions and methods of use
EP2215482A2 (en) 2007-10-31 2010-08-11 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
CA2780692C (en) 2009-12-10 2018-09-11 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CN102918061B (en) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 For antibody of people CSF-1R and uses thereof
RU2617971C2 (en) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Antibodies to human csf-1r and use thereof
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
AR084234A1 (en) 2010-12-13 2013-05-02 Novartis Ag PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17)
CA2852800A1 (en) 2011-10-21 2013-04-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
JP6005751B2 (en) 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Regulation of macrophage activation
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI713436B (en) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ENDO ET AL., BIOTECHNOL. ADV., vol. 21, 2003, pages 695 - 713
HAMILTON, NAT. REV., vol. 8, 2008, pages 533 - 44
KITAURA ET AL., J. CLIN. INVEST., vol. 115, 2005, pages 3418 - 3427
LIN ET AL., SCIENCE, vol. 320, 2008, pages 807 - 11
OLMO ET AL., MOL. CANCER THER., vol. 5, 2006, pages 2634 - 43
PAULUS ET AL., CANCER RES., vol. 66, 2006, pages 4349 - 56
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SHERR ET AL., BLOOD, vol. 73, no. 7, 1989, pages 1786 - 1793
SITARAMAN ET AL., METHODS MOL. BIOL., vol. 498, 2009, pages 229 - 44
SPIRIN, TRENDS BIOTECHNOL., vol. 22, 2004, pages 538 - 45
TSUBOI ET AL., LEUKEMIA, vol. 14, 2000, pages 1460 - 1466

Cited By (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879085B2 (en) 2009-12-10 2018-01-30 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9499626B2 (en) 2009-12-10 2016-11-22 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9499625B2 (en) 2009-12-10 2016-11-22 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US10287358B2 (en) 2009-12-10 2019-05-14 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US8999327B2 (en) 2009-12-10 2015-04-07 Hoffman-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9663580B2 (en) 2009-12-10 2017-05-30 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9499624B2 (en) 2009-12-10 2016-11-22 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US10077314B1 (en) 2009-12-10 2018-09-18 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US10072087B2 (en) 2009-12-10 2018-09-11 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9624302B2 (en) 2010-03-05 2017-04-18 Hoffmann-La Roche Inc. Nucleic acids encoding antibodies against human CSF-1R
US10030073B2 (en) 2010-03-05 2018-07-24 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US9617342B2 (en) 2010-03-05 2017-04-11 Hoffman-La Roche Inc. Nucleic acids encoding antibodies against human CSF-1R and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9988458B2 (en) 2010-03-05 2018-06-05 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US8747845B2 (en) 2010-05-04 2014-06-10 Five Prime Therapeutics, Inc. Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9243066B2 (en) 2011-07-18 2016-01-26 University Of Melbourne Use of M-CSF antibodies in the treatment of osteoarthritis or pain
US10005840B2 (en) 2011-07-18 2018-06-26 Morphosys Ag Method for treatment of osteoarthritis with C-Fms antagonists
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US10336830B2 (en) 2011-12-15 2019-07-02 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
EP2812355A4 (en) * 2012-02-06 2016-03-02 Hoffmann La Roche Compositions and methods for using csf1r inhibitors
JP2015510510A (en) * 2012-02-06 2015-04-09 ジェネンテック， インコーポレイテッド Compositions and methods for using CSF1R inhibitors
CN104093740B (en) * 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 Use the composition and method of CSF1R inhibitor
CN104093740A (en) * 2012-02-06 2014-10-08 弗·哈夫曼-拉罗切有限公司 Compositions and methods for using CSF1R inhibitors
JP2015514811A (en) * 2012-04-26 2015-05-21 バクシネックス インコーポレーティッド Fusion protein to facilitate the selection of cells infected with specific immunoglobulin transgenic vaccinia virus
US10662422B2 (en) 2012-04-26 2020-05-26 Vaccinex, Inc. Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
AU2019204985B2 (en) * 2012-05-11 2021-07-15 Five Prime Therapeutics, Inc. Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US10982001B2 (en) 2012-05-11 2021-04-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
JP2015517490A (en) * 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド Method of treating a condition using an antibody that binds colony stimulating factor 1 receptor (CSF1R)
RU2670743C2 (en) * 2012-05-11 2018-10-25 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3539984A1 (en) 2012-05-11 2019-09-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2670743C9 (en) * 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3679949A1 (en) 2012-08-31 2020-07-15 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP2018197250A (en) * 2012-08-31 2018-12-13 ファイブ プライム セラピューティックス インコーポレイテッド Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI713436B (en) * 2012-08-31 2020-12-21 美商戊瑞治療有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US10822421B2 (en) 2012-08-31 2020-11-03 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN107759690A (en) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R)
US10221243B2 (en) 2012-08-31 2019-03-05 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
JP2015533787A (en) * 2012-08-31 2015-11-26 ファイブ プライム セラピューティックス インコーポレイテッド Method of treating a condition with an antibody that binds colony stimulating factor 1 receptor (CSF1R)
RU2718751C2 (en) * 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Methods of treating pathological conditions with antibodies which bind to the colony-stimulating factor 1 receptor (csf1r)
EP2890398A4 (en) * 2012-08-31 2016-03-09 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JPWO2014054820A1 (en) * 2012-10-03 2016-08-25 株式会社カイオム・バイオサイエンス Anti-human Dlk-1 antibody having antitumor activity in vivo
US9856316B2 (en) 2013-04-12 2018-01-02 Morphosys Ag Antibodies targeting M-CSF
US10081675B2 (en) 2013-04-12 2018-09-25 Morphosys Ag Antibodies targeting M-CSF
US9192667B2 (en) 2013-04-22 2015-11-24 Hoffmann-La Roche Inc. Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist
EP4282881A2 (en) 2013-08-30 2023-11-29 UCB Biopharma SRL Antibodies against csf-1r
EA036255B1 (en) * 2013-08-30 2020-10-20 Юсб Биофарма Спрл Anti-csf-1r antibodies and methods of use thereof
JP2016529266A (en) * 2013-08-30 2016-09-23 ユーシービー バイオファルマ エスピーアールエル antibody
US10421814B2 (en) 2013-08-30 2019-09-24 Ucb Biopharma Sprl Antibodies
KR102303130B1 (en) * 2013-08-30 2021-09-16 유씨비 바이오파마 에스알엘 Antibodies
EP4282881A3 (en) * 2013-08-30 2024-02-21 UCB Biopharma SRL Antibodies against csf-1r
AU2014314304B2 (en) * 2013-08-30 2019-12-05 Ucb Biopharma Sprl Antibodies
KR20160044018A (en) * 2013-08-30 2016-04-22 유씨비 바이오파마 에스피알엘 Antibodies
JP2020005652A (en) * 2013-08-30 2020-01-16 ユーシービー バイオファルマ エスピーアールエル Antibodies
US9908939B2 (en) 2013-08-30 2018-03-06 Ucb Biopharma Sprl Antibodies
EP3549599A1 (en) 2013-08-30 2019-10-09 UCB Biopharma SPRL Antibodies against csf-1r
WO2015028455A1 (en) * 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies
US11512133B2 (en) 2013-09-12 2022-11-29 Hoffmann-La Roche Inc. Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1
WO2015100282A1 (en) 2013-12-24 2015-07-02 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3466949A1 (en) 2013-12-24 2019-04-10 Bristol-Myers Squibb Company Tricyclic compound as anticancer agents
EP3998079A1 (en) 2014-06-06 2022-05-18 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
EP3610924A1 (en) 2014-06-06 2020-02-19 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10975153B2 (en) 2014-06-23 2021-04-13 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EA037561B1 (en) * 2014-06-23 2021-04-14 Файв Прайм Терапьютикс, Инк. Methods of treating diseases with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US11566076B2 (en) 2014-10-29 2023-01-31 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
KR20170074962A (en) * 2014-10-29 2017-06-30 파이브 프라임 테라퓨틱스, 인크. Combination therapy for cancer
KR102636539B1 (en) * 2014-10-29 2024-02-13 파이브 프라임 테라퓨틱스, 인크. Combination therapy for cancer
EP3835323A1 (en) 2014-10-29 2021-06-16 Five Prime Therapeutics, Inc. Combination therapy for cancer
US10618967B2 (en) 2014-10-29 2020-04-14 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
US11932601B2 (en) 2014-11-05 2024-03-19 Flexus Biosciences, Inc. Immunoregulatory agents
US10106546B2 (en) 2014-11-05 2018-10-23 Flexus Biosciences, Inc. Immunoregulatory agents
US10206893B2 (en) 2014-11-05 2019-02-19 Flexus Biosciences, Inc. Immunoregulatory agents
US9598422B2 (en) 2014-11-05 2017-03-21 Flexus Biosciences, Inc. Immunoregulatory agents
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
US10533014B2 (en) 2014-11-05 2020-01-14 Flexus Biosciences, Inc. Immunoregulatory agents
US9643972B2 (en) 2014-11-05 2017-05-09 Flexus Biosciences, Inc. Immunoregulatory agents
EP3854394A1 (en) 2014-11-05 2021-07-28 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
EP3725808A1 (en) 2014-11-21 2020-10-21 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
US10040858B2 (en) 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
US10730949B2 (en) 2014-12-22 2020-08-04 Five Prime Therapeutics, Inc. Method of treating PVNS with anti-CSF1R antibodies
WO2016106266A1 (en) 2014-12-22 2016-06-30 Bristol-Myers Squibb Company TGFβ RECEPTOR ANTAGONISTS
EP4249066A2 (en) 2014-12-23 2023-09-27 Bristol-Myers Squibb Company Antibodies to tigit
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
KR102684038B1 (en) * 2015-02-09 2024-07-10 유씨비 바이오파마 에스알엘 pharmaceutical preparations
WO2016140884A1 (en) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
US10167254B2 (en) 2015-04-03 2019-01-01 Bristol-Myers Squibb Company IDO inhibitors
WO2016161279A1 (en) 2015-04-03 2016-10-06 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
US10399932B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
US10399933B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
WO2016161269A1 (en) 2015-04-03 2016-10-06 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
US9790169B2 (en) 2015-04-03 2017-10-17 Bristol-Myers Squibb Company IDO inhibitors
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
EP3283527B1 (en) * 2015-04-13 2021-01-13 Five Prime Therapeutics, Inc. Combination therapy for cancer
US11559583B2 (en) 2015-04-13 2023-01-24 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
TWI725966B (en) * 2015-04-13 2021-05-01 戊瑞治療有限公司 Combination therapy for cancer
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3964527A2 (en) 2015-04-13 2022-03-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
WO2016183118A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017106291A1 (en) 2015-12-15 2017-06-22 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10633342B2 (en) 2016-05-04 2020-04-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10323004B2 (en) 2016-05-04 2019-06-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US10533052B2 (en) 2016-07-14 2020-01-14 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US11591392B2 (en) 2016-07-14 2023-02-28 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
US10640765B2 (en) 2016-08-02 2020-05-05 Vaccinex, Inc. Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
US11542335B2 (en) 2016-08-25 2023-01-03 Hoffmann-La Roche Inc. Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R)
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
US11337970B2 (en) 2016-08-26 2022-05-24 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US11498968B2 (en) 2016-12-22 2022-11-15 Hoffmann-La Roche Inc. Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP4310082A2 (en) 2017-01-20 2024-01-24 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
WO2018136700A1 (en) 2017-01-20 2018-07-26 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
JP2017125040A (en) * 2017-02-28 2017-07-20 ファイブ プライム セラピューティックス インコーポレイテッド Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
WO2018187613A2 (en) 2017-04-07 2018-10-11 Bristol-Myers Squibb Company Anti-icos agonist antibodies and uses thereof
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
US10689388B1 (en) 2017-04-21 2020-06-23 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
US10570138B2 (en) 2017-04-21 2020-02-25 Kyn Therapeutics Indole AHR inhibitors and uses thereof
US11358969B2 (en) 2017-04-21 2022-06-14 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11607453B2 (en) 2017-05-12 2023-03-21 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018213377A1 (en) 2017-05-17 2018-11-22 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
WO2019006283A1 (en) 2017-06-30 2019-01-03 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US12049520B2 (en) 2017-08-04 2024-07-30 Bicycletx Limited Bicyclic peptide ligands specific for CD137
US10696650B2 (en) 2017-08-17 2020-06-30 Ikena Oncology, Inc. AHR inhibitors and uses thereof
US11555026B2 (en) 2017-08-17 2023-01-17 Ikena Oncology, Inc. AHR inhibitors and uses thereof
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11421034B2 (en) 2017-09-13 2022-08-23 Five Prime Therapeutics, Inc. Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
WO2019055537A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11976125B2 (en) 2017-10-13 2024-05-07 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019089921A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US11952427B2 (en) 2017-12-27 2024-04-09 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12006329B2 (en) 2018-01-12 2024-06-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019147982A1 (en) 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
WO2019160884A1 (en) 2018-02-13 2019-08-22 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
US11655300B2 (en) 2018-02-28 2023-05-23 Ultrahuman Twelve Limited Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
WO2019166596A1 (en) 2018-02-28 2019-09-06 Ultrahuman Twelve Limited Csf1r binding agents
JP2021514654A (en) * 2018-02-28 2021-06-17 ウルトラヒューマン トゥエルブ リミテッド CSF1R binder
CN111788229A (en) * 2018-02-28 2020-10-16 超人十二有限公司 CSF1R binding agents
WO2019173587A1 (en) 2018-03-08 2019-09-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
WO2019191295A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019200256A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
WO2019204257A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
WO2019243833A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
US11453702B2 (en) 2018-06-22 2022-09-27 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US11912792B2 (en) 2018-06-22 2024-02-27 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2019243832A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020006016A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2020006018A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020014132A2 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
US11401328B2 (en) 2018-07-09 2022-08-02 Five Prime Therapeutics, Inc. Antibodies binding to ILT4
WO2020014327A2 (en) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
US11807692B2 (en) 2018-09-25 2023-11-07 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
WO2020127853A1 (en) 2018-12-20 2020-06-25 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2019089840A (en) * 2019-02-22 2019-06-13 ファイブ プライム セラピューティックス インコーポレイテッド Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025177A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021041588A1 (en) 2019-08-28 2021-03-04 Bristol-Myers Squibb Company Substituted pyridopyrimidinonyl compounds useful as t cell activators
US11028085B2 (en) 2019-09-13 2021-06-08 Nimbus Saturn, Inc. Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists
US11034694B2 (en) 2019-09-13 2021-06-15 Nimbus Saturn, Inc. Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
US11078201B2 (en) 2019-09-13 2021-08-03 Nimbus Saturn, Inc. Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
US11021481B2 (en) 2019-09-13 2021-06-01 Nimbus Saturn, Inc. Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
US11548890B1 (en) 2019-09-13 2023-01-10 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2021055698A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
WO2021101919A1 (en) 2019-11-19 2021-05-27 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
WO2021108528A1 (en) 2019-11-26 2021-06-03 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133748A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
WO2021133749A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
WO2021133750A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted bicyclic piperidine derivatives useful as t cell activators
WO2021133752A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as t cell activators
WO2021129673A1 (en) * 2019-12-24 2021-07-01 Adagene (Suzhou) Limited Anti-csf1r molecules and use thereof
CN114835811B (en) * 2019-12-24 2024-03-26 宝船生物医药科技(上海)有限公司 anti-CSF 1R molecules and uses thereof
CN114835811A (en) * 2019-12-24 2022-08-02 宝船生物医药科技(上海)有限公司 anti-CSF 1R molecules and uses thereof
TWI844756B (en) 2019-12-24 2024-06-11 大陸商寶船生物醫藥科技（上海）有限公司 Anti-csf1r molecules and use thereof
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
WO2021178488A1 (en) 2020-03-03 2021-09-10 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2021188769A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
WO2021194914A1 (en) 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Substituted oxoisoindoline compounds for the treatment of cancer
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120354A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022136266A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022136255A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022136257A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022148979A1 (en) 2021-01-11 2022-07-14 Bicycletx Limited Methods for treating cancer
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022216573A1 (en) 2021-04-05 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
WO2022216644A1 (en) 2021-04-06 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023061930A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Also Published As

Publication number Publication date
HRP20190047T1 (en) 2019-02-22
NZ603193A (en) 2014-07-25
RS58211B1 (en) 2019-03-29
US20180215830A1 (en) 2018-08-02
TW201809002A (en) 2018-03-16
US20110274683A1 (en) 2011-11-10
IL257712A (en) 2018-04-30
US11186646B2 (en) 2021-11-30
KR20130108078A (en) 2013-10-02
CN106977603B (en) 2020-11-27
US9957327B2 (en) 2018-05-01
AU2015202477B2 (en) 2017-03-09
NZ626610A (en) 2015-11-27
US20120219524A1 (en) 2012-08-30
US8206715B2 (en) 2012-06-26
SG10201911345WA (en) 2020-01-30
EA201291161A3 (en) 2013-10-30
EA201291161A2 (en) 2013-04-30
EP3943154A1 (en) 2022-01-26
EP2566517A4 (en) 2015-05-20
TW201641517A (en) 2016-12-01
KR102105776B1 (en) 2020-04-28
PL2566517T3 (en) 2019-04-30
JP2016193898A (en) 2016-11-17
AU2011248083A1 (en) 2012-11-15
SG10201604798SA (en) 2016-07-28
AU2011248083B2 (en) 2015-09-10
CN112480256A (en) 2021-03-12
KR101838698B1 (en) 2018-03-16
KR20200044999A (en) 2020-04-29
JP2022008382A (en) 2022-01-13
JP2013535952A (en) 2013-09-19
US20220153851A1 (en) 2022-05-19
CN106977603A (en) 2017-07-25
US8747845B2 (en) 2014-06-10
BR112012027994A2 (en) 2017-03-21
US20200223931A1 (en) 2020-07-16
US20170081415A1 (en) 2017-03-23
IL257712B (en) 2020-07-30
JP6008842B2 (en) 2016-10-19
BR112012027994B1 (en) 2021-10-13
JP6529552B2 (en) 2019-06-12
AU2016262662A1 (en) 2016-12-08
MX355418B (en) 2018-04-18
HUE042898T2 (en) 2019-07-29
TW201925232A (en) 2019-07-01
TW202112827A (en) 2021-04-01
KR20180028560A (en) 2018-03-16
CN103179985A (en) 2013-06-26
AU2015202477C1 (en) 2017-11-16
EA036336B1 (en) 2020-10-28
AU2019200691B2 (en) 2021-01-21
SI2566517T1 (en) 2019-01-31
AU2019200691A1 (en) 2019-02-21
IL222629A0 (en) 2012-12-31
JP6196347B2 (en) 2017-09-13
CY1121102T1 (en) 2019-12-11
CA2797399A1 (en) 2011-11-10
IL255524B (en) 2018-10-31
MX2012012790A (en) 2013-02-15
EP2566517A2 (en) 2013-03-13
LT2566517T (en) 2019-01-10
EP2566517B1 (en) 2018-10-24
DK2566517T3 (en) 2019-01-07
ES2706412T3 (en) 2019-03-28
ES2820517T3 (en) 2021-04-21
TR201900368T4 (en) 2019-02-21
EP3357510B1 (en) 2020-08-05
US10562970B2 (en) 2020-02-18
US20140322757A1 (en) 2014-10-30
TWI713942B (en) 2020-12-21
CN107011438B (en) 2020-11-20
TWI651331B (en) 2019-02-21
US20160046719A1 (en) 2016-02-18
CN107011438A (en) 2017-08-04
US9200075B2 (en) 2015-12-01
CA2797399C (en) 2021-03-02
IL222629B (en) 2020-10-29
JP2019180413A (en) 2019-10-24
EP3357510A1 (en) 2018-08-08
TWI542361B (en) 2016-07-21
JP2017221215A (en) 2017-12-21
AU2015202477A1 (en) 2015-05-28
NZ712765A (en) 2017-01-27
TWI595008B (en) 2017-08-11
US9695243B2 (en) 2017-07-04
JP2023144055A (en) 2023-10-06
PT2566517T (en) 2019-01-24
CN103179985B (en) 2016-10-26
AU2016262662B2 (en) 2018-11-01
SG185035A1 (en) 2012-11-29
TW201206467A (en) 2012-02-16
WO2011140249A3 (en) 2013-08-15
IL255524A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US11186646B2 (en) Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778283

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 9074/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2797399

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/012790

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013509230

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011778283

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011248083

Country of ref document: AU

Date of ref document: 20110504

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127031635

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201291161

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012027994

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012027994

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121031